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ABSTRACT 
 
The tissue microenvironment is a key determinant of pathology in both 
inflammation and cancer. It is now understood that the tumour microenvironment 
is a niche that favours tumour growth over anti-tumour immune surveillance. 
Accumulation of lactate in the tumour microenvironment, largely due to the 
accelerated metabolism of cancer cells avidly consuming most of the scarcely 
available nutrients, has been shown to drive regulatory T cell responses favouring 
tumour growth. 
Immune cells that infiltrate the tissue microenvironments in inflammatory 
disorders find similarly harsh conditions, including scarce nutrients and high 
levels of lactate and other metabolites. Yet opposite to the tumour 
microenvironment, the inflamed tissue features high levels of inflammatory 
cytokines with impairment of Treg in favour of Th1 and Th17 immune responses, 
contributing to the perpetuation of the chronic inflammatory disease process. 
Indeed, in inflammatory disorders lactate is an amplifier of the inflammatory 
response. 
Here, I explored the response of CD4
+
 T cells to lactate in the context of 
inflammation.  
Specifically, the project aimed at characterizing whether the lactate/SLC5A12-
induced metabolic signalling pathway modulates inflammatory immune 
responses.  
I employed a combination of immunology, mass spectrometry and biochemistry 
approaches on human peripheral blood mononuclear cells from healthy controls 
(HC) and rheumatoid arthritis (RA) subjects, as well as mononuclear cells from 
inflamed arthritic synovia and tonsils. I also used RNA-sequencing and clinical 
scores from a well-characterized early rheumatoid arthritis cohort and a murine 
model of CD4
+
 T cell-driven arthritis. 
I found that: 
1. SLC5A12 is up-regulated by CD4+ but not CD8+ T cells upon T-cell-
receptor (TCR) triggering. This expression is higher on CD4
+
 T cells isolated 
from RA synovial joints, where lactate is more abundant, as compared to 
peripheral RA and HC CD4
+
 T-cells.  
2. Lactate-uptake by CD4+ T cells through SLC5A12 causes a 
reprogramming of intracellular metabolism, including reduced glycolysis and 
enhanced TCA cycle and fatty acid synthesis substrates.  
3. SLC5A12-mediated lactate influx into human CD4+ T cells contributed 
to reshaping their effector phenotype, leading to increased IL- 
4. 17 production via nuclear PKM2/Stat3 signalling and enhanced fatty 
acid synthesis. 
5. SLC5A12-mediated lactate influx caused increased CD4+ T cell 
retention at the inflamed tissue as a consequence of impaired cell motility caused 
by reduced glycolysis and enhanced fatty acid synthesis. 
6. Antibody-mediated blockade of SLC5A12 ameliorates the clinical course 
of CD4
+
 T cell-driven human glucose 6 phosphate isomerase (hG6PI)-induced 
arthritis. 
7. Lactate/SLC5A12-induced metabolic reprogramming in CD4+ T cells is 
a distinctive mechanism of lymphoid RA pathogenesis. 
These findings establish lactate as an active signalling metabolite that contributes 
to the perpetuation of chronic inflammation and provide a novel therapeutic 
rationale to combat chronic inflammatory diseases. 
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1 ABBREVIATIONS 
 
1, 3-BPG  1,3-bisphosphoglycerate 
2-DG  2-Deoxyglucose 
AAV   ANCA-associated vasculitis  
Ab   Antibody 
ACC  acetyl-CoA Carboxylase 
ADP  Adenosine bi phosphate 
ADPGK   ADP-dependent glucokinase 
AICAR   5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside  
AID   Activation-induced cytidine deaminase  
Akt / PkB Protein kinase B  
AMPK  5’-AMP activated protein kinase 
ANLS  Astrocyte neuron lactate shuttle 
ANT  Adenine nucleotide translocase  
APC  Antigen Presenting Cell 
Arg2  Arginase 2 
AS  Ankylosing spondylitis 
ATM  Ataxia telangiectasia mutated 
ATP  Adenosine tri phosphate 
BAX  BCL-2 associated X 
BCL  B-cell lymphoma  
BrPa   Bromopyruvate  
BS  Blood serum 
BSA  Bovine serum albumin 
C1q  Complement component 1q  
C3  Complement component 3  
C75  4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid 
Ca2
+
  Calcium ion 
CAD   Coronary artery disease  
cAMP  Cyclic Adenosine monophsophate 
CCR/L  -CC- motif receptor / ligand 
CD  Cluster of differentiation 
CD62L   Leukocyte receptor L-selectin 
cDNA  Complementary DNA 
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CFA  Complete freund adjuvant  
CFSE  Carboxyfluorescein succinimidyl ester 
CIA   Collagen-induced arthritis  
CNS  Central nervous system  
CO2  Carbon dioxide 
COX   Cytochrome c oxidase 
CPT1a  Carntine palytoyl transferase 1a 
CR2  Complement receptor 2 
CRP  C reactive protein 
CRTH2  Prostaglandin D2 receptor 2 
CSF   Cerebrospinal fluid  
CTL  Cytotoxic T lymphocyte 
CTLA4  Cytotoxic T-Lymphocyte Antigen 4 
CVD  Cardiovascular disease 
CXCR/L  -CXC-motif receptor / ligand 
DAG  Diacylglycerol 
DAPI  4',6-diamidino-2-phenylindole 
DASA   N,N’-diarylsulfonamide  
DC  Dendritic cell 
DHEA   Dehydroepiandrosterone  
DMEM  Dulbecco's Modified Eagle Medium 
DMS  Dimethyl fumarate 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide triphosphate 
EAE  Experimental autoimmune encephalomyelitis 
EBV   Epstein–Barr virus 
EC  Endothelial cell 
EC50  Half maximal effective concentration 
ECAR  Extracellular acidification rate 
ECL   Enhanced chemiluminescence  
ECSIT  Evolutionarily conserved signaling intermediate in toll pathway 
ELISA  Enzyme linked immunosorbent assay 
ELS  Ectopic lymphoid structures 
ETC  Electron transport chain 
FA  Fatty acid 
FACS  Fluorescent activated cell sorting 
FAO  Fatty acid oxidation 
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FAS  Fatty acid synthesis 
FBP  Fructose-bisphosphatase  
FBS  Fetal bovine serum 
Fc  Fragment crystallizable 
FCCP  Carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
FDC  Follicular dendritic cells 
FLS  Fibroblast 
FOXP3  Forkhead box P3 
FSC  Forward scatter  
G6P  Glucose-6-Phosphate 
G6PD  Glucose-6-phosphate dehydrogenase 
G6PI  Glucose-6-phosphate isomerase  
GAPDH  Glyceraldehyde 3 phosphate dehydrogenase 
GATA3  GATA binding protein 3 
GCK  Glucokinase  
GLUT  Glucose transporter 
GPCRs   G protein-coupled receptors 
GPD2  Glycerol-3-phosphate dehydrogenase 2 
GPR  G protein receptor 
GSH  Glutathione (reduced) 
GSK3b  Glycogen synthase kinase 3b 
GSSH   Oxidized glutathione  
GTP  Guanosin Tri Phosphate 
H&E   Haematoxylin and eosin 
H2DCFDA  2',7'-Dichlorodihydrofluorescein diacetate  
H2O2  Hydrogen peroxide 
HC  Healthy controls 
HCl  Hydrochloric acid 
HDACs   Histone deacetylases 
HEV  High endothelial venules 
HIF1α  Hypoxia inducible factor 1α 
HK  Hexokinase  
IBD  Intestinal bowel disease 
ICAM1  Intercellular adhesion molecule 1 
ICOS   Inducible T-cell costimulator   
Ig  Immunoglobulin 
IL  Interleukin 
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IP3  Inositol triphosphate 
ITAM  Immunoreceptor tyrosine based activation motif 
Itk  Inducible T cell kinase 
JNK  c-Jun N-terminal kinases  
KATs  Lysine acetyltransferases  
KEAP  Kelch-like ECH-associated protein 1  
LD  Lipid droplets 
LDH  Lactate dehydrogenase 
LDHA  LDH subunit A 
LDHB  LDH subunit B 
LFA1  Leukocyte function associated antigen 1 
LPS  Lipopolysaccharide 
mAbs  Monoclonal antibodies 
MAM  Mitochondria-associated membranes 
MAPK   Mitogen-activated protein kinase  
MCs  Mononuclear cells 
MCT  Monocarbocylate transporter 
MCT  Monocarboxylic transporter 
MDSCs   Myeloid-derived suppressor cells  
MetS   Metabolic syndrome 
MHC  Major Histocompatibility complex 
MMP  Metalloproteinase 
MnSOD   Manganese-dependent superoxide dismutase (SOD2) 
MS  Multiple sclerosis 
mTOR  Mammalian target of rapamycin 
NaCl  Sodium chloride 
NAD
+
(H) Nicotinamide dinucleotide oxidized (reduced) 
NADP
+
(H) Nicotinamide dinucleotide phosphate (reduced) 
NCK  Non-catalytic region of tyrosine kinase adaptor protein  
NDRG3  N-Myc downstream-regulated gene 3 
NFAT  Nuclear Factor of Activated T cells 
NF-κB  Nuclear Factor κB 
NK   Natural killer 
NRF2  Nuclear factor erythroid 2–related factor 2 
NSCLC  Non-small cell lung carcinomas  
OA  Osteoarthritis 
OCR  Oxygen consumption rate 
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OD  Optical density 
OXPHOS Oxidative phosphorylation 
PAMP  Pathogen associated molecular pattern 
PBMC  Peripheral blood mononuclear cells 
PBS  Phosphate buffered saline 
PCA  Perchloric acid 
PD1  Programmed cell death 1 
PDH  Pyruvate dehydrogenase 
PFK  Phosphofructokinase 
PFKFB3  Phsophofructokinase / Fructose-bisphosphatase 
PGK  Phosphoglyceryl-lysine 
PHDs  Prolyl-hydroxylase containing enzymes 
PI3K  Phosphoinositide 3 kinase 
PK  Pyruvate kinase 
PKM  Pyruvate kinase muscle  
PLC  Phospholipase C 
PMA  Phorbol 12-myristate 13-acetate 
PNAD  Peripheral node addressin 
PPP  Pentose Phosphate Pathway 
PRR  Pattern recognition receptors 
PTPN22  Protein tyrosine phosphatase, non-receptor type 22  
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RA  Rheumatoid arthritis 
RASF  Rheumatoid arthritis synovial fluid 
RA-ST  Rheumatoid arthritis synovial tissue 
RIPA  Radio immunoprecipitation assay buffer 
RNA  Ribonucleic acid 
RNA-seq  RNA sequencing 
RORγ   RAR-related orphan receptor gamma 
ROS  Reactive oxygen species 
RPM   Revolutions per minute 
S1P(R)  Sphingosine-1-phosphate (receptor) 
SDS  Sodium dodecylsulphate 
SDS-PAGE SDS – Polyacrylamide gel electrophoresis 
SF  Synovial fluid 
SFMCs  Synovial fluid mononuclear cells  
SH3PXD2A SH3 and PX domain-containing protein 2A 
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SIRT  Sirtuin 
SLC  Solute Carrier 
SLE  Systemic lupus erythematosus 
SLO  Secondary lymphoid organ 
SLP76  SH2 domain containing leukocyte protein of 76kDa 
SMCTs   Sodium-coupled transporters  
SOD2  Superoxide dismutase 2  
SSC  Side scatter  
STAT   Signal transducer and activator of transcription proteins 
SUCNR  Succinate receptor 
TAM  Tumour associated macrophages 
TBST  Tween containing tris buffered saline 
TCA  Tri cyclic acid cycle 
Tconv  Conventional T cells 
TCR  T Cell Receptor 
TDAG8  T cell death-associated gene 8  
Tfh  Follicular helper T cells 
TGF  Transforming grow factor 
Th  Helper T cells 
TLR  Toll like receptor 
TMB  3,3,5,5’ Tetramethylbenzidine 
TNFα  Tumour necrosis factor α 
TOFA   5-(Tetradecyloxy)-2-furoic acid 
TRAF  TNF receptor associated factors 
Treg  Regulatory T cells 
VDAC   Voltage-dependent anion-selective channel protein 
VEGF  Vascular endothelial growth factor 
VLA-4  Very late antigen-4 
ZAP70  Z-chain associated protein kinase 
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2  INTRODUCTION 
 
2.1 The immune system 
 
The immune system consists of the innate and the adaptive arms, which are closely 
interconnected. The innate arm includes physical, chemical, and microbiological barriers, 
immune cells such as neutrophils, monocytes, macrophages, molecules (i.e. complement, 
cytokines) and acute phase proteins, which provide immediate host defense. 
Adaptive immunity consists of antigen-specific reactions through T and B-lymphocytes. 
The adaptive response has memory, so that subsequent exposure to the same antigen 
leads to a more vigorous and rapid response (Delves PJ, 2000, Delves PJ, 2000). More 
details on the adaptive immune system are described in the section 2.1.2. 
 
2.1.1 Cellular communication 
 
In order to work effectively cells need to be recruited to sites of inflammation where they 
can be appropriately activated. This is achieved via intracellular signal pathways induced 
by external factors, such as cytokines, adhesion molecules or chemokines, which are able 
to bind the receptors. 
Cytokines are small molecules produced by immune cells. They share a wide variety of 
functions such as regulation of cell activation, division, apoptosis, or chemotaxis. 
Cytokines act as autocrine, paracrine, or endocrine messengers. Cytokines produced by 
leucocytes and having effects mainly on other white cells are termed interleukins. 
Chemokines are members of the cytokine family that have a key role in leucocyte 
migration. Chemokines are classified according to the position of two cysteine (C) 
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residues compared with the other amino acids (X). The two main subgroups are CXC (-
chemokines) and CC (-chemokines). Chemokines can address leucocytes to the 
inflammatory sites (inflammatory chemokines) or to the secondary lymphoid tissues such 
as the spleen or limph nodes (homing chemokines). 
 
2.1.2 Innate immunity 
 
The innate system, although not antigen specific, is able to recognize foreign pathogens 
via pattern-recognition receptors (PRR). These recognize pathogen-associated molecular 
pattern structure (i.e.lipopolysaccharide, lipotechoic acid, mannans etc.) present on 
microbes. The pattern-recognition receptor molecules include: 1) those inducing 
endocytosis and thus enhancing antigen presentation; 2) those initiating nuclear factor 
transduction and cell activation (toll-like receptors) and 3) those, which act as opsonins 
for example mannan-binding lectin. 
The processed product is then presented by APCs favoring the adaptive immune 
response, phagocytosis, opsonisation, and complement-mediated lysis (Takeuchi O, 
2010). 
 
2.1.3 The adaptive immune system 
 
The adaptive immune system includes T and B cells, which are specialized in protecting 
the body in an antigen-specific manner (Guermonprez P, 2002). The antigen is firstly 
presented to and then recognized by the antigen specific T or B cell. This leads to cell 
priming, activation, and differentiation, which usually occur within the specialized 
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environment of lymphoid tissues. Then the effector response takes place generally in the 
inflammatory sites.  
 
2.1.3.1 Antigen presentation to T cells 
 
The first contact with the antigen occurs via highly specialized antigen presenting cells 
(APCs), such as dendritic cells (DC), macrophages, NK and B cells (Guermonprez et al., 
2002). These cells are generally located in areas like skin or mucosal surfaces where the 
availability of antigens is high (Steinman RM and Banchereau J, 2007). There they can 
interact with the antigen via surface receptor (i.e. lectins), which recognize pathogen 
carbohydrate recognition element. This allows the APCs to bind and internalize the 
pathogen. Processed antigens are presented to T cells in association with major 
histocompatibility complex (MHC) class I or class II molecules. When the antigen is 
produced endogenously within the cell (such as viral or tumour proteins) it is complexed 
with MHC class I through intracellular processing pathways. Alternatively, APCs can 
take up the antigen by endocytosis after receptor recognition. Exogenous antigen is 
processed via a different pathway to endogenous, and presented on the cell membrane in 
association with MHC class II molecules. The MHC ensures that only antigens derived 
from foreign molecules are recognized. Co-receptor stimulation, other than antigen-MHC 
complex, is required in order to obtain a correct T cell activation. 
Generally, T lymphocytes meet the antigen in the secondary lymphoid organs (SLO) such 
as lymph nodes. The antigen is brought directly in the lymphatics, or within APCs that 
have endocytosed the antigen locally. 
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2.1.3.2 T-cell receptor signaling and cell activation 
 
Responsible for the recognition of peptide MHC complexes by naïve T cells is the T-cell 
receptor (TCR). The TCR is a heterodimer consisting of a α- and β-chain that are each 
anchored to the cell membrane and in complex with the signaling molecule CD3 (Weiss 
A and Stobo JD, 1984). The majority of T cells express the α- and β-chain, in about 5% 
of T cells these are replaced by a γ- and δ-chain. 
When antigen is bound to the TCR it creates a complex with the CD3 on the cell surface. 
The phosphorylation of tyrosines within the cytoplasmic tail of the CD3 complex called 
immunoreceptor tyrosine-based activation motifs (ITAMs), starts a downstream cascade 
of signal transduction leading to the activation of genes that coordinate T cell activation 
and proliferation programmes. 
In brief, the phosphorylation of lymphocyte protein tyrosine kinase (Lck) in turn activates 
the -chain associated protein kinase (Zap70), which promotes the recruitment and 
activation of the adaptor proteins Slp-76, Vav, NCK, GADS and inducible T cell kinase 
(Itk, Figure I).  
Early studies on TCR transduction signals started with TCR-deficient Jurkat T cells that 
could be stimulated pharmacologically with the combination of phorbol esters and Ca2
+
 
ionophores (Weiss A, 1987). This observation was followed by the findings of an 
increase in intracellular free Ca2
+
 upon TCR stimulation in both Jurkat cells and primary 
T cells. The rise of intracellular Ca2
+
 was demonstrated to be associated to inositol 
trisphosphate (IP3) production and to the influx of Ca2
+
 from the extracellular space 
(Imboden JB, 1985). The downstream target of TCR activation was then identified in the 
phospholipase C (PLC), which generates diacylglycerol (DAG) an IP3 leading to the 
accumulation of intracellular Ca2
+
 (Smith-Garvin JE, 2009; Figure I). 
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The activation of naïve T cells is a complex process that requires not only the TCR 
signal, but also the stimulation of several other costimulatory molecules (Chen L and 
Flies DB, 2013). Without these co-signals the cell will either become anergic (unreactive 
to TCR stimulation) or die by programmed cell death. The main co-receptors for T-cell 
activation are CD80 (B7-1), CD86 (B7-2) and CD40 expressed on APCs, that bind 
CD28, CTLA-4, and CD40 ligand on the T cell, respectively. Activated dendritic cells 
are the most potent stimulators of naïve T cells, producing large amounts of B7 and 
CD40.  
Furthermore, CD28 signalling activation stabilizes TCR activation and IL2 expression, 
which in turn favors T cell survival (Rudd CE, 1996).  
Inflammatory mediators also induce the upregulation of co-stimulatory molecules; 
therefore, a T cell is much more likely to be activated if it meets its specific antigen via 
an antigen-presenting cell, which has been previously exposed to an inflammatory 
environment. T cell receptor activation and downstream signaling lead to dramatic 
changes in gene expression, metabolic activity and macromolecule synthesis. This, in 
turn, enables the T cell to alter its morphology, grow and start to proliferate. 
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Figure I - TCR signaling model. Following antigen recognition, TCR induces multiple 
intracellular signals. This includes the activation of proteins, transcription factors that in 
turn modulate gene expression and immune homeostasis (Adapted from: Abraham RT, 
2004).  
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2.1.3.3 Acquisition of effector functions 
 
Naïve T cells are characterized by surface expression of CCR7, L-selectin (CD62L) and 
the IL-7R (CD127) that enable them to effectively patrol secondary lymphoid organs. 
Upon TCR activation naïve T cells undergo morphological changes that are fundamental 
to achieve an efficient adaptive immune response. More specifically, after the formation 
of the complex antigen-MHC-TCR, T cells increase their size, start to produce cytokines 
and express surface markers of T cell activation such as CD25, CD44 and CD69, 
integrins (i.e. LFA-1 and VLA-4), and chemokine receptors such as CCR5 and CXCR3 
on the Th1 subset, CCR4 and CRTH2 on the type 2 helper subset as well as CCR6 on the 
Th17 subset (Islam SA and Luster AD, 2012). All these events enable T cells to egress 
from the lymph nodes and travel towards the site of inflammation. 
 
2.1.3.4 T cell trafficking 
 
T cells undergo four distinct steps during their migration through blood vessels. These 
include tethering, rolling, activation and arrest (Marelli-Berg F, 2008). Naïve T cells 
enter into secondary lymphoid organs (SLO) via high endothelial venules (HEV), which 
expresses PNAd – an O-linked carbohydrate moiety. PNAd binds the leukocyte receptor 
L-selectin (CD62L) based on the T cell membrane. Subsequently, T cell rolling is 
facilitated by the interaction between integrin leukocyte function-associated antigen 1 
(LFA-1) with the endothelial inter-cellular adhesion molecule 1 (ICAM 1) (von Andrian 
and Mempel, 2003). Once in the lymph node, T cell upregulate LFA1 that interacts with 
ICAM1 on the endothelium favoring the T cell arrest. CCR7, the receptor for CCL19 or 
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CCL21 chemokines, is also up-regulated by naïve T cells thus reinforcing the T cell 
adhesion (Marelli-Berg F, 2008). 
Recent studies also revealed the importance of sphingosine-1-phosphate (S1P) as a 
regulator of T cell trafficking. Sphingosine-1-phosphate (S1P) is a lipid second 
messenger that signals via five G protein-coupled receptors (S1P1–5R). Further studies 
established that conditional deletion of S1PR1 in T cells alone was sufficient to block 
their egress from the thymus (Chun J, 2010; Schwab SR, 2005). 
The balance between CCR7 retention signals and S1P1 egress signals is also important 
for the modulation of T cell activation (Pham THM, 2008; Spiegel S, 2011). 
Exposure to high concentrations of S1P results in S1P1 internalization, making cells 
unresponsive to migration cues in blood or lymph nodes whereas CCL19 can desensitize 
CCR7 signalling (Kohout TA, 2004). 
Loss of CCR7 results in reduced T-lymphocyte dwell time in the lymph node, implying 
that CCR7 provides a signal to counter S1P1-mediated egress (Kohout TA, 2004)..  
Recently it has been shown that during an inflammatory response, lymphocyte 
recruitment into tissue is tightly controlled. In particular, in response to adiponectin, B 
cells, which express adiponectin receptor (AdipoR1/2), are able to inhibit T cell 
trafficking by secreting a peptide (PEPITEM) proteolytically derived from 14.3.3 zeta 
delta (14.3.3.ζδ) protein. PEPITEM binds to cadherin-15 on endothelial cells, promoting 
synthesis and release of sphingosine-1 phosphate, which inhibits trafficking of T cells 
without affecting recruitment of other leukocytes (Figure II, Chimen M, 2015). 
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Figure II - T cell trafficking during inflammation. Inflammatory stimuli such as pro-
inflammatory cytokines (i.e. TNF-α and IFN-γ) activate a cascade of signals including 
the expression of chemokine receptors, integrins, S1PR1-4 on T cell surface and 
endothelial cells respectively. This allows T cells to flow in the blood vessels and reach 
inflammatory sites (Adapted from: Chimen M, 2015). 
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2.1.3.5 T helper differentiation 
 
In the SLO, T cells become efficiently activated and increased in number and can finally 
migrate to the inflamed tissues. This is due to pro-inflammatory chemokines and 
cytokines that are mainly secreted by endothelial cells, and local inflammatory immune 
cells in the inflammatory environment such as TNF-α, IL-1, and IL-17 (Haas R, 2013). 
A "cross talk" between the innate and adaptive immune systems is necessary in order to 
achieve an efficient defense against invading pathogens.  
Presenting cells such as dendritic cells (DCs), upon antigen recognition, help CD4+ T 
cells to differentiate into a variety of effector subsets, Th1, Th2, Th17, follicular helper T 
(Tfh) cells, and induced Treg (iTreg) cells. Cytokines in the microenvironment and the 
strength of the interaction of the T cell antigen receptor with antigen orchestrate the 
differentiation pathway (Boyton RJ, 2002, Sethi A, 2013). Th1 cells are characterized by 
microorganisms. The signal transducer and activator of transcription 4 (Stat4), Stat1, and 
T box transcription factor T-bet are activated during Th1 polarization (Figure III, Leung 
S, 2010). 
Th2 cells produce IL-4, IL-5, and IL-13 and are required for humoral immunity to control 
helminths and other extracellular pathogens. GATA3 and Stat6 are needed for the 
differentiation of Th2 cells. Th17 cells produce IL-17A, IL-17F, and IL-22 and play 
important roles in the clearance of extracellular bacteria and fungi, especially at the level 
of mucosal surfaces. Th17 cell differentiation requires retinoid related orphan receptor 
uced by TGF in combination with the pro-
inflammatory cytokines IL-6, IL-21, and IL-23, all of which activate Stat3 
phosphorylation (Chen Z, 2007). Tfh cells are a subset of helper T cells that regulate the 
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maturation of B cell responses. Differentiation of these cells requires the cytokine IL-21 
(Vogelzang A, 2008; Nurieva RI, 2008) and the expression of the transcription factor 
BCL6 (Fazilleau N, 2009). 
Regulation of effector T cell responses is required for effective control of infections and 
autoimmune diseases. Aberrant Th1 and Th17 cell responses play critical roles in organ-
specific autoimmunity, whereas Th2 cells are mainly involved in allergy and asthma. 
Treg cells have essential roles in maintenance of immune homeostasis, regulating these 
effector T cell responses and thus preventing their potentially pathogenic effects through 
a variety of mechanisms (Liang B, 2008; Shevach EM, 2009; Figure III).  
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Figure III - CD4
+
 T cell differentiation. Upon TCR activation triggered by antigen-
presenting cells, naive CD4 T cells differentiate into distinct Th subsets producing 
specific cytokines. The differentiation process involves upregulation of master 
transcriptional regulators and activation of Stat proteins (Adapted from: Leung S, 2010). 
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2.2 The inflammatory environment 
 
Once in the inflammatory site, T cells are exposed to numerous factors that might affect 
their functions i.e., low pH and oxygen, high lactate and other metabolites as well as 
reactive oxygen species. All these components modulate T cells as well as other immune 
cell responses and contribute to the establishment of chronic inflammation (Haas R, 
2013). 
 
2.2.1 Hypoxia 
 
Hypoxia, low oxygen concentrations (<2%), is a prominent feature of the inflammatory 
microenvironment. The occurrence of hypoxia at sites of inflammation is due to a 
combination of increased oxygen demand and decreased supply. Oxygen consumption is 
elevated at inflammatory sites due to the high metabolic demand associated with active 
inflammation, which is necessary to sustain the synthesis of inflammatory mediators, 
enzymes, and cytokines (Haas R, 2013; Taylor CT 2016). 
A number of recent studies have demonstrated that the microenvironment at sites of 
inflammation often becomes profoundly hypoxic. Inflammatory pathologies in which 
tissue hypoxia has been documented include atherosclerosis, rheumatoid arthritis, 
obesity, infection, ischemic disease, cancer, and inflammatory bowel disease (Eltzschig 
HK, 2011; Lalonde C, 1988) 
Hypoxia can actively affect inflammatory processes through the regulation of oxygen-
sensitive signalling pathways in multiple immune cell subtypes that are either resident 
within the inflamed tissue or have migrated from the oxygen-rich bloodstream to the 
hypoxic inflammatory milieu (Eltzschig HK, 2011; Scholz CC, 2013). 
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Hypoxia-inducible factor (HIF) is considered a master regulator of the cellular response 
to hypoxia (Semenza GL, 2012; Semenza GL, 1998). Under normoxic conditions (2-3% 
oxygen) HIF1 is hydroxylated by prolyl-hydroxy-domain (PHD) containing enzymes 
which is a signal for ubiquitinylation-dependent proteosomal degradation. Hypoxia on 
the other hand inactivates the PHDs and in turn activates the translocation of HIF1 into 
the nucleus and transcription of its more than 200 target genes responsible for energy 
metabolism, cell differentiation, migration and apoptosis (Ong SG and Hausenloy DJ, 
2012). HIF1 activation promotes a metabolic shift to glycolysis as well as altered 
transcriptional responses in differentiating T cells (via regulation of the nuclear hormone 
receptor RORγt and the transcriptional regulator FOXP3), creating an environment 
favorable for the differentiation to Th17 cells rather than Tregs (Barbi J, 2013; Dang EV, 
2011). 
 
2.2.2 Reactive oxygen species 
 
During mitochondrial electron transport chain (ETC) leakage of electrons occurs 
naturally reducing molecular oxygen only partially (one-electron reduction), thus 
generating the superoxide anion O
2-
, mainly at complexes I, II and III. Superoxide is then 
converted to hydrogen peroxide H2O2 by superoxide dismutase 2 (SOD2) into the 
mitochondria or by SOD1 in the cytosol. Superoxide, H2O2 and hydroxyl radical (OH) 
are reactive oxygen species (ROS) able to oxidize many different targets (lipids, proteins 
and DNA) because of their unstable chemical nature. ROS have been thought for decades 
to be unwanted by-products of cellular metabolism only involved in inducing damages to 
cellular components. This idea is now rapidly changing, as evidence of physiological 
roles of ROS as signals in the regulation of cellular processes are growing, showing that 
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finely tuned levels of ROS is necessary for the proper activation of specific cellular 
responses. 
Inflammation is one of those processes in which ROS production seems to have an 
important role. In 2011 West et al demonstrated that mitochondrial (mROS) production is 
positively regulated after triggering TLRs localized on the cytoplasmic membrane 
(TLR1/2/4) to enhance macrophages bactericidal activity, via the recruitment of 
mitochondria to phagosomes and increasing the production of mROS by the complex I of 
the ETC (West AP, 2011). The inhibition of the production of mROS results in decreased 
bactericidal activity of macrophages, both in vitro and in vivo. This effect is mediated via 
the interaction between TRAF6 (an adapter protein downstream of TLR signaling) and 
ECSIT (a protein implicated in assembly of complex I) (Vogel RO, 2007), leading to the 
production of ROS (West AP, 2011). In the same year, Bulua and co-workers showed 
that blocking mROS generation blunts the production of pro-inflammatory cytokines 
upon LPS treatment, thus decreasing LPS-induced MAPK activation (in MEFs cells and 
human PBMC), confirming a physiological role of mROS in orchestrating immune 
responses (Bulua AC, 2011). mROS play a role also in the adaptive immune system; 
indeed, Sena et al. have demonstrated that following TCR engagement there is a peak in 
mROS levels induced by the influx of calcium, and these ROS are necessary for the 
induction of IL-2 (Bulua AC, 2011). The authors showed that complex III is mainly 
responsible for the production of mROS in activated T cells. Indeed, T cells lacking a 
protein necessary for the functionality of complex III (Uqcrfs1) fail to induce IL-2 in 
vitro and are unable to expand antigen-specific T cells (both CD4
+ 
and CD8
+
 T cells) in 
vivo. The induction of IL-2 was rescued upon providing exogenous H2O2. They provide a 
partial mechanism to explain this effect, showing that cells with impaired complex III 
activity fail to induce the activation of NFAT1, which is required for IL-2 induction 
(Sena LA, 2013; Figure IV). 
36 / 231 
 
Calcium stored in the endoplasmic reticulum regulates mROS generation. Once it is 
released upon TCR engagement, calcium is taken up by mitochondria to fuel the Kreb 
cycle (Figure IV), thereby increasing the amounts of NADH and Krebs cycle 
intermediates. Mitochondrial calcium influx contributes to mROS generation in T cells, 
and succinate drives mROS generation in macrophages. ROS production is related to 
mitochondrial membrane potential (Suski JM, 2012). A reduction of membrane potential 
in CD8
+
 T cells decreases ROS production and increases the expression of the ROS 
detoxifiers catalase, glutathione peroxidase 4 and superoxide dismutase (SOD1 and 
SOD2). Th1 and Th17 cells with high membrane potential have increased expression of 
IFNγ or IL-17A and IL-17F, respectively (Sukumar M, 2016). 
Another source of mROS in T cells is the inner mitochondrial membrane enzyme 
glycerol-3-phosphate dehydrogenase (GPD2; Kamiński MM, 2012; Figure IV).  
Briefly, it was shown that TCR-triggered activation induces the glycolytic enzyme 
ADP-dependent glucokinase (ADPGK), which mediates the generation of the 
oxidative signal. This leads to excessive production of glycerol-3-phosphate, which is 
imported into mitochondria for biosynthesis of lipids or nucleotides. Here GPD2 
oxidizes glycerol-3-phosphate to dihydroxyacetone phosphate, providing electrons to 
hyper-reduce ubiquinone and subsequently support ROS release from mitochondria. 
Downregulation of ADPGK or GPD2 by small interfering RNA inhibits oxidative 
signal generation and induction of NF-κB-dependent gene expression (Kamiński MM, 
2012). 
This evidence provides that physiological levels of mROS are necessary to activate 
specific responses, particularly in the immune system, and its abrogation results in 
impairment of both the innate and adaptive immune function. Our knowledge of the exact 
mechanism of action of ROS still needs to be further expanded, but it is becoming clear 
that ROS production and redox signalling play a crucial role in orchestrating and 
37 / 231 
 
regulating cellular biology, highlighting that anti-oxidant therapies, in some instances, 
might be detrimental if they were to completely blunt basal levels of ROS. The question 
remains as to whether any additional signaling modules in the ETC can indeed modulate 
cytoplasmic or even extracellular pathways resulting in specific biological outcomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure IV - Mitochondrial ROS formation. TCR stimulation leads to Ca2
+
 release from 
endoplasmic reticulum, which in turn is taken up by mitochondria and stimulates the 
activity of TCA-cycle enzymes and flux through the ETC. Two are the possible sources 
of ROS: 1) mitochondrial complex III (Sena LA, 2013) and 2) mitochondrial GPD2 
(Kamiński MM, 2012). Both processes can generate O2- (Adapted from: Murphy MP, 
2013). 
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2.2.3 pH in inflammation 
 
pH is the molar concentration of protons in aqueous solution (pH = - log[H
+
] where 
[H
+
]). The pH scale, ranges from 0 (strongly acidic) to 14 (strongly basic) with a neutral 
pH in the middle of this scale. Blood is normally slightly basic, with a normal pH range 
of 7.35 to 7.45. The body uses different mechanisms to control the blood's acid-base 
balance. These mechanisms involve the lungs, kidney and buffer systems such as the 
production of bicarbonate. The importance of acid-base homeostasis in the regulation of 
physiological cellular responses has been recognized for many years (Lardner A, 2001).  
The pH affects the ionization state the carboxylic acid and the amino group leading to a 
change of the confirmation and function of the enzyme. This phenomenon might affect 
most cellular functions, including cAMP and calcium signalling, DNA and 
protein/enzyme synthesis as well as cell function and viability (Busa WB, 1994).  
A characteristic feature of the inﬂammatory site is local acidosis, which is partly due to 
the accumulation of lactate, the end product of glycolytic cells, and to the presence of 
bacterial metabolism products (Menkin V, 1956). 
There are a number of studies, mostly done in vitro, investigating extracellular pH effects 
on immune cells (Lardner A, 2001). Interestingly there is much evidence of an 
impairment of chemotaxis of leukocytes as well as a reduced cytotoxicity in 
macrophages, neutrophils, NK and CD8
+
 T cells at acidic pH. This phenomenon 
particularly takes place in the tumour microenvironment where the loss of immune cell 
effector functions, attributed to the low pH, would favor the tumour growth (Lardner A, 
2001; Nahas GG, 1971; Gabig TG, Simchowitz L, 1985; Geffner JR, 1993).  
In conclusion, the inflammatory microenvironment harbors several physical and chemical 
factors that influence the activity and function of infiltrating immune cells and might 
contribute to the progression and outcome of chronic inflammatory diseases.  
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2.3 Metabolites as signalling molecules 
 
The metabolic regulation of immune cells during health and disease has gained much 
attention as the active reconfiguration of immune cell metabolism enables these cells to 
sustain certain effector functions. The focus has been so far on the necessity of the main 
catabolic pathways glycolysis, fatty acid oxidation (FAO), the tricarboxylic acid (TCA) 
cycle, and oxidative phosphorylation as well as amino acid metabolism during activation, 
proliferation, differentiation, and function as a response to extracellular signals. 
It is now becoming increasingly evident that small-molecule intermediates of these 
metabolic pathways, besides their anabolic and catabolic function, can act as intra- and 
extracellular signals that influence the outcome of an immune response. The roles of 
metabolite signalling stretch from regulation of cytokine production via indirect effects 
on the cellular redox state (Kesarwani P, 2013) or direct interaction with transcription 
factors binding the specific cytokine promoter elements (Tannahill GM, 2013) and 
modulating the activity of transmembrane ion channels (Yu Y, 2014), to interference with 
cell migration and differentiation. Interestingly, a few G protein-coupled receptors, such 
as GPR81, that are activated by intermediates of metabolism have recently been 
identified, supporting a role for metabolites as extracellular signals (Cai TQ, 2008; He W, 
2004).  
Enhanced mitochondrial metabolism increases TCA intermediates and ATP, which can 
be used for posttranslational modification of proteins. In addition to the well-established 
phosphorylation (ATP) and acetylation of proteins (acetate), other TCA intermediates 
such as malate and succinate can be used to modify proteins through malonylation (Peng 
C, 2011) and succinylation (Zhang Z, 2011), respectively.  
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Succinate was also observed to stabilize HIF1 in LPS-treated macrophages and was 
associated with enhanced production of IL-1 (Tannahill GM, 2013). In addition, 
increased mitochondrial oxidation of succinate via succinate dehydrogenase (SDH) and 
an elevation of mitochondrial membrane potential combine to drive mitochondrial 
reactive oxygen species (ROS) production (Mills EL, 2016). Conversely, to succinate, 
itaconate exerts anti-inflammatory effects in vitro and in vivo by inhibiting SDH and 
regulating succinate levels in LPS activated macrophages. Itaconate was also found to 
limit the production of IL-1, IL-18, IL-6, IL-12, NO, and HIF1 (Lampropoulou V, 
2016). On the same line, a paper from the O’Neill lab, has recently described that 
itaconate is required for the activation of the anti-inflammatory transcription factor 
NRF2 by LPS in mouse and human macrophages. In particular the authors found that 
itaconate alkylates cysteine residues on the protein KEAP1, enabling NRF2 to increase 
the expression of downstream genes with anti-oxidant and anti-inflammatory 
capacities (Mills EL, 2018). 
The tryptophan metabolite 6-formylindolo[3,2-b] carbazole (FICZ) was shown to have 
very high affinity for AhR. Exposure of CD4 T cells to FICZ under Th17-polarizing 
conditions enhances Th17 development and functions (Veldohen M, 2009). 
The NAD
+
-dependent lysine deacylase SIRT5, which removes both succinyl and malonyl 
groups, targets GAPDH and alters its enzymatic activity, directly tying metabolites 
generated in the TCA cycle to a key glycolytic mediator (Nishida Y, 2015). Also, the 
glycolytic metabolite 1,3-bisphosphoglycerate (1,3-BPG) reacts with selected lysine 
residues to form 3-phosphoglyceryl-lysine (PGK), affecting protein structure and 
function (Moellering RE, 2013). PGK modifications inhibit glycolytic enzymes, and 
when cells are exposed to high glucose levels these modifications accumulate, redirecting 
glycolytic intermediates to other biosynthetic pathways (Moellering RE, 2013). Similarly, 
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modification of metabolite transporters and cytokine receptors by sugar moieties 
generated in central carbon metabolism (N-linked glycosylation or O-GlcNAcylation) 
can modify subcellular localization and activity, thereby affecting T cell functions 
(Swamy M, 2016). Furthermore, amino acids such as hypusine and citrulline are 
generated through polyamine and arginine metabolism, respectively, contributing to 
posttranslational modifications of proteins that influence cell function (Mowen KA, 
2014). How metabolites acting as signalling intermediates contribute to the indispensable 
role of mitochondrial metabolism during early T cell activation, and for the later 
engagement of glycolytic metabolism and effector functions, remains to be resolved. In 
the following section 2.3.1, I will describe in more details the role of lactate in 
inflammation. 
 
2.3.1  Lactate at the crossroad of metabolism, inflammation and cancer 
 
Lactate is a ubiquitous metabolite, described for the first time at the beginning of the 20th 
century (Baumann F, 2009). Lactate production occurs mainly in the cell cytoplasm in 
hypoxic conditions or as a consequence of high rates of glycolysis in proliferating cells 
via lactate dehydrogenase (LDH), an enzyme that also regenerates the reduced form of 
nicotinamide adenine dinucleotide (NADH) (Bonuccelli G, 2010). Activated immune 
cells as well as cancer cells rely on glycolysis more than oxidative phosphorylation 
(OXPHOS) as an ATP energy source even in presence of oxygen. This phenomenon is 
called the ‘Warburg effect’ (Haas R, 2016; Bonuccelli G, 2010; Colegio OR, 2014; Su S, 
2014) and therefore lactate is produced and accumulates in the extracellular space. 
Lactate can be present in solution either in its undissociated form (i.e., lactic acid) at low 
pH or as the ion salt (i.e., sodium lactate) at higher pH. 
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Our lab has found that depending on the acidification of the microenvironment, lactate 
exerts different effects on T cells. 
More specifically, lactic acid is able to modulate CD8
+
 but not CD4
+ 
T cell functions 
(Haas R, 2015), whereas sodium lactate regulates CD4
+
 T cell migration and cytokine 
production without affecting CD8
+
 T cells. Notably, progressive acidification of medium 
containing sodium lactate (10 mM) with HCl, which increases the availability of lactic 
acid, reduced the motility of CD8
+
 T cells. Importantly, neither the presence in the 
culture media of sodium lactate (10 mM) alone nor acidifying the culture media to pH 4.5 
with HCl alone had any effects on the motility of CD8
+
 T cells. These data suggest that 
the inhibition of CD8
+
 T cell motility by lactic acid requires the simultaneous availability 
of lactate and H
+
 in order to take place (Haas R, 2015). 
Lactate uptake and secretion requires the presence of transporters on the cell plasma 
membrane. Four members of the solute carrier 16a family of 12-membrane pass, proton-
linked monocarboxylic acid symporters i.e. monocarboxylic transporter 1 (MCT1, also 
known as SLC16A1), MCT2 (also known as SLC16A7), MCT3 (also known as 
SLC16A8), and MCT4 (also known as SLC16A3), and two sodium-coupled lactate 
cotransporters (SLC5A12, SLC5A8) have been described (Halestrap AP, 2012; Srinivas 
SR, 2005).  
These channels, although sharing conserved sequence motifs, show different affinity for 
lactate and other monocarboxylates (Hirschhaeuser F, 2011; Doherty JR, 2013). The 
transport depends on pH, intra- and extracellular lactate concentration as well as other 
substrates such as pyruvate, butyrate, etc. (Hirschhaeuser F, 2011; Doherty JR, 2013). 
More details about lactate transporters are given in the following section 2.3.2. 
Lactate accumulates in the tumour and inflammatory environment as a consequence of 
high glycolytic rate. Here lactate, flowing through specific transporters, can modify and 
redirect metabolic pathways. Indeed, a recent paper shows how lactate is taken up by 
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cells which use it to fuel the TCA cycle in human non-small-cell lung cancers (NSCLCs) 
(Faubert B, 2017). This allows biomass synthesis for tumour growth. Later in 2017, Hui 
et al. published another important piece of research in Nature journal demonstrating the 
role of lactate in fuelling the TCA cycle, both in normal and cancerous tissues. Analysis 
of the flux of circulating metabolites in mice showed that lactate is a major source of 
carbon for the TCA cycle. The infusion of [
13
C]-lactate, in fed and fasted mice, showed 
extensive labelling of TCA cycle metabolites in all tissues, and in lung and pancreatic 
tumours the contribution of circulating lactate to the activity of TCA cycle was greater 
than that of glucose. These findings demonstrate that lactate is a main feeder of the TCA 
cycle both in normal and cancerous tissues, as well as that glycolysis and TCA cycle are 
uncoupled at the level of lactate, thus allowing the independent regulation of the two 
processes, which also happen in a tissue-specific manner (Hui S, 2017). 
The effects of lactate are not only due to its ability to feed metabolic pathways, but also 
to its ability to trigger a signalling pathway via its receptor Gpr81. This is a surface 
lactate receptor involved in the regulation of lipolysis (Lafontan M, 2009) but also in 
cancer cell survival (Roland CL, 2014). Feng et al., recently showed that lactate, through 
Gpr81, is able to regulate the expression of PD-L1 in human lung cancer cells. PD-L1 is 
the ligand of PD1; a receptor expressed on the membrane of activated T cells, responsible 
for reduced proliferation and effector function of T cells, and a major target for cancer 
immunotherapy (Feng J, 2017). The authors show that lactate upregulates the expression 
of PD-L1 at a transcriptional level, in a Gpr81-dependent manner, and this upregulation 
leads to suppression of the effector function of T cells in co-culture experiments. Overall, 
the data point to a role for lactate in tumour escape from immune-surveillance. 
Different subsets of T cells show different metabolic requirements, with cytotoxic and 
effector T cells relying more on glycolysis for proliferation and cytokine production 
(Macintyre AN, 2014) and, conversely, Tregs being more dependent on oxidative 
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phosphorylation (OXPHOS) (Michalek RD, 2011; Gerriets VA, 2015). Recently, Angelin 
et al, demonstrated that FOXP3 is able to reprogram the metabolism of Tregs, allowing 
them to cope with low-glucose, high-lactate microenvironments. The authors found that 
the transcription factor FOXP3 promotes an increase in the oxygen consumption rate in 
induced Tregs (iTregs) and the production of ROS. Moreover, in the same paper the 
authors show that FOXP3 is able to suppress the activity of Myc by binding to its 
promoter and reducing the expression of Myc-dependent transcripts, most of which are 
involved in the regulation of glycolysis. FOXP3 was also able to regulate the direction of 
the LDH reaction in favour of the oxidation of L-lactate to pyruvate, leading to a 
decreased production of lactate by Tregs (as compared to conventional T cells). The 
authors also conclude that Tregs can sustain exposure to lactate much better than effector 
and cytotoxic T cells, which are instead impaired by it. Indeed, effector T cells require 
NAD
+
 replenishment to sustain the flux of glycolysis, but the excess of utilization of 
lactate by LDH depletes the available pool of NAD
+
, leading to a decreased glycolytic 
flux; Tregs instead possess higher levels of NAD
+
 and due to their intrinsic metabolism 
are less affected by reduced glycolysis. The authors discuss that this adaptation could be 
detrimental in the tumour microenvironment, where the high concentration of lactate may 
inhibit anti-tumour immunity without affecting the regulatory component, which can 
further dampen the immune response against the tumour (Angelin A, 2017).  
The role of lactate in immune disorders has been studied at a lesser extent than in cancer 
biology. Nonetheless, recent evidence demonstrate how lactate has a crucial role also in 
orchestrating immune responses in inflammatory conditions. In 2016, Peng et al. formally 
demonstrated that LDHA activity is necessary in CD4
+
 T cells to sustain aerobic 
glycolysis and express interferon-γ (IFNγ), thus allowing a proper differentiation in T 
helper 1 (Th1) cells. The authors found that genetic deletion of LDH isoform A (LDHA) 
in CD4
+
 T cells, reduced significantly glucose consumption, promoting a shift towards an 
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oxidative metabolism, and, more importantly, led to a reduction of IFNγ expression at a 
transcriptional level. The reduction of INFγ transcript (along with many others), was due 
to an overall decrease of histone acetylation. Histone acetylation requires acetyl-
coenzyme A (acetyl-CoA), but in the absence of LDHA, the consequent increased 
activity of the TCA cycle does not allow the export of acetyl-CoA from the mitochondria 
to the cytosol, reducing the pool of acetyl groups. These data demonstrate that LDHA 
regulates INFγ production in Th1 cells, through a fine-tuned epigenetic mechanism of 
histone acetylation coupled with the cellular metabolism (Peng C, 2011). 
Lactate is also able, as previously mentioned, to orchestrate immune cells functions. Acid 
lactate, for example, can suppress the proliferation and cytokine production of human 
cytotoxic T lymphocytes (CTLs) in cancer patients (Fischer K, 2007) as well as their 
migratory abilities (Haas R, 2015). This effect can be at least in part explained by lactate 
inhibition of TCR-triggered phosphorylation of JNK, c-Jun and p38, which is implicated 
in IFNγ production (Mendler AN, 2012). An inhibitor of monocarboxylate transporters, 
alpha-cyano-4-hydroxycinnamic acid, was reported to block lactate-augmented 
inflammatory gene expression and NF-kappaB activity in human macrophages, indicating 
that lactate transport through monocarboxylate transporters is required for macrophage 
effector functions (Samuvel DJ, 2009). 
On the same line, Colegio et al. show that tumour-associated macrophages (TAMs) 
‘sense’ metabolic changes typical of the tumour microenvironment. Cancer cells produce 
high amount of lactic acid, which is extruded in the intercellular space via MCT4. 
Released lactic acid is then taken up by tumour-associated macrophages via MCT1, 
promoting in turn macrophage polarization toward a TAM phenotype via the induction of 
HIF1 and arginase 2. These effects induce vascular endothelial growth factor (VEGF) 
production and ultimately support tumour growth in a feed forward loop (Colegio OR, 
2014). Notably, TNF secretion by human monocytes was found to be suppressed in the 
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presence of high lactate concentration and reduced pH in tumour microenvironment 
(Mendler AN, 2012). Neutralizing tumour acidity with bicarbonate monotherapy was 
able to impair the growth of some cancer types (Pilon-Thomas S, 2016). Similarly, 
another study pointed to the role of lactic acid in the TAM regulation of the epithelial-to-
mesenchymal transition (Su S, 2014). 
Besides MCTs, proton-sensing GPCRs such as T cell death-associated gene 8 (TDAG8) 
have been shown to be important for the modulation of T cells in an acidic tumour 
environment and during inflammation (Pilon-Thomas S, 2016; Ishii S, 2005).  
Targeting lactate transporters has become a promising therapeutic avenue in oncology. A 
recent study found that blocking the lactate transporter MCT1 reduced the proliferation of 
breast cancer cells co-expressing MCT1 and MCT4 (Hong CS, 2016) and reduced HIF1 
induced angiogenesis in cervix squamous carcinoma (Sonveaux P 2008; Sonveaux P, 
2012). On the other hand, other authors showed that lactate mediated angiogenesis is 
independent of HIF1 but is due to direct binding to NDRG3 during hypoxia. This event 
leads to Raf/ERK1/2 signalling pathway activation and promotes proliferation and 
angiogenesis (Lee DC, 2015). LDH, the enzyme that converts pyruvate to lactate, is 
increased in tumour cells (Fantin VR, 2006; Husain Z, 2013). A decreased frequency of 
myeloid-derived suppressor cells (MDSCs) was observed in the spleens of mice carrying 
LDHA-depleted tumours. NK cells isolated from LDH-A-depleted tumours had improved 
cytolytic function. The addition of exogenous lactate increased the frequency of MDSCs 
generated from murine bone marrow cells and inhibited cytolytic function of both human 
and murine NK cells in vitro. This reduction of NK cytotoxic activity was accompanied 
by lower expression of perforin and granzyme. Therefore, tumour-derived lactate hinders 
NK cell-mediated responses directly via inhibition of cytolytic function as well as 
indirectly by increasing the numbers of MDSCs that inhibit NK cytotoxicity (Husain Z, 
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2013). This evidence is also supported by the recent paper by Brand et al showing that 
lactate leads to tumour immune escape by inhibiting the function and survival of T and 
NK cells (Brand A, 2016). On the same line, another study supports the role of LDHA in 
tumour maintenance (Fantin VR, 2006). Knocking down LDHA by short hairpin RNAs 
resulted in a reduced ability of tumour cells to proliferate under hypoxic conditions. This 
phenomenon was accompanied by increased mitochondrial respiration and decrease of 
mitochondrial membrane potential. The tumourigenicity of the LDHA-deficient cells was 
severely diminished, and this phenotype was reversed by complementation with the 
human LDHA (Fantin VR, 2006). 
Lactate has been proven to be important also for the physiology of the brain, through the 
astrocyte-neuron lactate shuttle (ANLS). This lactate exchange was first described in 
1994 and highlights the existence of lactate-producing cells (astrocytes) and lactate-
consuming cells (neurons): in this model, the neurotransmitter glutamate released in the 
synapse triggers glucose uptake and therefore lactate production by astrocytes; lactate so 
produced is then utilized by neurons as a source of energy (Pellerin L, 1994; Magistretti 
PJ, 2018). 
Taken together, it is clear that lactate is not just a metabolic end-product, but rather a 
proper source of carbon and, more importantly, a signal that affects the behavior and the 
differentiation of many different cell types. 
 
2.3.2 Lactate and autoimmunity 
 
Lactate regulates many homeostatic functions. For example, it fuels gluconeogenesis in 
the liver and oxidative metabolism in the brain (Cornell NW, 1973; Pellerin L, 1994). 
Interestingly, in T cells, lactate acts as an immunomodulatory molecule able to control 
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their migratory capacity and effector functions (Haas R, 2015). While in tumour cells, 
lactate plays a key role in promoting their migration and expansion, in activated T cells 
isolated from healthy volunteers lactate activates a stop migration signal inside the 
inflamed tissue. This is due to the interaction of sodium lactate and lactic acid with the 
transporters SLC5A12 and SLC16A1, respectively, which are selectively expressed on 
the surface of CD4
+
 and CD8
+ 
subsets (Haas R, 2015). Sodium lactate-mediated 
inhibition of T cell migration is regulated via lactate interference with the glycolytic 
pathway (Haas R, 2015; Droge W, 1987). Indeed, CD4
+
 T cells, in the presence of 
sodium lactate, display a downregulation of glycolytic enzymes such as HK1. Lactate is 
also involved in the production of IL-17 and plastic acquisition of Th17 features in the 
inflamed site. In 2011, Yabu et al. showed how lactic acid enhances the production of IL-
23/IL-17 by CD4
+
 T cells, acting as a pro-inflammatory signal (Yabu M, 2011, Shime H, 
2008). More recently, in our lab Haas et al. demonstrated that sodium lactate is able to 
modulate effector T cells function, up-regulating the production of IL-17 in CD4
+
 T cells. 
As mentioned at the beginning of this paragraph, lactate is also able to impair the 
migratory capabilities of CD4
+
 T cells, thus causing their entrapment in the site of 
inflammation. This finding has an important impact on the understanding of the role of 
lactate in the inflammatory site, such as the inflamed synovium in rheumatoid arthritis, 
where lactate may act as an inflammatory signal leading to the entrapment of CD4
+
 T 
cells and the stimulation of IL-17 production, thus sustaining inflammation. Interestingly, 
all these effects are mediated by a specific sodium lactate transporter, SLC5A12, 
expressed on the membrane of CD4
+
 T cells (Haas R, 2015). 
Therefore, it seems fair to conclude that lactate behaves as a pro-inflammatory signal in 
the context of inflammation, leading to the production of cytokines necessary for the 
differentiation of specific T cell subsets and regulating their ability to migrate. 
Physiological lactate concentration is in the range of 1.5–3 mM in blood and tissues of 
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healthy individuals via specific absorption systems in the kidney operated by SLC5A8 
and SLC5A12. However, lactate levels can rise up to10 mM in inflammatory pathologies 
(e.g. rheumatic synovial fluid) and even 30–40 mM in cancerous tissues (Haas R 2015; 
Colegio OR, 2014; Hirschhaeuser F, 2011). Accumulation of lactate in the synovial fluid 
of RA patients is the result of high synovial cells metabolic demand (Haas R, 2015). 
Even though there is not a clear correlation between lactate concentration in the synovial 
fluid and the disease activity, some authors found that synovial lactate measurement 
could be a reliable indicator for differentiating inflammatory arthritis (Gobelet C, 1984). 
On the same line, LDH isoenzymes were found higher in serum and synovial fluid of RA 
compared to osteoarthritis (OA) patients (Pejovic M, 1992) and LDH activity was found 
increased in RA synovial tissues compared to healthy controls (Lindy S, 1971). 
Moreover, a positive correlation between LDH-A, high lactate levels and tumour 
progression has been widely documented in various tumours.  
Due to the ‘emerging’ role of lactate in the field of inflammation, lactate transporters are 
gaining much attention as novel therapeutic targets. In this regard, it has been recently 
found that monocarboxylate lactate transporter 4 (MCT4) is up-regulated by RA synovial 
fibroblast (RASFs) compared to osteoarthritis (OA) SF (Fujii W, 2015). The silencing of 
MCT4, by inducing apoptosis of synovial cells, inhibited the proliferation of RASFs and 
was able to reduce the severity of arthritis in mice with collagen-induced arthritis (CIA) 
(Fujii W, 2015).   
RA synovitis is characterized by distinctive histological patterns. In a 40% of RA patient 
immune cells can be found spatially grouped into follicular structures which can acquire 
features of SLO with high-endothelial venules (HEV), T/B-cell segregation, autoantibody 
production and follicular-dendritic cell (FDC)-networks. These structures, which develop 
in the inflammatory sites outside the SLO, are called ectopic lymphoid-like structures 
(ELS) (more details in section 2.5.1).  
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Although the mechanisms that are responsible for the preferential accumulation of 
autoreactive B and T cells in ELS are not fully understood, a direct role has been 
proposed for Epstein–Barr virus (EBV) and IL-17 production by Th17 cells in the 
development of autoimmunity (Pitzalis C, 2013; Pitzalis C, 2014; Croia C, 2013; Humby 
F, 2009). The rheumatoid synovial environment is paradigmatic of all the lactate-induced 
changes in T cells, including entrapment, IL-17 secretion and loss of antigen 
responsiveness (Haas R, 2015). Our group has recently found that SLC5A12 is highly 
expressed in human RA synovial tissues (ST). Strikingly, its levels significantly 
increased in correlation with the T cell score and with the formation of ELSs which are 
rich in IL-17 (Haas R, 2015; Peters A, 2011; Jones GW, 2015; Jones GW, 2016), thus 
suggesting a possible role of lactate/SLC5A12-induced metabolic signalling network in 
promoting chronic inflammation in RA. I will discuss more in depth about the role of 
lactate in the pathogenesis of RA in the section 2.5 and chapter V. 
The abundance of lactate in inflammatory sites is responsible, at least in part, for their 
acidity and hypoxia. Indeed the lactate signalling and subsequent biologic responses 
appear to be functionally coupled to the HIF1α-induced metabolic reprogramming, by 
employing NDRG3 as critical link (Lee DC, 2015). Indeed, it promotes the switch 
towards a Th17 phenotype while inhibits regulatory T cell differentiation (Shi LZ, 2011). 
This might explain a possible mechanism through which lactate enhances IL-17 
production during hypoxia.  
Taken together lactate plays an important role in inducing and promoting inflammation 
and in the modulation of immune cell functions. Targeting lactate transporters, LDH, and 
HIF1 may represent a novel therapeutic intervention in autoimmune and inflammatory 
diseases elicited by pro-inflammatory T cells. 
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2.3.3 Classification of lactate transporters 
 
Lactate flux in and out of the cells is facilitated by transporters, which are classified in 
monocarboxylate transporters (MCTs) and sodium-coupled transporters (SMCTs). MCTs 
include a family of 14 transmembrane proteins encoded by the SLC16A gene family. 
According to the Milton Saier classification (http://www.tcdb.org), MCTs belong to the 
monocarboxylate porter (MCP) family, which in turn is part of the facilitator superfamily 
(MFS). MCTs have been identified in all eukaryotic organisms and can transport a wide 
variety of substrates (Perez-Escuredo J, 2016; Table 1).  
MCT1-4 are proton-linked transporters responsible for transport of several 
monocarboxylate metabolites, such as pyruvate, L-lactate and ketone bodies (acetoacetate 
and D-β-hydroxybutyrate) together with a proton across the plasma membrane (Halestrap 
AP, 1999; Halestrap AP, 2004). Other identified MCTs are MCT8, which shows high 
affinity for the thyroid hormones T3 and T4, and MCT10/TAT1, a transporter of 
aromatic amino acids (Halestrap AP, 2004; Visser WE, 2011). MCT6 has been reported 
to facilitate the proton-linked transport of bumetanide (Murakami Y, 2005). MCT7 has 
been implicated in the export of ketone bodies by hepatocytes (Hugo SE, 2012).  
MCT9 has been identified as a sodium- and pH-independent carnitine efflux transporter 
when it was expressed in Xenopus oocytes injected with [
3
H]-carnitine (Suhre K, 2011). 
The substrates and functions of the other MCT family members are yet not known. 
MCTs are expressed in a wide range of tissues (such as brain, skeletal muscle, heart, 
bowel and liver) and display many physiological functions. In particular, they play a 
pivotal role in the control of the central metabolism of glucose, gluconeogenesis, 
activation of T-lymphocytes, spermatogenesis, pancreatic β cell activity, thyroid hormone 
metabolism and drug transport (Perez-Escuredo J, 2016). 
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Among others, MCTs are important regulators of intracellular lactate and pH. Indeed, 
highly glycolytic cells, such as during inflammation or tumours, utilize MCT transporters 
to export lactate. 
Lactate is one of the main substrates of MCT1–4. This metabolite is generated from 
pyruvate (produced from glycolysis and glutaminolysis) during lactic fermentation. In 
most normal tissues where lactate is produced, MCT1 is responsible for its export across 
the plasma membrane in to the extracellular space (Halestrap AP, 2004, Halestrap AP, 
2012).  
Lactate can be taken up from the extracellular space and used as a substrate to fuel 
metabolic pathways such as lipogenesis, gluconeogenesis, TCA cycle and oxidative 
phosphorylation (OXPHOS) (Perez-Escuredo, 2016; Faubert B, 2017). Cells that utilize 
lactate may express different MCTs depending on tissues and species (Halestrap AP, 
2004; Bonen A, 2001; Sonveaux P, 2008; Van Hée VF, 2015; Huang CK, 2017). 
In many cancer cells with an oxidative metabolic fingerprint, MCT1 is the most 
expressed MCT isoform (Sonveaux P, 2008; Kennedy KM, 2013). However, in 
glycolytic cancer cells and other specific tissues such as white muscle fibres and 
astrocytes, MCT4 is expressed at higher level than MCT1 and mediates lactate export 
(Ullah MS, 2006; Sonveaux P, 2008; Baltazar F, 2014). Accordingly, there is increasing 
evidence in support of the shuttling of this metabolite between cells with different 
metabolic behaviors within the same tissue. Such phenomenon has been described in the 
skeletal muscle where glycolytic/white fibres export lactate through MCT4 and 
oxidative/red fibers import lactate through MCT1 to fuel the TCA cycle (Juel C, 1999). A 
similar mechanism has been proposed to account for a metabolic symbiosis between 
glycolytic/hypoxic cancer cells and oxidative/oxygenated cancer cells in tumours 
(Sonveaux P, 2008). Notoriously in the brain, glycolytic oligodendrocytes and astrocytes 
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export lactate through MCT1 and MCT4 to fuel oxidative neurons expressing MCT2 
(Brooks GA, 2009; Pellerin L, 2012; Funfschilling U, 2012; Saab AS, 2013).  
In contrast to MCTs, which function as H
+
-coupled electroneutral transporters, SMCTs 
function as Na
+
-coupled electrogenic transporter. The transport process is electrogenic as 
more than 1 Na
+
 is transported per transport cycle with a Na
+
/monocarboxylate substrate 
ratio of ≥ 2. Two members of the sodium-coupled monocarboxylate transporter family 
(SMCT) have been identified so far, the high-affinity transporter SMCT1 (SLC5A8) and 
the low-affinity SMCT2 (SLC5A12) (Rodriguez AM, 2002; Srinivas SR, 2005). The 
SLC5A8 gene was originally identified from a library of kidney cDNA as a close 
structural relative of the human Na/I symporter (SLC5A5) (Rodriguez AM, 2002). Other 
than in the kidney, SMCT1 has been subsequently detected in intestine, salivary gland, 
thyroid gland, brain, and retina (Ganapathy V, 2008). Substrates of SMCT1 are similar to 
those of MCTs (Gopal E, 2005; Morris ME and Felmlee MA, 2008). SMCT1 mediates 
the transport of monocarboxylic acids such as lactate, pyruvate, propionate, butyrate, 
nicotinate, and short-chain fatty acids (Table 2). 
The affinity of the transporter for these monocarboxylates is quite high, with a Michaelis 
constant in the range of 200–400 μM.  
Less is known about SMCT2; mRNA expression of SMCT2 was detected in kidney, 
small intestine, and skeletal muscle and to a lesser level in brain and retina. Functional 
characterization of SMCT2 suggested substrate specificity similar to that of SMCT1. 
However, the affinities of SMCT2 for monocarboxylate substrates are approximately 35- 
to 80-fold lower than those of SMCT1 (Srinivas SR, 2005). 
In the kidney, SMCT1 is expressed in the apical membrane of tubular epithelial cells in 
the S2-S3 proximal tubule segments. Here SMCT1 is involved in renal reabsorption of 
lactate and pyruvate in a sodium-dependent transport (Gopal E, 2007b; Ganapathy V, 
2008; Barac-Nieto M, 1980; Yanase H, 2008). Indeed, SLC5A8-deficient or knockout 
54 / 231 
 
mice exhibit increased urinary excretion of lactate (Frank H, 2008). Renal SMCT2 is 
localized at the brush border with higher expression in the initial part of the proximal 
tubules and gradually decreasing toward the S3 segment. Thus, the proximal convoluted 
tubules provide low and high affinity transporters in the upper and lower proximal 
tubules, respectively. 
In the brain, SMCT1 exhibits a neuron-specific distribution and may mediate cellular 
uptake of lactate and ketone bodies, the primary energy substrates of neurons (Martin 
PM, 2006), while SMCT2 is specifically expressed by astrocytes. Besides the 
physiological functions, several reports suggested a tumour-suppressing role for SMCT1. 
High frequency of aberrant methylation or down-regulation of the SLC5A8 gene has 
been observed in human colon cancer, papillary thyroid carcinomas, pancreatic cancer, 
prostate tumour, acute myeloid leukemia, and glioma formation (Ganapathy V, 2008; 
Park JY, 2008, Li H, 2003).  
In the bowel, SLC5A8 is expressed in the lumen-facing apical membrane of colonic and 
intestinal epithelial cells, while SLC5A12 is expressed primarily in the small intestinal 
tract (Iwanaga T, 2006; Gopal E, 2007).  
Very recently, these transporters have been also linked with the function of immune cells. 
Interestingly, SLC5A12 has been found expressed by human and mice lymphocytes. In 
particular, it was found that SLC5A12 is selectively expressed on the surface of CD4
+
 but 
not of CD8
+
 T cells (Haas R, 2015; Haas R, 2016). Whether or not immune cells express 
SLC5A8 is still unknown.  
 
2.3.4 Lactate transporters in cancer and autoimmunity 
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MCTs, especially MCT1 and MCT4, are widely expressed in a variety of immune and 
cancer cells. In the tumour microenvironment, cancer cells produce high amount of 
lactate, which is extruded in the intercellular space via MCT4. Released lactate is then 
taken up by macrophages via MCT1, promoting their polarization toward a TAM 
phenotype via the induction of HIF1 and arginase 2. These effects induce neo-
angiogenesis, via vascular endothelial growth factor (VEGF) production, and ultimately 
promote tumour growth (Colegio OR, 2014; Figure V).  
MCT1 expression has been reported in a variety of human malignancies including head 
and neck, lung, stomach, colon, prostate and cervix cancers, as well as gliomas 
(Sonveaux P, 2008; Kennedy KM, 2010; Pinheiro C 2012; Miranda-Goncalves V, 2013; 
Afonso LL, 2015). MCT1 has also been proposed to be the most important isoform 
responsible for lactate transport across the plasma membrane in breast and bladder 
cancer, non-small cell lung carcinomas (NSCLC) and ovarian carcinomas (Afonso LL, 
2015).  
MCT4 is also widely distributed in different cancer types. Its expression has indeed been 
reported in breast, colon, bladder, and prostate cancers, as well as in cancers of the 
gynecologic tract and gliomas (Pinheiro C, 2012; Miranda-Goncalves V, 2013; Afonso 
LL, 2015).  
Recently, Pertega-Gomes and Baltazar (Pertega-Gomes N, 2014) reported a correlation 
between the expression of MCT1, MCT2 and MCT4 and the different stages of prostate 
cancer progression. MCT1 and MCT2 would play a role in tumour maintenance, whereas 
MCT4 would increase tumour aggressiveness. MCT2 was also proposed as an interesting 
biomarker for prostate cancer (Pertega-Gomes N, 2014). In another study focused at 
NSCLC, Eilertsen et al. proposed MCT1 as a biomarker for prognostic and survival 
(Eilertsen M, 2014). The co-expression of GLUT1 and MCT1 and of GLUT1 and MCT4 
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was found to be a negative prognostic factor associated with poor disease-specific 
survival. 
MCT2 and MCT4 show a high intracellular expression. This suggests a possible role of 
these transporters in mediating lactate and/or pyruvate transport across the membranes of 
intracellular vesicles or organelles (Baltazar F, 2014; Afonso LL, 2015).  
Lactate transporters have been described in inflammatory sites such as rheumatoid 
arthritis (RA) synovium (Haas R, 2015; Pucino V, 2018; Figure V). 
Unlike in tumours where lactate plays a key role in promoting cancer cell migration and 
growth, in inflammatory sites lactate activates a stop migration signal leading to local 
entrapment of T cells (Haas R, 2015; Figure V).  
This phenomenon is due to the interaction of sodium lactate and lactic acid with the 
transporters SLC5A12 and SLC16A1, which are selectively expressed on the surface of 
CD4
+
 and CD8
+
 subsets, respectively (Haas R, 2015). Sodium lactate-mediated inhibition 
of CD4
+
 T cell migration is regulated via lactate interference of metabolic pathways 
(Haas R, 2015; Droge W, 1987). Sodium lactate via SLC5A12 prompts CD4
+
 T cells to 
start producing higher amounts of pro-inflammatory cytokines, in particular IL-17A, 
while lactic acid causes impairment of CD8
+
 T cell-mediated killing through SLC16A1 
(Haas, 2015; Fisher K, 2007; Mendler AN, 2012). All these events promote T cell 
retention in the inflammatory sites and exacerbate the process of chronic inflammation 
(Haas R, 2015). 
Similar to cancer cells, highly proliferating RA synovial fibroblast (RASFs) express high 
levels of MCT4, thus promoting synovial fluid acidification (Fujii W, 2015). Silencing of 
MCT4 led to inhibited proliferation of RASFs and reduced the severity of arthritis in the 
mouse model of collagen-induced arthritis (CIA) (Fujii W, 2015). On the same line, other 
authors found that MCT4 is required for macrophage activation upon TLR2 and TLR4 
stimulations. MCT4 knockdown led to enhanced intracellular accumulation of lactate and 
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decreased glycolysis in LPS-treated macrophages reducing their active response during 
inflammation (Tan Z, 2015). This evidence suggests a potential role of lactate transporter 
inhibitors in the therapy of RA. Lactate transporter tissue expression and function is 
shown in Table 1 and 2. 
 
 
 
 
Figure V - Accumulation of lactate occurs in the inflamed tissue and in the tumour 
microenvironment where it promotes chronic inflammation and tumour growth. A) 
During the inflammatory process immune cells sense (via specific transporters) and 
respond to the high levels of lactate that is produced by endothelial and epithelial cells as 
well as by the infiltrating immune cells, which all consume the available glucose. The 
sodium lactate transporter SMCT2 (SLC5A12) and the lactic acid transporter MCT1 
(SLC16A1) are expressed by CD4
+
 and CD8
+
 T cells, respectively. MCT4 is expressed 
by fibroblasts and macrophages; the latter also display high levels of MCT1. Through 
these transporters, lactate modulates immune cell functions. In particular, lactate 
promotes fibroblast proliferation as well as macrophage (Mproliferation and 
activation. Lactate also inhibits T cell motility thus causing T cell entrapment in the 
inflamed tissue. There, in response to lactate CD4
+ 
T cells produce higher amounts of IL-
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17 and CD8
+
 cytotoxic activity is affected. Overall, these events promote chronic 
inflammation. B) Cancer cells express high levels of MCTs and release high amount of 
lactate in the tumour microenvironment, as the product of their pronounced glycolytic 
metabolism, which leaves infiltrating immune cells reliant on carbon sources other than 
glucose for their metabolism. There, lactate has an effect on wide range immune cell 
functions. It induces the switch of macrophages to an M2 phenotype via the transporters 
MCT1 and MCT4. It also promotes T cell differentiation to the Treg phenotype while 
suppressing Teff functions (i.e. cytokine production, cytotoxicity), thus leading to 
enhanced tumour growth (Adapted from: Pucino V, 2018).  
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Table 1 - MCTs transporters (Adapted from: Pucino V, 2018) 
 
 
  MCT 
transporter 
Common 
name 
Substrate Distribution 
SLC16A1 MCT1 Lactate, pyruvate, 
ketone bodies 
Ubiquitous 
SLC16A2 MCT8 T2, rT3, T3, T4 Ubiquitous 
SLC16A3 MCT4 Lactate, ketone 
bodies 
Skeletal muscle, chondrocytes, leucocytes, testis, 
lung, brain, ovary, placenta, heart,  leucocytes 
SLC16A4 MCT5 N/A 
 
Brain, muscle, liver, kidney, lung, ovary, 
placenta, heart 
SLC16A5 MCT6 Bumetanide 
probenecid 
nateglinide 
Kidney, muscle, brain, heart, pancreas, prostate, 
lung, placenta 
SLC16A6 MCT7 Ketone bodies Liver, brain, pancreas, muscle, prostate 
SLC16A7 MCT2 Pyruvate, lactate, 
ketone bodies 
High expression in testis, moderate to low in 
spleen, heart, kidney, pancreas, skeletal muscle, 
brain and leucocytes 
SLC16A8 MCT3 Lactate Retinal pigment epithelium, choroid plexus 
SLC16A9 MCT9 Carnitine 
 
Endometrium, testis, ovary, breast, brain, kidney, 
spleen, retina 
SLC16A10 MCT10 N/A 
 
Kidney (basolateral), intestine, muscle, placenta, 
heart 
SLC16A11 MCT11 N/A Skin, lung, ovary, breast, lung, pancreas, retinal 
pigment epithelium, choroid plexus 
SLC16A12 MCT12 N/A Kidney, retina, lung testis 
SLC16A13 MCT13 N/A Breast, bone marrow stem cells 
SLC16A14 MCT14 N/A Brain, heart, muscle, ovary, prostate, breast, 
lung, pancreas liver, spleen, thymus 
60 / 231 
 
Table 2 - SMCTs transporters (Adapted from: Pucino V, 2018)
HUGO 
nomenclature 
Common 
name 
Function Distribution 
SLC5A1 SGLT1 Na
+
/glucose or 
Na
+
/galactose 
 
Gastrointestinal tract, liver, kidney, male tissues 
SLC5A2 SGLT2 Na
+
/glucose Kidney, male tissues 
SLC5A3  SMIT1 Na+/myoinositol 
 
Ubiquitous 
SLC5A4 SGLT3 Glucose-sensitive 
Na
+
-channel 
 
Gastrointestinal tract 
SLC5A5 NIS Na
+
/iodide 
 
Gastrointestinal tract, endocrine tissues, female 
tissues 
SLC5A6 SMVT Na
+
/biotin or 
Na
+
/pantothenate 
 
Ubiquitous 
SLC5A7 CHT1 Na
+
/Cl−/choline 
 
Low expression  in gastrointestinal tract, kidney, 
endocrine tissues, female and male tissues 
SLC5A8 SMCT1 Na
+
/monocarboxylate 
 
Intestin, kidney (apical membrane of tubular 
epithelial cells), brain, salivary gland, thyroid 
gland 
SLC5A9 SMT Na
+
/mannose 
 
Gastrointestinal tract 
SLC5A10 N/A Unknown 
 
Kidney 
SLC5A11 SMIT2 Na
+
/myoinositol 
 
Gastrointestinal tract, kidney, female tissues, brain 
SLC5A12 SMCT2 Na
+
/monocarboxylate Small intestin, kidney, brain, retina, male tissues,  
lymphoid organs,  leucocytes 
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2.4 Crosstalk between immunity and metabolism 
 
Immune cells are able to respond to inflammatory stimuli by switching from a quiescent 
to an activated status. This phenomenon is mostly regulated by receptors and 
transcription factors, which determine changes in the expression of large numbers of 
genes and results in the acquisition of new functions. Immune cells acquire the capability 
to produce cytokines, lipid mediators and metabolites as well as the ability to proliferate, 
differentiate into specialized subtypes and migrate to target tissues. 
All these functions require the involvement of metabolic pathways. In the last few years, 
there has been an increasing appreciation of how metabolic pathways can modulate 
immune cell responses and be responsible of T cell fate (Pearce EL and Pearce EJ, 2013).  
 
2.4.1 T cell metabolism in health and autoimmunity 
 
Metabolic alterations have been shown to be associated with inflammatory disorders such 
as tumours and autoimmune diseases. Cancer, as well as immune cells, can switch their 
metabolic status according to the surrounding inflammatory environment. 
Effector T cells are key players of adaptive immunity and require high metabolic demand 
in order to activate, proliferate, migrate and differentiate. More specifically, they increase 
the glycolytic flux via the glucose transporter GLUT1, GLUT3 and the biosynthesis of 
proteins, nucleic acids and lipids that are essential for their functions (Palmer CS, 2015; 
Macintyre AN, 2014). On the other side quiescent T cells mainly rely upon fatty acid 
oxidation and mitochondrial respiration to fuel their energy demand (Buck MD, 2016; 
Pearce EL, 2013). 
62 / 231 
 
Memory T cells and/or chronically activated T cells do not proliferate and do not require 
high-energy demand. Indeed, they mainly utilize oxidative phosphorylation (OXPHOS) 
to produce the required amounts of ATP (Buck MD, 2016; Pearce EL, 2013). 
CD4
+ 
T cells can undergo a metabolic reprogramming according to their differentiation 
state. While effector T cells such as Th1, Th2 and Th17 increase glycolysis over 
mitochondrial metabolism, Tregs and memory T cells display a metabolic program 
involving mainly lipid oxidation and OXPHOS (Gerriets VA, 2012).  
Alterations of this delicate balance might lead to the establishment of a non-resolving-
inflammatory environment, chronic inflammation and autoimmunity (Nathan C, 2010). 
Molecular mechanisms underlining metabolic pathways in the immune system have 
mainly been studied in tumours; but their role in autoimmunity is still under investigation 
(Li Z, 2016). Evidence of metabolic alterations have been shown in mouse model and 
patients affected by autoimmune disorders. 
Splenocytes isolated from lupus prone mice preferentially convert glucose to CO2 
increasing mitochondrial metabolism for ATP synthesis (Wahl DR, 2010). Clinical, 
epidemiological and experimental data in humans have suggested that the pathogenesis of 
several immune-mediated disorders might involve factors, hormones and neural 
mediators that link metabolism and immune system (Procaccini C, 2014; Cantarini L, 
2016). For example, leptin, an adipocyte-derived hormone that control food intake and 
metabolism has been suggested to play an important role in the modulation of T cell 
functions (De Rosa V, 2015; Cassano S, 2015). Leptin production is altered in many 
autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), etc. (Procaccini C, 2014). 
Recently, also metabolites such as succinate, citrate, lactate, etc. - i.e. intermediate and 
end-products of metabolic pathways - have been shown to activate signalling resulting in 
the modulation of immune functions (Figure VI, Haas R, 2016; Haas R, 2015; O'Neill 
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LA, 2014).  
Metabolic pathway defects have been found in several autoimmune disorders. For 
instance, CD4
+
 T cells from patients with active SLE display a metabolic dysregulation in 
both humans and mice. Specifically CD4
+
 T cells from SLE patients exhibit enhanced 
glycolysis and mitochondrial metabolism (Yin Y, 2015; Mehta MM, 2015). Inhibition of 
these pathways with 2-deoxyglucose (2-DG, glycolysis inhibitor) and metformin 
(mitochondrial respiration inhibitor), respectively resulted in a reduced IFNγ production 
in vitro and normalized T cell metabolism and disease phenotypes in vivo. CD4
+
 T cells 
from SLE patients also display increased activity of the mammalian target of rapamycin 
(mTOR) (Yin Y, 2015). Rapamycin treatment ameliorated T cell function and prolonged 
survival in lupus-prone MRL/lpr mice and reduced disease manifestations and diseases 
activity in SLE patients (Fernandez DR, 2006; Fernandez D, 2009). There is evidence for 
a strong association between SLE and complement C1q deficiency. Interestingly, a recent 
study revealed that C1q, but not C3, restrains the response to self-antigens by modulating 
the mitochondrial metabolism of CD8
+
 T cells thus supporting the hypothesis that 
metabolic abnormalities in these cells play a key role in the pathogenesis of the disease 
(Ling GS, 2018). Conversely, another study carried on SLE, revealed reduced glycolysis, 
Krebs cycle, fatty acid  oxidation and amino acid metabolism in these patients compared 
to healthy controls. This dysregulation associates with dampened energy generation, high 
oxidative stress, inflammation, altered lipid profiles and a prothrombotic state (Wu T, 
2012). Furthermore, serum levels of total LDH, LDH1 and LDH2, were significantly 
higher in patients with diffuse proliferative lupus nephritis. Specifically the study showed 
a positive correlation between LDH isoforms with the SLE activity index, the renal 
pathologic score, and with the renal glomerular hyper-cellularity thus suggesting a 
possible role of LDH as novel biomarker for disease progression (Inoue T, 1986). 
A bioenergetic deregulation has also been associated to MS, a chronic inflammatory 
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disease, which leads to focal plaques of demyelination and tissue injury in the CNS.  
Studies on relapsing remitting MS patients have identified defects of mitochondrial 
respiratory chain complex IV [cytochrome c oxidase (COX)] in some active lesions 
(Mahad DJ, 2009). Furthermore, a metabolomic study has revealed changes in MS 
patient serum levels of different metabolites such as glutamine and glutamate and 
oxidants/antioxidants unbalance compared to healthy controls. Glutamate concentration 
correlated with disease severity and glutamine is critically required for naive CD4
+ 
T cell 
differentiation toward Th1 and Th17 pro-inflammatory T cells (Tavazzi B, 2011; Nakaya 
M, 2014). Studies on MS patients carried by Matarese’s group also revealed metabolic 
alterations (De Rosa V, 2015). A recent study from the same group shows how glycolysis 
is required for the expression of FOXP3, a master regulator in the development and 
suppressive function of regulatory T cells. MS subjects display impaired rates of 
glycolysis, FOXP3 expression deficiency that in turn determines altered peripheral Treg 
generation and function (De Rosa V, 2015). Conversely, other authors found increased 
glucose metabolism in the cerebrospinal fluid (CSF) as well as in the serum of MS 
patients with higher levels of lactate as compared to healthy controls. These parameters 
positively correlated and associated with disease progression and activity (Albanese M, 
2016; Regenold WT, 2008; Amorini AM, 2014). Metabolic dysregulation in RA will be 
discussed in the paragraph 2.5.3. 
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Figure VI - Metabolic pathways. Immune cells, i.e. T cells, use metabolic pathways 
[glycolysis, blue; tricarboxylic acid (TCA) cycle, red; fatty acid oxidation (FAO), green] 
in order to produce energy for their effector functions. Metabolic intermediates such as 
lactate and succinate are also produced. These are substrates for anabolic processes 
including lipid and nucleotide synthesis, but can also act as regulatory signalling 
molecules (Adapted from: Haas R, 2016). 
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2.4.2 Translational immunometabolism: metabolic comorbidities in 
autoimmune/rheumatic disorders 
 
Alteration of metabolic pathways in immune cells may in part explain the increase rate of 
metabolic complications in patients affected by autoimmune/rheumatic disorders 
especially cardiovascular diseases (CVD) and metabolic syndrome (MetS) compared to 
the healthy population. These events have a great effect on mortality (Medina G, 2018; 
Nurmohamed MT, 2015).  
The pathogenic factors involved are not yet fully understood. Metabolic syndrome 
(MetS), which includes insulin resistance, central obesity, dyslipidemia, and 
hypertension, may provide a link between accelerated atherosclerosis and inflammation 
in these diseases. Oxidative stress markers, thrombogenic or pro-inflammatory mediators 
released during the course of autoimmune rheumatic diseases may play a key role in the 
development in atherosclerosis, or metabolic disturbances frequently observed in these 
patients (Medina G, 2018; Nurmohamed MT, 2015). On the other side, pro-inflammatory 
molecules release by adipose tissue in the course of obesity can also potentiate the risk 
and the poor prognosis of rheumatic disorders (Nurmohamed MT, 2018; Procaccini C, 
2015). 
Obesity is linked to an increased risk of osteoarthritis (OA). Although mechanical factors 
can promote OA progression, the primary risk factors for OA onset are supposed to be 
body mass index (BMI) and fat tissue mass (Francisco V, 2018). Cytokines and 
adipokines, such as leptin, released by the adipose tissue have a pivotal role in the joint 
destruction in OA (Rosenbaum M 1996; J Ku JH, 2009). 
A link between SLE and MetS also exists (Katz P, 2011). The results are somehow 
controversial. In renal lupus, active inflammatory disease and damage are SLE-related 
factors that drive MetS development. The use of antimalarial agents appeared to be 
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protective in MetS development if started at early onset of the disease (Parker B, 2015). 
In another study, the frequency of MS was not significantly different from that of the 
control group, but almost half of the patients were found with this syndrome (Mobini M, 
2018). High incidence and variability of CVD risk factors was found in female lupus 
patients (Monção CSA, 2018).   
Ankylosing spondylitis (AS) has been associated with a risk of MetS. It has been reported 
that AS patients have higher risk of MetS and CVDs than in healthy controls. In 
particular, systolic blood pressure, triglyceride and LDL cholesterol were found 
significantly higher in AS pts than in controls; on the contrary, HDL cholesterol was 
lower (Malesci D, 2017). Overall MetS was found in higher in AS than controls, even 
after receiving anti-tumour necrosis factor (anti-TNF) therapy (Papadakis JA, 2009). 
Similar result were found in psoriatic arthritis patients (Haroon M, 2016). 
Several features of MetS, such as dyslipidemia, diabetes, hyperuricemia have also been 
reported, with higher prevalence in Sjögren's syndrome. Hypertriglyceridemia and 
diabetes were associated with a higher prevalence of extraglandular features, especially 
renal, liver, and vasculitic involvement (Ramos-Casals M, 2007). 
MetS has been shown in ANCA-associated vasculitis (AAV). MetS is associated with a 
more pro-inflammatory state in AAV and might increase the risk of developing a relapse 
of AAV (Petermann Smits DR, 2013). 
Finally, CVD is reported to be the primary cause of death in RA, which higher 
prevalence in RA than in the general population (Turesson C, 2004; Liang KP, 2010). 
High risk of metabolic syndrome has also been detected (Hallajzadeh J, 2017) thus 
suggesting that a metabolic dysregulation is present in these patients as discussed in the 
following section 2.5. 
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2.5 Rheumatoid arthritis 
 
RA is an autoimmune disease characterized by chronic synovial inflammation and 
hyperplasia (“swelling”), autoantibody production (rheumatoid factor and anti–
citrullinated protein antibody [ACPA]), cartilage and bone destruction (“deformity”), and 
systemic complications such as cardiovascular, pulmonary, psychological, and skeletal 
disorders. Progressive disability, systemic complications and early death are still a reality 
leading to socioeconomic costs and several unmet needs. Indeed, current conventional 
and biologic disease modifying therapies sometimes fail or produce only partial 
responses. Reliable predictive biomarkers of prognosis, therapeutic response, and toxicity 
are lacking (McInnes IB, 2011; Dennis GJr, 2014).  
Rheumatoid arthritis is a multifactorial disease involving a complex interplay among 
genotype and environmental triggers. Twin studies implicate genetic factors in 
rheumatoid arthritis, with concordance rates of 15 to 30% among monozygotic twins and 
5% among dizygotic twins. Patients who are positive for rheumatoid factor or ACPA also 
show an association with the human leukocyte antigen (HLA)–DRB1 locus. ACPA, are 
often detected in patients before the development of arthritis (Rantapää-Dahlqvist S, 
2003).  
Infectious agents (e.g., Epstein–Barr virus, cytomegalovirus, proteus species, and 
Escherichia coli) and their products (e.g., heat-shock proteins) as well as periodontal 
disease due to Porphyromonas gingivalis have been linked with rheumatoid arthritis 
(Kamphuis S, 2005; Sato K, 2017). 
Moreover, the gastrointestinal microbiome is now recognized to influence autoimmunity 
in mouse models of arthritis (Horta-Baas G, 2017). In this context, gut commensal 
segmented filamentous bacterium (SFB) was shown to have a role in promoting Th17 
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development and functions and promote autoimmunity in K/BxN mouse model of 
arthritis (Bradley CP, 2017). 
Why the loss of tolerance is associated with the onset of inflammation in the joint is still 
unclear (McInnes IB, 2011). 
RA synovitis is characterized by leukocyte infiltration in the synovial compartment and 
neo-angiogenesis due to the hypoxic environment. The increasing expression on vessels 
of adhesion molecules (including integrins, selectins, and members of the 
immunoglobulin superfamily) and chemokines enables cells to migrate in the inflamed 
site. Here, the insufficient lymphangiogenesis, which limits cellular egress, cytokines and 
local fibroblast activation, allows the buildup of synovial inflammation (Szekanecz Z, 
2009; Polzer K, 2008). 
There are several key players contributing to the arthritis pathobiology. T cells play a 
pivotal role in the pathogenesis of rheumatoid arthritis however direct targeting of T cells 
i.e. cyclosporine or T-cell–depleting therapeutics as well as abatacept (a fusion protein 
containing cytotoxic T-lymphocyte–associated antigen 4 and the FC fragment of IgG1 to 
disrupt antigen presentation by blocking T-cell costimulation) has shown limited or no 
efficacy (Panayi GS, 2006). 
There is an increasing interest in the role of type 17 helper T cells (Th17), a T cell subset 
that produces interleukin 17A, 17F, 21, and 22 and TNFα (Chabaud M, 1998; Miossec P, 
2009). This pro-inflammatory milieu sustains Th17 differentiation and suppresses 
differentiation and functionality of regulatory T cells, thus leading to activation of tissue-
resident fibroblasts and chondrocytes leading to bone and cartilage destruction (Genovese 
MC, 2010). 
Humoral adaptive immunity also displays an important role in rheumatoid arthritis. 
Synovial B cells are mainly localized in T-cell–B-cell aggregates; indeed, some tissues 
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develop ectopic lymphoid follicles (Seyler TM, 2005) whose function is still under 
investigation. 
 
2.5.1 Ectopic lymphoid structures 
 
Lymphoid tissues are classified into primary and secondary lymphoid organs. Primary 
lymphoid organs include the bone marrow and the thymus and are primarily responsible 
for the selection of naive B and T lymphocytes bearing highly diverse B and T cell 
receptors in their germline sequences. Secondary lymphoid organs (lymph nodes, spleen, 
mucosal-associated lymphoid tissues such as Peyer’s patches) regulate the recirculation 
of leukocytes and are critical for mounting high-affinity adaptive immune responses upon 
antigenic challenge (Pitzalis C, 2013; Pitzalis C, 2014). 
Tertiary lymphoid organs are defined as clusters of lymphomonocytic cells that form at 
sites of chronic inflammation. Hence, they are also known as ectopic lymphoid structures 
(ELSs) and they can acquire phenotypic features that are characteristic of secondary 
lymphoid organs (Humby F, 2009). 
Indeed, these structures show T and B cell segregation (B cell follicles surrounded by T 
cell rich areas). Furthermore, vascular structures with the appearance of high endothelial 
venules (HEVs) develop, and networks of stromal-derived follicular dendritic cells 
(FDCs) differentiate; these FDCs express the long isoform of complement receptor type 2 
(Cr2, also known as CD21), which contributes to the presentation of immune complexes 
necessary to generate activated B cells. Plasmablasts and plasma cells subsequently 
accumulate around the follicles of T cells and B cells. A considerable proportion of ELSs 
also display functional features of ectopic germinal centers, such as expression of the 
enzyme activation-induced cytidine deaminase (AID), also known as single-stranded 
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DNA cytosine deaminase and evidence of both in situ B cell affinity maturation and 
clonal selection (Bombardieri M, 2017). 
Immune cells recruited to the site of inflammation, in cross-talk with resident cells which 
are tissue-specific, exert an active role in the initiation of ELS development via the 
release of several chemokines such as CXCL13, CCL19, CCL21, and CXCL12 and their 
receptors CXCR5 (for CXCL13), CCR7 (for CCL19 and CCL21), and CXCR4 (for 
CXCL12) (Figure VII, Corsiero E, 2016). 
Cytokines such as IL-17, IL-21, IL-22, IL-23, and TNF, produced at the site of the 
inflammation, are also directly involved in ELSs formation (Figure VII, Jones GW, 
2016). In particular, IL-17 produced by a subset of podoplanin-expressing CD4 T cells 
has been associated with ELS formation in animal models of inducible ELS and the IL-
23/IL-17 axis has been recently linked with ELS formation in RA (Cañete JD, 2015). 
Another cytokine involved in ELSs formation is IL-22. Indeed, it was recently found that 
IL-22 is able to induce CXCL-13 by a subset of resident stromal cells expressing gp38 
(Barone F, 2015). 
Among CD4 T cell subsets, Tfh play a pivotal role in the germinal centre reaction, 
regulating B cell activation, antibody affinity maturation, and the expression of surface 
receptors such as inducible T-cell costimulator (ICOS) and programed cell death protein 
1 (PD1). They also express the transcription factor B cell lymphoma protein 6 (BCL6), 
which promotes the expression of CXC-R5 and represses other T-cell subset-specific 
transcription factors (Shulman Z, 2014; Liu D, 2015). IL-21 is the main cytokine released 
by Tfh. On B cells, IL-21/IL-21R interactions provide potent signalling for B-cell 
survival, proliferation, and differentiation (Zotos D, 2010). In addition, IL-21 has been 
shown to play a fundamental role in the function of ELSs formation (Linterman MA, 
2010).  
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Opposite to IL-17, IL-21 and IL-22, IL-27 exerts a negative regulation on ELSs 
formation. Indeed, it has been recently shown that IL27Rα−/− mice developed a more 
severe form of arthritis after immunization and multiple lymphoid aggregates forming in 
the inflamed synovial tissue (Jones GW, 2015). IL-27 can also restrict the expansion of 
Th17 cells and suppress secretion of IL-17, a cytokine associated also with survival and 
proliferation of B cells (Stumhofer JS, 2006; Jones GW, 2015). Concerning ELS 
development in human synovium, it has been observed that IL27 is inversely correlated 
with the degree of lymphocytic infiltration in the inflamed tissue as well as with the 
expression of IL17 and IL21 at mRNA level (Jones GW, 2015). Conversely a paper 
published by Batten et al who found that IL-27 supports germinal center function by 
enhancing IL-21 production and the function of T follicular helper cells (Batten M, 
2010). 
The formation of ELSs has been described in organ-specific autoimmune conditions, 
during solid tumourigenesis, in chronic infections and in graft rejection (Bombardieri M, 
2017). 
ELSs have been extensively studied in the synovium of patients with RA, salivary glands 
of patients with Sjögren syndrome as well as in the kidneys of patients with SLE and in 
the muscle of patients with dermatomyositis or polymyositis (Bombardieri M, 2017). 
In RA, the activation of resident synovial cells and the synovial microvasculature, 
together with the infiltration of immune cells from the peripheral pool, leads to chronic 
proliferative synovitis with the formation of the so called pannus, which directly damages 
cartilage and subchondral bone (McInnes IB, 2011). Advances in our understanding of 
the complex heterogeneity of the histopathology and the underlying molecular signatures 
have enabled the definition of at least three microstructural levels of organization 
(pathotypes) of synovial tissue in RA: follicular synovitis with the presence of aggregates 
of B cells and T cells that form ELSs (lymphoid pathotype, 40% of RA patients); a 
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diffuse pattern of infiltration with prevalent monocyte–macrophage infiltration (myeloid 
pathotype, 40% of RA patients); and a pauci-immune synovitis with scarce or no immune 
cell infiltration (fibroid pathotype, 20% of RA patients) (Figure VIII, Klimiuk PA, 1997; 
Manzo A, 2005; Dennis GJr, 2014; Pitzalis C, 2013; Takemura S, 2001).  
Although ELSs primarily develop within the sub-lining of the synovial tissue in patients 
with RA, they can also be detected at extra-articular sites (i.e. the lung and bone marrow) 
(Bugatti S, 2005; Rangel-Moreno J, 2006). ELSs in RA are characterized by the 
formation, by T cells and B cells, of discrete perivascular clusters, which can also be 
graded (G1, G2 or G3) according to the aggregate radial cell count (a central blood vessel 
surrounded by cell layers; Yanni G, 1992; Thurlings RM, 2008; Vos K, 2007). It is now 
generally accepted that ELSs form in approximately 40% of patients with RA, but this 
prevalence varies considerably depending on the site of the biopsy, the sampling 
technique (joint replacement versus arthroscopy versus ultrasound-guided biopsy), the 
stage of the disease, the treatments received by an individual patient, and the staining and 
scoring procedure (Manzo A, 2010).  
Taken together there is clear evidence that, in autoimmune diseases, ELS directly 
contribute to the maintenance of the immune response at the site of inflammation, hence 
participating in the local development of autoimmunity and tissue damage. The 
recognition that ELS development may play a key pathogenic role in autoimmunity and 
may be exploited as potential biomarker for disease evolution and response to therapy is 
gaining much attention (Pitzalis C, 2013). 
 
 
 
 
 
74 / 231 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure VII - Ectopic lymphoid structure (ELS) in autoimmune diseases. (A) 
Chemokines and cytokines involved in the formation and maintenance of ELS where the 
affinity maturation and clonal selection of autoantibodies toward specific autoantigens 
takes place. (B) Autoimmune diseases and the specific autoantigenes found associated 
with ELS formation (Adapted from: Corsiero E, 2015). 
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Figure VIII - Histological pattern of RA synovitis. Histomorphological features of RA 
synovitis. Three mm sections of paraffin embedded RA synovial tissues were stained 
with haematoxylin and eosin (H&E) and by immunohistochemisty (IHC) for B cells 
(CD20), T cells (CD3), macrophages (CD68) and plasma cells (CD138) (Adapted from: 
Pitzalis C, 2013). 
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2.5.2 Diagnosis of RA 
 
RA has a wide clinical spectrum ranging from mild joint symptoms to severe 
inflammation and joint erosion with systemic comorbidities which include include 
cardiovascular disease, osteoporosis, interstitial lung disease, infection, cancer, 
fatigue, depression, mental difficulties, and trouble working. The first classification 
criteria was proposed by the American College of Rheumatology (ACR) in 1956 and 
then revised in 1958 and 1987, and more recently a new classification criteria has been 
developed by the ACR and the European League Against Rheumatism (EULAR) in 
2010 (Table 4, Aletha D, 2010). For classification, diagnosis and treatments purposes, 
a patient with a score ≥ 6 is indicative of the presence of definite RA. This 
classification, compared to the earlier ACR 1987, includes also autoantibody status 
and acute phase response, showing a higher sensitivity but also a lower specificity, 
especially in patients aged ≥ 60 years (Berglin E, 2013). Once the diagnosis of RA is 
given, patients start treatment with conventional DMARDs such as metothrexate 
and/or sulphasalazine and/or hydroxychloroquine and/or corticosteroids. 
Disease Activity Score of 28 joints (DAS28) is widely used as an indicator of RA 
disease activity and response to treatment (Fransen J, 2009). Joints included are 
(bilaterally): proximal interphalangeal joints (10 joints), metacarpophalangeal joints 
(10), wrists (2), elbows (2), shoulders (2) and knees. When looking at these joints, 
both the number of joints with tenderness upon touching (TEN28) and swelling 
(SW28) are counted. The erythrocyte sedimentation rate (ESR) or C-reactive protein 
(CRP) are measured and the affected person makes a subjective assessment of disease 
activity on a scale between 0 and 100, where 0 is "no activity" and 100 is "highest 
activity possible" (Fransen J, 2009). Based on DAS28 a poor, moderate or good 
response to treatment is calculated with severe disease activity defined as a DAS28 of 
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> 5.1) and moderate disease activity (defined as a DAS28 of 3.2 to ≤ 5.1) (Table 5, 
Fransen J, 2009). The aim of the treatment is to reach a DAS28 ≤ 3.2, which is 
considered low disease activity and the therapy can be escalated accordingly. Patients 
with persistent high disease activity (DAS28 > 5.1) at 6 months from the disgnosis are 
commenced on biologic DMARDs according to National Institute for Clinical 
Excellemce (NICE) prescribing guidelines (https: 
//www.nice.org.uk/Recommendations/treat-to-target-strategy). Biologic DMARDs 
include etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab, which 
are all part of a class of drugs called tumour necrosis factor (TNF) inhibitors. Biologic 
DMARDs also include other agents with different targets, suc as anakinra (anti IL1 
receptor), abatacept (fusion protein composed of the Fc region of the immunoglobulin 
IgG1 fused to the extracellular domain of CTLA4), rituximab (anti CD20), and 
tocilizumab (anti IL6). Another group of DMARDs, called kinase inhibitors, includes 
tofacitinib. A biologic DMARD or a kinase inhibitor is often combined with 
methotrexate or other DMARDs to improve efficacy.  
Although the outcome and the obvious success of the current therapeutic approaches has 
significantly improved in recent years, RA remains a condition with large unmet clinical 
needs. Clinical studies have shown that achievement of treatment-free remission can be 
reached only by 9.4-15% of patients (van der Woude D, 2009). Additionally, 20-40% of 
the patients do not respond to the available therapeutics (Kremer JM, 2001; Taylor PC, 
2009).  
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Table 4 - 2010 ACR/EULAR classification criteria for rheumatoid arthritis 
 
 
 Score 
Joint involvement  
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least 1 small joint) 5 
Serology (at least 1 test result is needed for classification) 
Negative rheumatoid factor (RF) and anti citrullinated protein antibody (ACPA) 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or High-positive ACPA 3 
Acute-phase reactants (at least 1 test result is needed for classification) 
Normal CRP and normal ESR 0 
Abnormal CRP or abnormal ESR 1 
Duration of symptoms 
< 6 weeks 0 
≥ 6 weeks 1 
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Table 5 - EULAR response criteria based on DAS28 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Current DAS28 
DAS28 decrease from initial value 
> 1.2 > 0.6 and ≤ 1.2 ≤ 0.6 
≤ 3.2 Good response Moderate response No response 
> 3.2 and ≤ 5.1 Moderate response Moderate response No response 
> 5.1 Moderate response No response No response 
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2.5.3 Metabolic dysregulation in RA 
 
Metabolic alterations have been observed in several autoimmune diseases (Pucino V, 
2017; Cantarini L, 2017). A new field of study that investigates the interface and the link 
among immune response, nutrition, and metabolism has recently developed and many of 
the interactions between metabolic pathways and the immune system seem to be 
orchestrated by a complex network of soluble mediators derived from immune cells and 
adipocytes such as leptin and adiponectin (Procaccini C, 2015). An increasing number of 
human studies showed that adipocytokines could play a key role in the pathogenesis of 
RA but the results are still controversial. 
In this context, leptin, at the crossroad between metabolism and immunity, has been 
identified as a potential trigger for the breakdown of immune self-tolerance. Indeed, 
leptin is able to induce cell activation, pro-inflammatory cytokine secretion as well as 
production of autoantibodies and angiogenesis leading to autoimmunity and chronic 
inflammation (Procaccini C, 2015; Pucino V, 2014). In addition to leptin, other 
neuroendocrine factors are involved in the pathogenesis of autoimmune disorders 
(Procaccini C, 2014). 
Studies on RA patients have shown metabolic pathway alterations in these patients. 
Interestingly, some metabolism related enzymes such as enolase, aldolase and glucose-6-
phosphate isomerase have been described as autoantigens promoting autoimmunity in RA 
(Chang X, 2011). 
Proliferating cells, including lymphocytes, use aerobic glycolysis (Warburg effect) to 
quickly generate energy in the form of ATP. In particular, aerobic glycolysis is preferred 
over oxidative phosphorylation for its expedited production of energy and for the 
generation of necessary building materials to accommodate the increasing cell mass 
(Tsokos GC, 2016).  
81 / 231 
 
RA naive CD4
+
 T cells display a deficit in starting glycolysis in comparison to healthy T 
cells. In particular, these cells have a deficiency of 6-phosphofructo-2-kinase/fructose-
2,6-bisphosphatase (PFKFB3), a glycolytic regulator enzyme. This leads to a state of 
energy deprivation and a tendency towards senescence and defective autophagy. This 
glycolytic delay prompts RA CD4
+
 T cells to up-regulate glucose-6-phosphate 
dehydrogenase (G6PD) and shift their metabolic pathway towards the pentose phosphate 
pathway (PPP). These events lead to in the production of high amounts of NADPH 
(reduced form of nicotinamide adenine dinucleotide phosphate), ROS consumption and 
altered activation of ataxia telangiectasia mutated (ATM), a key enzyme involved in cell 
cycle. All these alterations result in a high cellular proliferation, a switch toward pro-
inflammatory CD4
+
 T cell subsets such as Th1 and Th17 and chronic inflammation 
(Yang Z, 2013; Yang Z, 2016). These abnormalities were reversible via replenishment of 
the ROS pool with the naphthoquinone menadione, inhibition of the synthesis of the ROS 
quencher glutathione, or blockade of glucose shunting into the PPP (Yang Z, 2013; Yang 
Z, 2016). 
ATP
 low
 pyruvate
 low
 NADPH
 high
 RA CD4
+
 T cells also display an excess synthesis of 
FAs (fatty acids) and cytoplasmic lipid droplet (LD) deposition. This resulted in an 
upregulated T cell locomotion program, high production of the podosome scaffolding 
protein TKS5, and ultimately a functional phenotype of hyper-motility. 
TKS5
hi
 RA T cells spontaneously formed actin- and cortactin-rich membrane ruffles, 
which empowered them to penetrate into non-lymphoid tissue and establish lasting 
inflammatory infiltrates. All these effects were restored after FA synthesis inhibitor 
treatment (Shen Y, 2017). 
FAS is essential for Th17 differentiation and functions in contrast of Treg cells, which 
rely on FA oxidation. Pharmacologic inhibition of acetyl-CoA carboxylase (ACC), a 
crucial FAS enzyme, was able to delay the disease and to reduce the severity of 
82 / 231 
 
experimental autoimmune encephalomyelitis (EAE). This suggests a potential role for 
FAS targets for immunomodulation (Berod L, 2014). 
If RA T cells display a deficit of glycolyis, synovial RA fibroblasts develop an intrinsic 
ability to employ glycolytic metabolism under metabolic stress. Indeed, glucose 
deprivation or glycolytic inhibitors such as such as 2-deoxy-D-glucose (2-DG), 
bromopyruvate (BrPa) and 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one, impaired 
synovial fibroblast cytokine secretion, proliferation, and migration as well as the disease 
severity in a mouse model of arthritis (Garcia-Carbonell R, 2010). In line with this 
evidence, the inducible isoform of hexokinase, HK2, which catalyzes the phosphorylation 
of glucose to G6P, the first committed step in glucose metabolism, was found highly 
expressed by RA synovial FLS in comparison to OA. Interestingly, after HK2 silencing, 
RA FLS were less invasive while the overexpression of HK2 enhanced the levels of 
MMP, IL6, and IL8 other then their migratory rate (Bustamante MF, 2018). These data 
were further confirmed in vivo in a mouse model of arthritis. The authors showed that the 
HK2 deletion in murine FLS ameliorates disease severity of arthritis. These data suggest 
a novel potential therapeutic target for RA (Bustamante MF, 2018). Altered metabolism 
in RA fibroblasts has also been associated to the hypoxic microenvironment typical of the 
inflamed sites. Specifically, it was found that hypoxia induced a downregulation of 
mitochondrial respiration and an increase of glycolysis in RA fibroblasts, which in turn 
promoted synovial invasive mechanisms (Biniecka M, 2016). This should support 
abnormal angiogenesis, cellular invasion and pannus formation (Biniecka M, 2014; 
Biniecka M, 2016). Altered mitochondrial respiration correlated with higher mtDNA 
mutations and ROS in RA compared to OA FLS (Da Sylva TR, 2005), and with elevated 
matrix metalloproteinase (MMP) expression and an invasive phenotype (Harty LC, 
2012). Another study, this time on macrophages, showed that RA mitochondria consume 
more oxygen, generated more ATP than healthy macrophages. This is due to 
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interorganelle connections with the endoplasmic reticulum, forming mitochondria-
associated membranes (MAM), which consist of some proteins and a region on ER 
containing lipid biosynthetic enzyme connected reversibly to mitochondria. This leads to 
1) the calcium transfer through MAM sites which was able to sustain mitochondrial 
hyperactivity, and 2) to the inactivation of glycogen synthase kinase 3b (GSK3b), a 
serine/threonine kinase functioning as a metabolic switch.  
Furthermore, MAM formation and GSK3b inactivation sustained production of the 
collagenase cathepsin K, a macrophage effector function closely correlated with clinical 
disease activity in RA (Zeisbrich M, 2018).  
 
2.5.4 Metabolites in RA 
 
The study of metabolic intermediates is becoming a new emerging field. More than 
intermediate bystanders, succinate, lactate, fumarate etc. function as  signalling molecule 
to link metabolic reprograming with immune and inflammatory responses in RA and 
other conditions. A gas chromatography–mass spectrometry (GC–MS) study, carried on 
RA sera samples, showed perturbations in different bioenergetic pathways such as 
glycolysis, fatty acid and amino acid metabolism and TCA cycle. In particular they found 
decreased levels of several amino acids (leucine, phenylalanine, pyroglutamate, serine, 
isoleucine, methionine, threonine, proline and valine) and glucose alongside with 
increased levels of fatty acids such as palmitelaidate, oleate, trans-9-octadecenoate,cis-
5,8,11-eicosatrienoate, docosahexaenoate, 2-ketoisocaproateand 3-methyl-2-oxovalerate 
and cholesterol (Zhou J, 2016).  On the same line, another very recent study describes a 
metabolite signature in serum that correlate with gene expression profiling in synovial 
tissue from patients with active RA. Specifically the authors observed an association of 
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serine/glycine/phenylalanine metabolism and aminoacyl-tRNA biosynthesis with 
lymphoid cell gene signature. Alanine/aspartate/glutamate metabolism and choline-
derived metabolites correlated with TNFα synovial expression. Circulating ketone bodies 
were associated with gene expression of synovial metalloproteinases. These data pointed 
out the relationship between serum metabolite profiles and synovial biomarker profiling 
suggesting that the 1H-nuclear magnetic resonance (NMR) may be a promising tool for 
predicting specific pathogenic pathways in the inflamed synovium of patients with RA 
(Narasimhan R, 2018). 
In vitro studies further highlighted the role of metabolites as signalling molecules. 
Studies on succinate have shown that LPS-activated inflammatory (M1) macrophages 
present an intracellular accumulation of this metabolite due to an altered Krebs cycle (Jha 
AK, 2015). Furthermore, intracellular succinate promoted the stabilization of HIF1α and 
enhanced pro-inflammatory IL-1β production (Tannahill GM, 2013). In addition, when 
activated by inflammatory stimuli, macrophages release succinate into the extracellular 
milieu and simultaneously up-regulate Gpr91, which functions as an autocrine and 
paracrine sensor for extracellular succinate to enhance IL-1β production. Gpr91-deficient 
mice lack this metabolic sensor and show reduced macrophage activation and production 
of IL1β during antigen-induced arthritis. Succinate is abundant in synovial fluids from 
RA patients, and these fluids elicit IL-1β release from macrophages in a Gpr91-
dependent manner. In this paper, the authors propose a model of Gpr91/succinate-
dependent feed-forward loop of macrophage activation and suggest Gpr91 antagonists as 
novel therapeutic principles to treat RA (Littlewood-Evans A, 2016). Notably, Sucnr1−/− 
knockout mice display a reduced arthritis by reducing dendritic cell traffic and expansion 
of Th17 cells in the lymph nodes (Saraiva AL, 2018). 
On the same line, it was found that intracellular succinate induced angiogenesis through 
HIF1α induction, while extracellular succinate acted on Gpr91 activation, working 
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together to disturb energy metabolism and exacerbate inflammation and angiogenesis in 
arthritis synovium. Suppression of SDH could prevent succinate accumulation and inhibit 
angiogenesis via blocking HIF1α/VEGF axis. This finding not only provides a novel 
insight into angiogenesis, but also reveals a potential therapeutic strategy to attenuate 
revascularization in arthritis (Li Y, 2018).  
If succinate exhibits pro-inflammatory activity, other metabolites such as fumarate and 
itaconate were found to have an anti-inflammatory function. With regard to fumarate, the 
methyl ester dimethyl fumarate (DMF) that is already approved for the treatment for the 
relapsing MS, inhibited RANKL‐mediated osteoclastogenesis and bone 
destruction via induction of NRF2‐mediated transcription of antioxidant genes and 
consequent decrease in intracellular ROS levels (Yamaguchi Y, 2018). 
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3 RATIONALE AND AIMS 
 
Inflammatory sites, including RA synovitis, are characterized by the accumulation of 
lactate, which is partly responsible for their acidity. For many years, lactate has been 
considered a "waste" glycolytic metabolite; only recently, lactate has been recognized as 
immunomodulatory molecule.  
In particular, lactate can affect CD4
+
 T cell migration and function, via the SLC5A12 
lactate transporter, leading to and perpetuating chronic inflammation. The project aimed 
at characterizing whether the lactate/SLC5A12-induced metabolic signalling pathway 
modulates inflammatory immune responses. In particular, I assessed the impact of this 
signalling pathway in vitro and ex vivo, in healthy and RA CD4
+ 
T cells, in RA tissues 
and in vivo in a murine model of arthritis. 
Based on previous evidence, I further elucidated the underlying mechanism through 
which lactate ties metabolic reprogramming to the modulation of T cell functions (IL-
17A production and T cell entrapment in the inflammatory sites). 
 These findings can open new therapeutic perspectives for the treatment of chronic 
inflammatory diseases. 
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4 MATERIALS AND METHODS  
 
4.1 Patients 
 
Blood, synovial fluid and synovial tissues were obtained from RA patients diagnosed 
according to the revised American College of Rheumatology (ACR) criteria (Aletaha D, 
2010). Demographic and clinical characteristics are presented in Table 6 (Appendix). 
Healthy controls (HC) were recruited through the NHS blood and transplant service. 
Individuals with cancer, infections or other inflammatory comorbidities were excluded. 
Written informed consent was obtained by all participants, HC and RA, according to 
ethics approval from National Research Ethics Service Committee London (EMR 
Biobank, LREC07/Q0605/129).  
For messenger RNA (mRNA) sequencing, mRNA was extracted from synovial tissue 
samples obtained by ultrasound‐guided biopsy from patients with early active RA (< 12 
months' duration) who were naïve-to treatment with disease modifying antirheumatic 
drugs (DMARDs) (n = 87). Patients were enrolled in the Pathobiology of Early Arthritis 
Cohort (PEAC, details at http://www.peac‐mrc.mds.qmul.ac.uk) at the Centre for 
Experimental Medicine and Rheumatology of Queen Mary University (REC 
05/Q0703/198, London, UK). All patients belonging to this cohort underwent to a 
baseline ultrasound‐guided biopsy on the most inflamed accessible joint as previously 
described (Kelly S, 2015); synovial fluid and blood were also collected. Afterward, 
patients started treatment with conventional DMARDs (methotrexate, leflunomide and/or 
sulphasalazine and/or hydroxychloroquine and/or corticosteroids). The response to 
treatment was evaluated at six months according to DAS28-CRP (see paragraph 2.5.2).  
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4.2 T cell isolation and in vitro activation  
 
Peripheral blood mononuclear cells (PBMCs) from HC and paired PBMCs and synovial 
fluid mononuclear cells (SFMCs) were obtained from RA patients. PBMCs and SFMCs 
were isolated by density gradient centrifugation [lymphoprep (GE Healthcare) and 
histopaque H-1070 (Sigma-Aldrich) respectively]. 
Cell were counted using a Neubauer counting chamber under light microscopy; cells 
were pre-diluted in RPMI 1640, then 1:1 in trypan blue (a cell viability dye that stains 
nuclei of dead cells). The number of cells was determined using the following formula: N 
= M x D x 10
4
 where N = number of cells, M = number of cells in the grid, D = diluition 
factor. 
Cells (2 × 10
6
/mL) were cultured in 48-well flat-bottomed plates in medium (RPMI 1640, 
ThernoFisher) supplemented with 100 U/mL penicillin/streptomycin (Invitrogen), 10% 
FBS (ThernoFisher) or 10% autologous blood serum or 10% RA synovial fluid. Cells 
were then stimulated, or not with 0.2 μg/mL anti-CD3 monoclonal antibody (CD3 mAb, 
eBioscience) in order to achieve an efficient T cell activation. I did not use CD28 mAb 
for the activation of T cells when using the whole PBMCs or MCs since the co-
stimulation for T cell activation is genearally given by other APC cells such as B cells, 
DC and monocytes (Kurrle R, 1986). 
For the experiments on human tonsils, tissues were mashed through a cell strainer and 
mononuclear cells (MCs) were isolated. Cells were washed twice with RPMI 1640 and 
re-suspended in pre-warmed RPMI 1640 plus 10% FBS and activated or not with 0.2 
μg/mL CD3 mAb (eBioscience).  
CD4
+
 T cells were purified from freshly isolated PBMCs and MCs by negative selection 
using a magnetic cell separation (EasySep, Stem Cell Technology) and then stimulated 
for 3 days in the presence of anti-CD3 and anti-CD28 mAbs coated dynabeads (0.1 beads 
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per cell; Invitrogen). For cytokine detection in the final 4 hours of culture, cells were 
treated with 50 ng/mL PMA and 500 ng/mL ionomycin and 1:1.000 brefeldin A (Sigma-
Aldrich), followed by surface staining for CD4 (RPA-T4, Biolegend). 
 
4.3 Flow cytometry 
 
In order to assess SLC5A12 expression on different immune cell types, RA/HC PBMCs, 
RA SFMCs or tonsil MCs were initially stained with Live/Dead dye (1:1000, 
ZOMBIE/NIR, fixable viability dye, Biologend) for 15 minutes at room temperature 
protected from light to allow detection and removal of dead cells from the analysis. 
Without washing, cells were then stained with BV711–labeled anti–CD4 (1:100, 
Biologend), Pedazzle–labeled anti–CD8 (0.25:100, Biologend), FITC–labeled anti–CD14 
(1:100, Biologend), PeCy7–labeled anti–CD19 (1:100, Biologend), (see gating strategy 
below). Rabbit SLC5A12 unconjugated primary antibody (0.4:100, HPA060904 - Atlas 
Antibodies) was added after fixing and permeabilizing cells (fixation-permeabilization 
buffer; eBioscience) for 30 min followed by AF555 goat anti-rabbit (1:1000, Invitrogen) 
secondary antibody. Rabbit IgG was used as isotype control (Dako). To assess the impact 
of SLC5A12 blockade on cytokine production and CD4
+ 
T cell subsets we stained tonsil 
MCs, treated with or without SLC5A12 Ab (48 hours), with BV711–labeled anti–CD4 
(1:100), BV-450–labeled anti–PD1 (1:100) and PE/Cy5.5-labeled anti–CXCR5 (4:100). 
Thereafter, I washed, fixed, and permeabilized cells (fixation-permeabilization buffer; 
eBioscience) and stained with BV450-labeled anti-IL-17A, APC-labeled anti-FOXP3, 
PE-labeled anti-IL-10, FITC-labeled IFN. Intracellular staining was assessed by flow 
cytometry using a LSR Fortessa II (BD Biosciences) and FlowJo version 7.6.5 software. 
All monoclonal antibodies were from Biolegend.  
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Gating strategy for SLC5A12 expression by immune cells 
Sequential gating strategy used for SLC5A12 expression by CD4
+
, CD8
+ 
T cells and 
CD19
+
/CD14
+ 
cells. CD19
+
/CD14
+ 
cells were gated on CD4
-
CD8
-
 double negative cells. 
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4.4 Immunofluorescence and confocal microscopy 
 
For SLC5A12 single and double (with CD4, CD8, CD20, CD68) immunofluorescence, 
after antigen retrieval (S2367, Dako) (45 minutes) and block of non-specific binding (1 
hour), paraffin-embedded tonsil tissue sections were incubated for 1 hour with anti-
SLC5A12 Ab (1:50, Novus Biologicals) and then overnight at 4°C with anti-CD4, anti-
CD8, anti-CD20 or anti-CD68 (1:50, Dako). The day after were washed in PBS and 
incubated with fluorochrome-conjugated secondary antibodies (1:300, Invitrogen). The 
slides were washed in PBS for up to 5 minutes, mounted in fluorescence mounting 
medium (DakoCytomation) containing 1 μg/mL DAPI, and examined by Olympus IX81 
fluorescence microscope. The list of primary and secondary antibodies is shown in Table 
6 (Appendix). 
For the intracellular detection of HK2, human CD4
+
 T cells cultured on glass coverslips 
were incubated for 5 minutes with 300 nM mitotracker deep red FM (Molecular Probes) 
at 37°C in 5% CO2 atmosphere. After the incubation period, cells were washed twice and 
fixed/permeabilized in permeabilization/fixation buffer (eBioscience) overnight at 4°C. 
After washing with PBS, the cells were incubated with the primary antibodies against 
anti-HK2 (1:200, Cell Signalling Technology) for 1 hour at room temperature followed 
by 30 minutes incubation with 1:200 secondary Alexa Fluor 555 conjugated goat anti-
rabbit (Invitrogen). Alexa Fluor 488 phalloidin (ThermoFisher) for the actin staining was 
also added at this stage. One million cells resuspeded in 100 uL PBS were counterstained 
with DAPI to detect nuclei, spun in the cytospin (250 rpm for 5 min) to allow the 
attachment to the coverslips and then mounted for microscopy. All images were acquired 
using a confocal microscope LSM880 (Zeiss). 
 
 
92 / 231 
 
4.5 Chemokinesis assays and tissue organ culture  
 
Chemotaxis assays were performed in 7μm trans-well inlays (Corning). One h before the 
assay cells were incubated with sodium lactate (10 mM) and pre-treated or not (1 hour) 
with SLC5A12 polyclonal Ab (2.5 ug/mL, HPA060904 - Atlas antibodies) or monoclonal 
mAbs (1:50; SLC5A12 mAb clones: 3C7, 4G2, 6E1, 7C1, 9G4, 9G7 and 10E11) purified 
from sera of rat immunized with SLC5A12 recombinant peptide (see paragraph 4.8). In 
some experiments sodium lactate treated cells were pre-treated (2 hours) or not with 
metabolic drugs: C75 (10 uM), TOFA (20 uM), DHEA (20 uM), DASA (20 uM), 
AICAR (1 mM). In all the assays 3x10
5
 lymphocytes suspended in migration medium 
(RPMI 1640 2% FBS), were seeded in the upper trans-well chamber; CXCL10 
chemokine (300 ng/mL) was added to the lower chamber. Migrated T cells were counted 
in cell counting chambers 4h after seeding, then percent of migrated cells was calculated 
(Schematic A). 
For the analysis of egressed MCs, small pieces (1-3 mm
2
) of tonsil or synovial tissue 
were placed in 48-well plate in RPMI 1640 10% FBS. The amount of cell egressed from 
the tissue in the cell culture supernatant was analyzed by FACS after 4 hours (Schematic 
B). 
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4.6 Molecular signalling and western blot analyses 
 
For western blot analyses, protein were extracted by lysing CD4
+
 T cells (2 x 10
6
) in 
RIPA lysis buffer (65 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Nonidet 
P-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail tablets 
(#04693132001, Roche). Equivalent amounts of protein (30 μg of total), as determined 
by standard Bradford assay (Bio-Rad), were loaded, fractionated by SDS-PAGE and 
transferred to polyvinyildene difluoride membranes using a transfer apparatus according 
to the manufacturer’s protocols (Bio-Rad). After incubation with 5% nonfat milk in 
TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 60 minutes, membranes 
were washed once with TBST and incubated overnight at 4°C with a 1:1000 dilution of 
primary antibodies against pStat3, Stat3, pStat1, Stat1, PKM1/2, pACC, ACC, pAMPK, 
AMPK, HK1, HK2, Enolase 1 alpha, GCK, aldolase, acetyl-lysine, histone H3, VDAC 
(Cell Signalling Technology), PFK (Novus Biologicals), SLC5A12 (Sigma) and ß-Actin 
(Santa Cruz Biotechnology). Membranes were then incubated for 1 hour at room 
temperature with horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies 
(1:2000). Blots were washed twice with TBST and developed with the ECL system 
(Amersham Biosciences) according to the manufacturer’s protocols. Density of bands 
was calculated via the use of ImageJ software. 
 
4.7 Cell organelle fractionation 
 
Fractionation of nuclear, mitochondrial and cytosolic extracts was performed by using 
nuclear extraction kit (Abcam) and mitochondria isolation kit for cultured cells (Thermo 
Scientific) according to the manufacturer's instructions. Cell compartments were enriched 
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according to the manufacturer’s instructions. Here, 6-20x106 CD4+ T cells per condition 
were subjected to a series of lysis and centrifugation steps to yield cytosolic, 
mitochondrial and nuclear fractions. 
 
4.8 Measurement of extra- and intracellular metabolites and ROS  
 
Intracellular metabolites (NAD
+
/NADH, acetyl-CoA, citrate) were measured with 
colorimetric or fluorescent kits (Biovision) according to the instructions. 
NADP
+
/NADPH were measured using a colorimetric assay kit (Abcam). 
Samples were collected after washing in RPMI 1640 culture media and quenched in 
liquid nitrogen to stop metabolism. For acetyl-CoA, citrate measurements, samples were 
lysed with RIPA buffer and deproteinized with perchloric acid (PCA) and sodium 
hydroxide prior to the assay. For NAD
+
/NADH and NADP
+
/NADPH, after a series of 
spinning and washing, pellet cells were extracted with a specific buffer provided. After 
spinning, supernatants were transferred in labelled tubes and kept on ice. An aliquot of 
200 uL was transferred in micro centrifuge tubes and heated at 60°C in a heating block to 
allow all NADP
+
 or NAD
+
 to be decomposed and NADPH and NADH to remain intact. 
Reaction mix was then added to samples labelled as: total NAD, NADH, total NADP and 
NADPH followed by developer for 1-4 hours incubation.  The optical density (OD) of 
each well was then determined using a microplate reader set to 450 nm taking multiple 
readings. 
Reactive oxygen species were measured using the fluorescent probe carboxy-H2DCFDA 
(Invitrogen, Molecular Probes). Briefly, CD4
+
 T cells were incubated with 1 μM 
H2DCFDA/PBS for 30 minutes in the dark. The excess dye was removed with three 
washes in warm PBS and 2.5x10
5
 cells /100 μL PBS were plated in a black 96 well plate. 
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After addition of 10 mM sodium lactate or 1 mM H2O2 fluorescence was recorded in a 
time wise manner at Ex 492 nm / Em 520 nm. 
 
4.9 Lactate mesurement in human samples 
 
Lactate concentration was measured in the synovial fluid of RA or OA patients using the 
lactate colorimetric assay kit (Biovision). Briefly, for the standard curve preparation 
lactate standard 1 nmol/µL was prepared by adding 10 µL of the 100 nmol/µL lactate 
standard (stock solution) to 990 µL of lactate assay buffer. After mixing well 0, 2, 4, 6, 8 
and 10 µL were added into a series of wells and the volume was adjusted to 50 µL/well 
with lactate assay buffer to generate 0, 2, 4, 6, 8 and 10 nmol/well of the lactate standard. 
Samples (1 µL/well) were added in other wells and the volume adjusted to 50 µL/well 
with lactate assay buffer. A reaction mix (50 µL/well) containing the enzyme, the probe 
and the buffer was then added. After an incubation for 30 minutes at room temperature, 
protected from light I measured the absorbance (OD 570 nm) in a microplate reader. 
 
4.10 Metabolomics, stable isotype tracing and fatty acid labelling 
 
Following extraction, CD4
+
 T cells were activated in media with anti-CD3 and anti-
CD28 mAbs for 24 hours followed by further 48 hour culture with lactate alone or in the 
presence of SLC5A12 Ab in medium containing low glucose (5 mM) and 5% FBS. Spent 
medium was collected and processed for metabolite extraction as described (Mackay 
GM, 2015). Briefly, medium from each condition is diluted 50 fold with cold extraction 
solvent consisting of 50% methanol, 30% acetonitrile and 20% water. Polar metabolites 
were extracted by vortexing the tubes for 10 minutes and then centrifugation at 16.000 × 
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g for 10 minutes at 4 °C. The supernatants are transferred to glass vials and kept at -75 °C 
prior to LC-MS analysis. Glucose, lactate and glutamine concentrations in the spent 
medium were quantified using external calibration curves generated by spiking in 
different concentrations of 
13
C-glucose, 
13
C-lactate, and 
13
C-glutamine in the medium and 
extraction into extraction solvent. Peak areas from the samples were extrapolated to the 
standard curve peak areas and absolute concentrations of glucose, lactate and glutamine 
were obtained. Uptake rates of metabolites were calculated as difference in 
concentrations normalized to the area under the growth curve of cells. 
For 
13
C-lactate tracing into polar metabolites, CD4
+
 T cells were activated for 48h in low 
glucose medium with 5% FBS in a 24-well cell culture plate in triplicate, with or without 
SLC5A12 Ab. After 48 hours, the medium was replaced with fresh medium containing 
10 mM 
13
C-U-lactate (Sigma) with or without SLC5A12 Ab for 2 hours. Medium was 
removed by centrifugation and metabolites were extracted from the cell pellets with cold 
extraction solvent (50% methanol, 30% acetonitrile and 20% water). The LC-MS 
parameters for data acquisition were kept the same as previously described (Mackay GM, 
2015). 
For 
13
C lactate tracing into palmitate, CD4
+
 T cells were activated in low glucose 
medium (5 mM) and 10% FBS in a 24-well cell culture plate in duplicate in presence of 
10 mM 
13
C-U-lactate (Sigma) with or without SLC5A12 Ab for 0, 24, 48 and 72 hours. 
At the end of each time point, medium was aspirated and cell pellets were treated with 
750 µL of 1:1 cold PBS: methanol and total lipid fraction was extracted in 500 µL of 
chloroform. This extract was dried under inert nitrogen, reconstituted in 90 µL 
chloroform and total fatty acids were derivatized using the transesterification reagent 
MethPrep II (Thermofisher Scientific, UK) before analysis by GC-MS as described 
(Tumanov S, 2015). 
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4.11 Seahorse 
 
Glycolytic and mitochondrial metabolism was evaluated by measuring the extracellular 
acidification rate (ECAR) and the oxygen consumption rate (OCR) respectively with a 
Seahorse XF96e Extracellular Flux Analyzer. Briefly, T cells were activated in RPMI 
1640 supplemented with 10% FBS for 12 hours. One hour before the experiment, 3x10
5
 
T cells were seeded in a 96-well microplate in XF Assay Dulbecco's Modified Eagle 
Medium (DMEM), in presence of 10 mM of glucose, and incubated in a non-CO2 
incubator.  
Fatty acid oxidation was analyzed by measuring the OCR with a Seahorse XF96e 
Extracellular Flux Analyzer according to the manufacturer protocol. Briefly, 2.5x10
5
 T 
cells were seeded in a 96 well micro plate in XF-DMEM-medium containing 2.5 mM 
glucose and incubated for 45 minutes in a CO2 free incubator. 15 minutes prior to the 
assay, control cells were treated with 40 μM etomoxir to block CPT1a. Just before 
starting the assay, the cells were treated with 167 μM BSA-palmitate or BSA alone. 
During the assay 1 μM oligomycin and 1 μM FCCP were injected. Experiments with the 
seahorse system were done with the following assay conditions: 3 minutes of mixture; 3 
minutes waiting; and 3 minutes of measurement. Sodium lactate (10 mM) metabolic 
drugs or PBS, was injected during the assay at the indicated time points. 
 
4.12 RNA isolation, reverse transcription and qRT-PCR 
 
Total RNA was isolated from 10
6
 CD4
+
 T cells or 10 mg RA synovial tissue using 
RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions and assessed for 
quality and quantity using absorption ratios of 260/280 nm and 260/230 nm. Hereby cells 
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were lysed in lysis buffer RLT, nucleic acids were precipitated with 70% ethanol and 
RNA bound to spin columns. Following several washing steps, RNA was eluted in dH2O. 
The isolated RNA was reverse transcribed to complementary DNA (cDNA) using 
commercially available kits according to the manufacturer’s instructions (Applied 
Biosystems). Briefly, 1 ug of total RNA was mixed with buffer, deoxy-nucleotides 
(dNTPs) and reverse transcriptase and incubated for 2 hours at 30°C, followed by a 5 
minutes heat inactivation step at 85°C. cDNA was diluted to 10 ng/μL and stored at -
20°C or -80°C for subsequent use. 
Quantitative gene expression analysis was performed using SYBR Green Supermix 
(Biorad) in CFX connect light cycler (Biorad), according to the manufacturer’s 
instructions. Gene relative expression was calculated using the ΔΔct method (Livak KJ, 
Schmittgen TD, 2001) and normalized to a reference control (GAPDH or Actin). A 
complete list of primers used is available in the supporting information (Table 7, 
Appendix).  
 
4.13 Tissue biopsy procedure 
 
For the RNA sequencing data, 87 synovial samples from patients presenting with early 
inflammatory arthritis were analyzed. The immune-histological features of rheumatoid 
synovitis in each patient were assessed by ultrasound (US) guided synovial biopsy of 
clinically involved (swollen) joints. US examination (in grey scale and power Doppler) 
and US-guided synovial biopsy were performed using a General Electric (GE Healthcare, 
Fairfield, Connecticut, USA) Logiq 9 ultrasound machine with a two-dimensional M12L 
transducer, grey-scale frequency 12MHz. Synovial thickening and degree of power 
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Doppler signal were scored using a previously reported semi-quantitative score (0–3) 
(Pitzalis C, 2013). 
 
4.14 Tissue RNA extraction 
 
All tissue samples were maintained on ice and homogenized in a fume hood using a 
Polytron benchtop laboratory homogenizer. Samples were homogenized at short five-
second intervals until all the tissue had been sheared/homogenized. The probe of the 
homogenizer was cleaned thoroughly in between samples by washing initially in RNase 
Away solution, followed by four washes in sterile/RNase-free Baxter water. RNA was 
extracted from a minimum of 10 mg of synovial tissue homogenized at 4°C in Trizol 
reagent (Life Technologies, Invitrogen Division, UK). Chloroform was mixed with the 
lysate and following centrifugation the aqueous RNA layer was transferred to a new 
microcentrifuge tube. Isopropanol at 4°C was mixed with the RNA layer. Following 
incubation and centrifugation, the isopropanol was removed and the RNA pellet washed 
with 70% ethanol. The pellet was re-dissolved in RNase-free water. The 
concentration/purity of the RNA sample(s) were measured using the NanoDrop 2000C 
(Lab Tech, UK) and the quality (RIN) was assessed using the Agilent 2100 Bioanalyser 
(Agilent Technologies, UK). 
 
4.15 RNA sequencing, read alignment, and transcript assembly 
 
Metabolic genes were chosen by using KEGG pathway database. The sequencing 
workflow was conducted by Illumina TruSeq platform. Raw data FASTQ files were first 
screened for quality using FastQC (http: // www.bioinformatics.babraham.ac.uk /projects 
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/fastqc/), inspecting multiple aspects of sequencing quality, including GC content, overall 
read quality, individual base qualities and read length distribution. The quality-checked 
FASTQ files were aligned to the human genome reference (GRCh37/hg19) using The 
Genomic Short-read Nucleotide Alignment Program (GSNAP) with an associated 
transcriptome map (GTF file, 
http://support.illumina.com/sequencing/sequencing_software/igenome.html) used to 
guide transcriptome assembly. To determine transcript abundances, i.e., read counts, the 
‘multicov’ function of BEDTools 2.15.0 was used and counts were computed as the total 
number of reads that aligned to a transcript region (50x10
6
 reads per tissue, pair-end). 
Additionally counts were computed over individual exons in each transcript. All 
subsequent bioinformatics analyses were conducted in the R Programming Language 
environment. RNA-seq data are uploaded to ArrayExpress and are accessible via 
accession E-MTAB-6141 at: https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-
6141. 
 
4.16 H&E procedure 
 
FFPE tissue blocks were sectioned at a thickness of 3 μm using a Leica RM1235 
microtome. Sections were mounted on to Superfrost plus (+) slides and left to dry in a 
slide rack at room temperature for 30 minutes. Slides were heated (60ºC) for a minimum 
of 30 minutes prior to staining. Tissue sections were stained with haemotoxylin and eosin 
(H&E), mounted with DePex and left to dry overnight. Slides were imaged using an 
Olympus BX61 microscope for initial grading. 0 = normal; 1 = minimal infiltration of 
inflammatory cells in synovium and periarticular tissue of affected joints; 2 = mild 
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infiltration; 3 = moderate infiltration with moderate edema; 4 = marked infiltration 
affecting most area with marked edema. 
The histological assessment of synovial tissues is carried out in order to define the 
predominant histological pattern of synovitis as either diffuse or aggregate. In addition, 
each section underwent semi-quantitative assessment for three synovial membrane 
features: (i) thickness of the synovial lining cell layer, (ii) stroma cell density and (iii) 
inflammatory cell infiltrate. The ranking of alterations is on a scale from none (0), slight 
(1) and moderate (2) to strong (3) very strong (4) for each feature. Max score of 4 was 
given. 
 
4.17 Enzyme Linked Immunosorbent Assay 
 
Secreted IL-17A and IFN were measured in cell culture supernatants from 2-4x106 
CD4
+
 T cells/well with a human IL-17A (homodimer) or IFN ELISA Ready-SET-Go 
Assay (eBioscience) according to the instructions. Briefly after coating a 96-well plate 
with a capture antibody (overnight at - 4°C), I washed (3 times) with wash buffer (PBS, 
0.05% tween -20) and then blocked the wells with ELISA/ELISPOT diluent (eBioscence) 
for 1 hour. Once the incubation with blocking solution was complete, after washing, 
samples and curve were added at the final volume of 100 uL/well and incubated for 2 
hours. The curve was built doing seven 2-fold serial dilutions from a standard stock 
solution. Afterward a detection antibody (1 hour) was added, following by avidin-HRP 
(30 minutes) and TMB (3,3,5,5’ tetramethylbenzidine, 15 minutes) solution. Upon color 
development (usually 15-30 minutes), the reaction was stopped with 50 uL/well of 2N 
sulfuric acid solution (H2SO4). The OD of each well was then determined using a 
microplate reader set to 450 nm. The standard curve is then constructed by plotting the 
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mean absorbance for each standard on the y-axis against the concentration (known) on 
the x-axis and draw the best-fit curve through the points on the graph. 
 
4.18 Human glucose 6 phosphate isomerase-induced mouse model of arthritis 
 
DBA/1 mice purchased from Charles River were immunized s.c. with 20 μg human 
hG6PI synthetic peptide (hG6PI325-339; ThermoFisher Scientific) in CFA (Sigma-
Aldrich). The indicated amount of peptide was mixed with CFA in a 1:1 ratio (v/v) and 
emulsified by sonication. For induction of arthritis, 100 μL of the emulsion was given 
s.c. at the base of the tail. On day 7 – a time point at the onset of disease – and 11 post 
induction (as indicated by the arrows in the Figure 11A), mice were left untreated or 
treated sub-plantar into the rear paws with 20 uL of 0.1 mg/mL antibody; infliximab 
(Remicade, Janssen Biologics), TNF mAb (TN3-19.12, BD bioscience), SLC5A12 Ab 
(Abcam), iso-TNF Ab (BD biosciences) and iso-SLC5A12 Ab (Abcam). Antibody and 
the corresponding isotype control was injected into the right or left back paw 
respectively of the same mouse. The development of disease was monitored daily by 
visually assessing the clinical score. A score of 0 indicates no clinical signs of arthritis; 
a score of 1 for each of the fingers, pad and ankle indicates swelling and redness. 
Maximum score for each paw is 7. A trained observer who was blinded to the 
immunization status of the mice performed the scoring. The grade of inflammation 
was assessed by H&E as described in section 4.5. 
 
4.19 Generation of neutralizing monoclonal antibodies (mAbs) targeting SLC5A12  
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The generation of neutralizing monoclonal antibodies (mAbs) targeting SLC5A12 was 
performed by Aldevron. 
Rats were immunized with SLC5A12 peptide (sequence of the peptide: QGSTH‐
AGGFH‐NVLEQ‐STNGS‐RLHIF‐DFDVD‐PLRRH‐C). After 45 days of 
immunization and 4 applications, very strong reactivity of the immune sera could be 
detected in the animals immunized with the peptide when tested by an enzyme‐linked 
immunosorbent assay (ELISA) on plates coated with the target antigen (peptide 
SLC5A12 – hum – KLH). No reactivity could be detected in any of the immune sera 
against the protein used as control (BSA). In view of these very encouraging results 
animals were sacrificed, the lymphocytes isolated and cell fusion and ~400 clones were 
screened via ELISA/IQue. In the first round of screening 4 clones were selected based on 
IQue (FACS) results. These supernatants bound to the full‐length cell surface protein 
and are thus strong candidates for binding to the native protein. Additional 50 clones 
were selected based on the good results from ELISA. 
In the last round of the screening the top 7 candidates (3C7, 4G2, 6E1, 7C1, 9G4, 9G7 
and 10E11 mAbs clones) were selected based on ELISA and FACS-measured binding on 
cells expressing the full‐length protein. 
Finally three clones were chosen and were propagated into T25 flasks; BTK-3B10-C7 
(IgG2a / kappa), BTK-3C7-C7 (IgG2a / kappa), BTK-10E11-G8-G8 (IgG1/IgG2a/c 
kappa/lambda) were successfully sub-cloned. 
FACS-measured binding analysis of these 3 clones on human activated CD4+ T cells 
expressing the full-length protein in presence or not of SLC5A12 peptide in the culture 
was further performed. 
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4.20 Statistical analysis 
 
In all experiments, data are expressed as mean ± SEM unless stated otherwise. Statistical 
tests were selected based on appropriate assumptions with respect to data distribution and 
variance characteristics. Student's t-test (two-tailed) or ANOVA test (one-way or two-
ways) were used for the statistical analysis as appropriate. Statistical significance was 
defined as P≤0.05. GraphPad Prism software (GraphPad Software) was used for the 
analysis.  
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5 RESULTS  
 
5.1 CHAPTER I – SLC5A12 EXPRESSION IN HEALTH AND DISEASE 
 
5.1.1 The expression of the lactate transporter SLC5A12 by immune cells is 
regulated by activation and inflammatory stimuli 
 
Lactate modulates CD4
+
 T cell migratory abilities and cytokine production via the 
sodium-coupled lactate transporter SLC5A12, which is selectively expressed by CD4
+
 
but not by CD8
+ 
T cells (Haas R, 2015). To assess whether the expression of SLC5A12 
may be regulated by activation stimuli, peripheral blood mononuclear cells (PBMCs) 
from healthy control (HC) subjects were treated for 48 hours with anti-CD3 monoclonal 
antibody (mAb) or left untreated. TCR activation led to upregulation of SLC5A12 by 
peripheral CD4
+  
but not CD8
+
 T cells (Figure 1A-C). In the same experiment, activation 
led to up-regulation of SLC5A12 also in peripheral CD14
+
 and CD19
+
 cells (monocytes 
and B cells, respectively) (Figure 1D-F). In comparison, the same immune cell subsets 
were negative for SLC5A12 or expressed it at low levels in untreated PBMCs (Figure 
1A, C, Figure 1D, F). Interestingly, when I analysed mononuclear cells (MCs) from 
inflamed tonsils excised from patients subjected to tonsillectomy, CD4
+
 T cells were 
SLC5A12
+
, irrespective of any activation stimuli (Figure 2A-C). Likewise, 
CD14
+
/CD68
+
 and CD19
+
/CD20
+
 cells were SLC5A12
+
, independent of any activation 
(Figure 2D-F). In contrast, CD8
+
 T cells were mostly negative for SLC5A12 (Figure 2 
A-C, G), which was consistent with data in Figure 1A-C. 
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Figure 1 - SLC5A12 up-regulation by T cells requires TCR engagement. (A, B, D, E) 
Representative flow cytometry plots of SLC5A12 expression and (C, F) quantification of 
percentage of CD4
+
SLC5A12
+
, CD8
+
SLC5A12
+
, CD14
+
SLC5A12
+
 and 
CD19
+
SLC5A12
+ 
cells in non-activated (n = 3) (A, D) and anti-CD3 mAb activated (n = 
6) (B, E) PBMCs gated for CD4
+
, CD8
+
, CD14
+
, CD19
+
 freshly isolated from HC. 
Comparisons were evaluated using one-way ANOVA. Data are expressed as mean ± 
s.e.m. *P≤0.05; **P≤0.01; ***P≤0.001; ns=not significant. 
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Figure 2 – SLC5A12 expression by peripheral and tissue-resident immune cells. (A-
E) Representative flow cytometry plots of SLC5A12 expression in non-activated (n = 4, 
A, D) and anti-CD3 mAb activated (n = 4, B, E) tonsil MCs, gated for CD4+, CD8+, 
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CD14+, CD19+ and quantification of the percentage (C, F). (G) Double 
immunofluorescence staining for SLC5A12 (red) and CD4, CD8, CD20 or CD68 (green). 
Merging (orange\yellow) of green and red channels demonstrates that SLC5A12 is 
expressed by CD3
+
CD4
+
 (T cells), CD20
+
 (B cells) and CD68
+
 (macrophages). Scale bars 
50 uM. Comparisons were evaluated using one-way ANOVA. Data are expressed as 
mean ± s.e.m. *P≤0.05; **P≤0.01; ***P≤0.001; ns=not significant.  
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5.1.2 SLC5A12 is upregulated in activated peripheral RA CD4+ T cells cultured in 
autologous synovial fluid 
 
To confirm whether the inflammatory environment has a role in the regulation of 
SLC5A12 expression by CD4
+
 T cells, I next compared the SLC5A12 expression in HC 
versus RA CD4
+
 T cells. I used RA patients as model of autoimmune/inflammatory 
disorder. Furthermore, during these years I have had the opportunity to use RA patient 
samples as part of the HTA-approved EMR Early Arthritis Biobank. Age-matched HC 
and RA PBMCs were defrosted, washed two times and seeded in 24-well plates at the 
concentration of 2x10
6
 cells/mL. Cells were treated or not with anti-CD3 mAb and 
cultured in medium supplemented with matched 5% autologous blood serum (BS) or 5% 
RA synovial fluid (RA SF).  
Surprisingly, no difference was observed in the percentage of CD4
+
SLC5A12
+ 
T cells 
when we compared non-activated HC and RA PBMCs cultured in medium containing 
autologous BS or RA SF (Figure 3A-C). Even though anti-CD3 mAb-mediated 
activation led to up-regulation of SLC5A12 by CD4
+
 T cells, again no difference was 
observed in the percentage of CD4
+
SLC5A12
+
 T cells when we compared HC and RA 
PBMCs activated in medium containing autologous BS (Figure 3A-C). In contrast, anti-
CD3 mAb-mediated activation of RA but not of HC PBMCs in the presence of 5% RA 
SF led to a robust further upregulation of SLC5A12 by CD4
+
 T cells as compared to HC 
or RA activated CD4
+
 T cells in the presence of BS (Figure 3A-C). Importantly, I 
observed that SLC5A12 expression levels by CD4
+
 T cells in RA PBMCs, activated in 
the presence of RA SF, were comparable to those expressed by CD4
+
 T cells in synovial 
fluid mononuclear cells (SFMCs) from RA joints (Figure 3C) consistent with the data in 
Figure 2. I also found that CD4
+
 T cells in RA SFMCs presented high levels of 
SLC5A12 irrespective of any activation or inflammatory stimuli, as compared to CD4
+
 T 
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cells in RA PBMCs activated in the presence of autologous BS (Figure 3D). In a further 
experiment, I tested a novel mAb targeting SLC5A12. This antibody was generated by 
immunizing rats with a peptide comprising the predicted extracellular loop 3 of 
SLC5A12 (see section 4.8). Out of ~400 screened clones, 3C7 was selected for its ability 
to specifically recognize SLC5A12 (Figure 3E). Treatment of freshly isolated RA 
SFMCs with 3C7 mAb led to a reduced expression of the transporter itself by CD4
+
 T 
cells (Figure 3F). I then wondered whether lactate, at concentrations similar to that 
measured in RA SF (Haas R, 2015) might play a direct role in the regulation of the 
expression of SLC5A12. Incubation of activated peripheral CD4
+
 T cells – isolated from 
HC PBMCs with negative selection magnetic beads – with 10 mM sodium lactate 
contributed to the induction of SLC5A12 expression both at mRNA and protein level. 
Furthermore, pre-incubation with an anti-SLC5A12 polyclonal antibody (SLC5A12 Ab) 
prevented lactate-induced upregulation of SLC5A12 (Figure 3G, H). These data 
suggested that accumulation of extracellular lactate, such as at inflammatory sites, may 
cause a feedforward signal leading to the upregulation of the lactate transporter SLC5A12 
by CD4
+
 T cells. This effect is counteracted by SLC5A12 blockade. 
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Figure 3 - SLC5A12 expression is regulated by inflammation. (A-C) Representative 
histograms (A, B) and graph bars (C) of SLC5A12 expression by CD4
+
 T cells in 
unstimulated (A) and CD3 mAb stimulated HC (n = 4, B) and RA (n = 5, C) PBMCs. 
Cells were cultured in RPMI 1640 medium supplemented with 5% RA or HC autologous 
blood serum (BS) or 5% RA synovial fluid (SF) (A-C). (D) Representative plots (left) 
and quantifications (right) showing the expression of SLC5A12 in anti-CD3 mAb 
activated or not-activated RA SFMCs (n = 8) gated for CD4
+
 T cells. MFI, mean 
fluorescent intensity. Cells were cultured in RPMI 1640 medium supplemented with 5% 
FBS (n = 3), 5% autologous BS (n = 8) or 5% RA SF (n = 8). Anti-CD3 mAb activated 
BS RA PBMCs (n = 5) were used as control. (E) Representative flow cytometry plots of 
SLC5A12 expression in anti-CD3 mAb stimulated PBMCs from HC gated for CD4
+
 T 
cells. Cells were pre-incubated for 1 hour in the presence or absence of SLC5A12 
recombinant peptide (rhSLC5A12, 1:100) before a further incubation with anti-SLC5A12 
mAbs (3C7 IgG or 10E11 IgG). Goat anti-rat IgG ALEXA-555 (Invitrogen) (1:200) was 
used as secondary antibody and rat serum was used as control. (F) Representative 
histogram (left) and quantifications (right) analyzing the expression of SLC5A12 in RA 
SF CD4
+
 T cells treated or not with 3C7 mAb (n = 5) or control rat sera. (G, H) 
SLC5A12 mRNA expression (n = 5, G) and protein (representative, H) in anti-
CD3/CD28 mAbs activated CD4
+
 T cells isolated from HC treated or not with sodium 
lactate (10 mM) in presence or not of SLC5A12 blocking Ab (2.5 ug/mL, HPA060904 - 
Atlas Antibodies). Comparisons were evaluated using one-way ANOVA (C) or two-
tailed Student’s t-test (D, F-G). Data are expressed as mean ± s.e.m. *P<0.05; **P<0.01; 
***P<0.001. 
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5.2 CHAPTER II – LACTATE MODULATES INTRA- AND 
EXTRACELLULAR METABOLITES AND METABOLIC PATHWAYS  
 
5.2.1 Lactate influx into CD4+ T cells via SLC5A12 causes reduced glycolysis and 
increased TCA cycle-derived citrate but no major changes in mitochondrial oxygen 
consumption 
 
Having observed both an increase in the expression levels of the lactate transporter 
SLC5A12 in response to activation and inflammatory (including lactate itself) stimuli, 
and the absence of other lactate transporters, i.e. MCT1, in CD4
+
 T cells (Haas R, 2015; 
Figure 1-3), I wondered whether SLC5A12 may serve as a main carrier for an influx of 
lactate in to CD4
+
 T cells that have reached the inflamed tissue and hence are exposed to 
high concentration of extracellular lactate. To address this question, several extracellular 
and intracellular metabolites were measured via mass spectrometry analysis (Figure 4A), 
cellular metabolism assay kits (Figure 4B, F-G), seahorse flux analyser (Figure 4C) and 
mass spec-based metabolic tracer analysis (Figure 4D, E).  
Peripheral CD4
+
 T cells were isolated from HC PBMCs with negative selection magnetic 
beads and then activated with anti-CD3 and anti-CD28 mAbs. After 24 hours, cells were 
switched to a medium containing low glucose (5 mM) and 5% FBS in which they were 
incubated for additional 48 hours with lactate in the presence or absence of SLC5A12 Ab 
or were left untreated. Finally, culture media were collected and analysed by mass 
spectrometry. Exposure to lactate caused a decrease in glucose uptake along with a 
reduction in lactate release and a non-significant reduction in glutamine uptake by 
activated CD4
+
 T cells (Figure 4A). All these effects were reversed by cell incubation 
with anti-SLC5A12 Ab (Figure 4A).  
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I then asked whether a reduced glucose flux, due to lactate exposure, could lead to a 
decreased glycolysis. To address this question, I looked at the levels of NAD
+
 and NADH 
in CD4
+
 T cells treated with lactate. 
NAD
+
 is a key co-factor of the sixth reaction of the glycolytic cascade catalysed by 
glyceraldehyde 3-phosphate dehydrogenase. As a consequence of this reaction, NAD
+
 is 
reduced to NADH, which acts as an inhibitory feedback on glycolysis. NADH can be re-
oxidised to NAD
+ 
via the lactate dehydrogenase reaction converting pyruvate to lactate. 
This reaction is key to maintain a steady flow of glycolysis (reaction below).  
 
 
 
 
 
However, lactate dehydrogenase can perform the reverse reaction when cells are exposed 
to high levels of extracellular lactate as it happens at the site of inflammation, with 
reduction of NAD
+
 to NADH and consequent inhibitory feedback on glycolysis. Indeed, 
upon exposure to lactate I observed a drop in the NAD
+
/NADH ratio in CD4
+
 T cells, 
indicating a relative increase of intracellular NADH over NAD
+
 (Figure 4B). NADH has 
many biological functions in the cell, including acting as a cofactor in the NADH 
dehydrogenase / complex I of the mitochondrial electron transport chain (ETC). The ETC 
generates ATP and ROS during its activation (Finkel T and Holbrook NJ, 2000).  
Prompted by this finding, I then tested the effects of lactate on both the glycolytic energy 
metabolism and the mitochondrial respiration of 12 hours anti-CD3/CD28 mAbs 
activated CD4
+
 T by measuring the extracellular acidification rate (ECAR) and the 
oxygen consumption rate (OCR) via the use of the seahorse analyzer. ECAR was 
decreased upon lactate treatment. The drop had an average of 47 mpH/min in the 
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untreated control to a level of less than 40 mpH/min with lactate exposure. This effect 
was reverted by the treatment with the SLC5A12 Ab where ECAR increased from 40 
mpH/min to an average of 53 mpH/min (Figure 4C, left). An increase of ECAR, from 51 
mpH/min to 63 mpH/min was observed before lactate injection in CD4
+
 T cells pre-
treated with anti-SLC5A12 Ab.  
As lactate has been shown to fuel OXPHOS in a number of cells, including neurons and 
muscle cells (Cornell, NW 1973; Kompanje EJ, 2007; Pellerin L, 1998), OCR, which is 
an indicator of OXPHOS or mitochondrial respiration, was also measured. Surprisingly, 
OCR levels were not affected by sodium lactate. Conversely, CD4
+
 T cells, pre-treated 
with SLC5A12 Ab showed a drop in OCR before and after lactate injection (Figure 4C, 
right) an effect that will require further investigations. 
I reasoned that these findings might be explained by an influx of lactate in to CD4
+
 T 
cells when they are in a lactate-rich environment with consequent conversion to pyruvate 
and reduction of NAD
+
 to NADH slowing down the glycolytic flow. Pyruvate may then 
enter the tricarboxylic (TCA) cycle, but considering that I have not observed an increase 
in mitochondrial oxygen consumption rate, I wondered what the fate of the lactate-
derived carbons was. To test our rationale in a direct fashion, mass spectrometry-based 
tracer analysis of [
13
C]-lactate was performed. Specifically, CD4
+
 T cells were activated 
and incubated with [
13
C]-lactate in the presence or absence of anti-SLC5A12 Ab. 
Intracellular metabolites were then exctracted and analysed by mass-spectrometry. I 
found that a significant proportion of [
13
C]-lactate was converted to pyruvate and citrate, 
and that this effect was abrogated by incubation with SLC5A12 Ab (Figure 4D, E). 
Consistent with these data, by using commercial cellular metabolism assay kits, an 
increase in acetyl-CoA and citrate levels was also found in CD4
+
 T cells exposed to 
lactate at different time points (Figure 4F, G). These data suggest that when exposed to 
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high levels of lactate, such as in an inflamed tissue, CD4
+
 T cells can take up lactate via 
the specific carrier SLC5A12 and convert it to citrate. 
This process promotes an inhibitory feedback on glycolysis without affecting 
mitochondrial oxygen consumption rate, leaving with the question of what the fate of 
citrate would be. 
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Figure 4 - Lactate uptake by CD4+ T cells impacts intracellular utilization of central 
carbon metabolic pathways. (A) Glucose, and glutamine uptake rates and lactate release 
rate for activated CD4
+
 T cells isolated from HC PBMCs, then activated with anti-CD3 
and anti-CD28 mAbs for 24 hours followed by further 48-hour culture with lactate alone 
or in the presence of SLC5A12 Ab, or left untreated, in medium containing low glucose 
(5 mM) and 5% FB. (B) NAD
+
 and NADH intracellular levels in CD4
+
 T cells treated 
with sodium lactate (10 mM) for the indicated time points after 72-hour activation and 
shown as NAD
+
/NADH ratio. Lactate-untreated CD4
+
 T cells (Ctrl - dotted line) set to 1. 
(C) Seahorse measurements of extracellular acidification (left) and oxygen consumption 
(right) rates (ECAR and OCR, respectively) by CD4
+
 T cells treated with sodium lactate 
(10 mM) and/or SLC5A12 Ab, or left untreated after 72-hour activation. (D-E)
13
C tracing 
of 
13
C-U-lactate into pyruvate and citrate. Activated CD4
+
 T cells were incubated for 48 
hours with 
13
C-U-lactate in the presence or absence of SLC5A12 Ab (2.5 ug/mL, 
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HPA060904 - Atlas Antibodies) in medium containing low glucose (5 mM) and 5% FBS. 
Polar metabolites were extracted, analysed by LC-MS and peak areas of mass 
isotopologues normalized to cell number are represented. (F-G) acetyl-CoA (F) and 
citrate (G) intracellular levels in CD4
+
 T cells treated with sodium lactate (10 mM) for 
the indicated time points after 72-hour activation. Lactate-untreated CD4
+
 T cells (Ctrl - 
dotted line) set to 1. Data is representative of n = 3 biological replicates (A, C, G), n = 2 
biological replicates (B, D F). Two-tailed Student’s t-test (A-G) was used for 
comparisons. Data are expressed as mean ± s.e.m. *P<0.05; **P<0.01; ***P<0.001.  
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5.3 CHAPTER III – LACTATE MODULATES IL-17A PRODUCTION BY 
HUMAN CD4
+
 T CELLS 
 
5.3.1 Lactate shapes the effector phenotype of CD4+ T cells at the site of 
inflammation via SLC5A12 
 
Based on the findings showing that lactate modulates SLC5A12 expression by CD4
+
 T 
cells, I then tested the effects of exposure to high levels of lactate in the presence or 
absence of SLC5A12 Ab on the effector phenotype of activated tissue-resident CD4
+
 T 
cells isolated from inflamed human tonsils. I observed an up-regulation of IL17A and 
IFN mRNAs in response to lactate, which was reversed by incubation with SLC5A12 
Ab. IL17-family member IL22 also showed a tendency to upregulation in response to 
lactate. I did not observe any significant modulation in other cytokines (i.e. inflammatory 
IL6 or immunosuppressive IL10 and TGF; Figure 5A). However, the observed 
upregulations at the mRNA level resulted in only IL17A but not IFN upregulation at the 
protein level upon treatment with lactate and again this response was abolished by 
incubation with SLC5A12 Ab (Figure 5B). 
Supporting the findings of IL17 upregulation, also the mRNA of RORT, the signature 
transcription factor of the Th17 T cell subset, was elevated as a consequence of exposure 
to lactate and again this response was abolished by incubation with SLC5A12 Ab 
(Figure 5C). Interestingly, the expression of the transcription factor FOXO1, which 
limits the differentiation of CD4
+
 T cells to the Th17 subset and the consequent 
production of IL-17 (Ouyang W, 2009), was reduced by treatment with lactate, even 
though incubation with anti-SLC5A12 Ab did not have any effects on its expression 
(Figure 5C). Consistent with data in Figure 5A, expression of FOXP3, the signature 
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transcription factor of regulatory T (Treg) cells producing TGF and IL10 was not 
modified by lactate treatment (Figure 5C). Furthermore, I observed a lactate-dependent 
regulation of PD1 but not of the transcription factor BCL6 or the chemokine receptor 
CXCR5 (Figure 5C). 
To gain direct insights on the impact of lactate on the effector phenotype of CD4
+
 T cells 
at the site of inflammation, we conducted intracellular staining of CD4
+
IL17
+ 
(Th17), 
CD4+IFN+ (Th1), CD4+PD1+CXCR5+ (Tfh) and CD4+FOXP3+ or CD4+IL10+ (Treg) 
subsets isolated from highly inflamed tonsils (Figure 5D). Incubation with SLC5A12 Ab 
resulted in a reduction in the Th17 and Tfh T cell subsets with a less pronounced but still 
significant reduction in the Th1 and no modulation of the Treg subsets (Figure 5D). 
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Figure 5 - Lactate modulates T cell effector functions and these effects are 
counteracted by SLC5A12 blockade. (A) Relative mRNA expression levels of the 
cytokines IL17A, IL22, IFN, IL10, IL6, TGF as assessed by qRT-PCR in 12h anti-
CD3/CD28 mAbs activated CD4
+
 T cells treated with sodium lactate (10 mM) +/- anti-
SLC5A12 Ab (2.5 ug/mL, HPA060904 - Atlas Antibodies); mRNA levels of each 
cytokine expressed by untreated CD4
+
 T cells were set to 1 (Ctrl - dotted line). (B) IL-
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17A and IFN ELISAs (pg/mL), from supernatants of 24h activated CD4+ T cells. Cells 
were treated with sodium lactate +/- SLC5A12 Ab or left untreated. (C) Relative mRNA 
expression levels of RORT, FOXP3, FOXO1, BCL6, PD1, CXCR5, as assessed by qRT-
PCR in 12h anti-CD3/CD28 mAbs activated CD4
+
 T cells treated with sodium lactate in 
presence or not of anti-SLC5A12 Ab. mRNA levels in untreated CD4
+
 T cells (Ctrl - 
dotted line) were set to 1. (D) Representative flow cytometry plots (left) and percentage 
(right) of CD4
+
IL17
+
 (Th17), CD4
+
IFN+ (Th1), CD4+PD1+CXCR5+ (Tfh) and 
CD4
+
FOXP3
+
/CD4
+
IL10
+
 (Tregs) tonsil-resident CD4
+
 T cells. Cells were treated or not 
with anti-SLC5A12 Ab. Data is representative of n = 5 biological replicates (A, C), n = 5 
biological replicates with technical duplicates (B, left), n = 5 biological replicates (B, 
right) and n = 3 biological replicates (D). Comparisons were evaluated Student’s t-test. 
Data are expressed as mean ± s.e.m. *P<0.05; **P<0.01; ***P<0.001.  
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5.3.2 Lactate induces IL-17 expression via nuclear PKM2-mediated Stat3 
phosphorylation and enhanced fatty acid synthesis (FAS) 
 
I next asked how lactate may promote IL-17 expression and whether the lactate influx via 
SLC5A12 and its intracellular conversion to citrate may play a role in this response of 
CD4
+
 T cells. Exposure of activated CD4
+
 T cells to inflamed tissue levels of lactate 
caused a rapid, marked elevation of intracellular reactive oxygen species (ROS; Figure 
6A) in line with increased NADH levels described in Figure 4B. PKM2 molecules 
normally function as homo-tetramers in the cytosol converting phosphorenolpyruvate to 
pyruvate in the last reaction of glycolysis. ROS can promote the dimerization of the 
glycolytic enzyme pyruvate kinase M2 (PKM2). PKM2 dimers are found in the nucleus 
where they can phosphorylate transcription factors, including signal transducer and 
activator of transcription 3 (Stat3), a known transcriptional regulator of IL-17 (Shirai T, 
2016; Yang XO, 2007). Indeed, I found that lactate also promoted the translocation of 
PKM2 in the nucleus and the phosphorylation of Stat3 (Figure 6B). Activation of Stat3 
occurred as early as 1 hour after cell treatment with lactate (Figure 6B) and could still be 
observed at 12 hours (Figure 6C). Stat1, another Stat family-member implicated in Th17 
differentiation (Peters A, 2015), was also phosphorylated at the same time point (Figure 
6C). Phosphorylation of Stat1/3 was ablated by incubation with SLC5A12 Ab (Figure 
6C). 
The involvement of glycolysis in the lactate-mediated IL-17A production has been ruled 
out previously (Haas R, 2016). In particular, neither glycolysis activators nor inhibitors 
were able to reverse lactate-induced IL-17 (Haas R, 2016). 
For this reason, I investigated other possible metabolic pathways that could be involved 
in this phenomenon. In this context, de novo fatty acid synthesis (FAS) is a biological 
process that is implicated in the differentiation of the Th17 T cell subset (Berod L, 2014). 
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In addition, I observed that activated CD4
+
 T cells can take up lactate and convert it to 
citrate and acetyl-CoA (Figure 4D-G), which are the substrates of FAS. 
I therefore asked whether exposure to lactate may induce FAS in these cells by assessing 
the activation levels of A5’-AMP activated protein kinase (AMPK) and acetyl-CoA-
Carboxylase (ACC) key enzymes in the regulation of cellular fatty acid metabolism. I 
found that lactate caused a decrease in phosphorylated ACC at Serine 79 indicating 
increased ACC enzymatic activity (Figure 6D). Moreover, I also detected a decrease in 
phosphorylated AMPKα at Threonine 172 (Figure 6D), indicating reduced AMPK 
enzymatic activity. 
ACC is a key enzyme in the regulation of cellular fatty acid metabolism and exists in 
humans and other mammals in two isoforms, ACC1 and ACC2. Both enzymes catalyse 
the ATP-dependent carboxylation of CoA. Whereas ACC1 is present in the cytosol and is 
crucial for de novo synthesis of fatty acids (Chirala SS, 2004), ACC2 is associated with 
the outer mitochondrial membrane and functions as an important regulator of 
mitochondrial fatty acid oxidation (FAO, Abu-Elheiga L, 2001; Abu-Elheiga L, 2009). It 
has been recently found that the inhibition of ACC1 restrains the formation of human and 
mouse Th17 and promotes Tregs development (Berod L, 2014). Opposite to Th17, Treg 
cells rely on mitochondrial lipid oxidation in order to proliferate following the activation 
of AMP-activated kinase (AMPK) (Michalek RD, 2011). However, AMPK does not only 
regulate FAO but it also inhibits de novo FAS (Everts B, 2014; Lee J, 2014).  
ACC catalyzes the carboxylation of acetyl-CoA to form malonyl-CoA, the main 
molecular precursor for fatty acid synthesis. When FAS is activated, malonyl-CoA also 
acts as an inhibitor for mitochondrial β-oxidation as it inhibits carnitine palmitoyl 
transferase 1a (CPT1a) by direct interaction and thus the transport of fatty acids into the 
mitochondrial matrix (Foster DW, 2012).  
125 / 231 
 
In line with this, I found a marked decrease in phosphorylated ACC in the cytosol of 
activated, lactate-treated CD4
+
 T cells but no major change in phosphorylated ACC in the 
mitochondria (Figure 6E). Taken together these data suggest that lactate may not have 
major effects on fatty acid oxidation (FAO) but that lactate-derived citrate and acetyl-
CoA may serve as substrates for de novo synthesis of fatty acids, in activated CD4
+
 T 
cells.  
To test any effects of lactate on FAO in a more direct fashion, OCR was measured in 
activated CD4
+
 T cells cultured in 2.5 mM glucose and 1 μM BSA-palmitate that served 
as a substrate for FAO, or BSA alone. BSA-palmitate raised OCR as compared to BSA 
alone, but lactate did not affect either condition. Addition of etomoxir, an inhibitor of the 
key enzyme carnitine palmitoyltransferase-1 (CPT1) in the initiation of FAO, reduced 
BSA-palmitate OCR to the levels observed in the BSA alone control and again this effect 
was not affected by lactate (Figure 6F). 
To then test whether lactate-derived citrate and acetyl-CoA maybe utilized for de novo 
synthesis of fatty acids, activated CD4
+
 T were incubated with [
13
C]-U-lactate and traced 
[
13
C] labelling in palmitate. As shown in Figure 6G, lactate [
13
C] labels nearly 50% of 
newly synthesized palmitate. This effect was inhibited in cells that were incubated with 
SLC5A12 Ab indicating incorporation of lactate derived carbons in palmitate backbone 
(Figure 6G). 
Given the importance of both Stat3 and FAS in the differentiation of the Th17 T cell 
subset (Berod L, 2014; Shi, LZ 2011), I finally asked whether lactate may modulate the 
expression of IL-17 via either or both pathways. Activated CD4
+
 T cells were treated 
with: 5-(tetradecyloxy)-2-furoic acid (TOFA), a competitive inhibitor of acetyl-CoA 
carboxylase (ACC; Berod L, 2014); 4-methylene-2-octyl-5-oxotetrahydrofuran-3-
carboxylic acid, inhibitor of fatty acid synthase (C75; Shen Yi, 2017). 
dehydroepiandrosterone (DHEA), an inhibitor of glucose-6-phosphate dehydrogenase 
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(G6PDH, Raineri R and Levy HR, 1970), key step in the pentose phosphate pathway 
(PPP) providing NADPH equivalents for FAS (Schwartz AG, 2004; Dugan RE and 
Porter JW, 1969) was also added. As expected, all three inhibitors increased 
phosphorylated ACC levels, indicating an inhibitory effect on FAS. DHEA also increased 
phosphorylated AMPK (Figure 6H). With these three compounds, I then tested the 
impact of lactate-induced FAS on Stat3 activation and IL-17 synthesis. All three drugs 
reduced lactate-induced phosphorylation of Stat3 (Figure 6I) and expression of IL-17A 
(Figure 6J). Also the AMPK activator 5-Aminoimidazole-4-carboxamide 1-β-D-
ribofuranoside (AICAR; Corton JM, 1995) and the potent and selective PKM2 activator 
N,N’-diarylsulfonamide (DASA), which stabilizes cytosolic PKM2 homo-tetramers and 
prevents PKM2 dimer translocation in the nucleus (Anastasiou D, 2011), markedly 
reduced the expression of IL-17A (Figure 6J). Interestingly, a combination treatment 
with DASA and C75 or TOFA resulted in an additional reduction of lactate-induced IL-
17A production as compared to each compound alone (Figure 6J). 
Taken together these data indicate that lactate modulates IL-17 expression by activating 
two pathways, PKM2 translocation in the nucleus and enhanced FAS, converging on 
Stat3-induced transcription of IL-17 (Figure 6K). 
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Figure 6 - Lactate induces IL-17A via PKM2-mediated STAT3 phosphorylation and 
FAS. (A) Reactive oxygen species (ROS) in activated CD4
+
 T cells in presence of 
sodium lactate (10 mM, time course). PBS only or H2O2 were used as negative and 
positive control respectively. (B) Western blots of cytosolic or nuclear fractions of anti-
CD3/CD28 mAbs (TCR)-activated CD4
+
 T cells untreated or treated with sodium lactate 
(10 mM) for 1h and 4h, detected with antibodies against PKM1/2, P-Stat3 (P-T705-
Stat3), Stat3,  β-actin and Histone H3. (C) Western blot and densitometric analysis of P-
Stat3 (P-T705-Stat3), Stat3, P-Stat1 (P-T701-Stat1), Stat1 in activated human CD4
+
 T 
cells in presence or not of sodium lactate. Cells were pre-treated (1 hour) with anti-
SLC5A12 Ab or left untreated. (D) Western blot analysis and densitometric 
quantifications of P-ACC (P-S79-ACC), ACC, P-AMPK (P-T172-AMPK) and AMPK in 
activated CD4
+
 T cells in presence of sodium lactate (time course). Beta-actin was used 
as control. (E) Western blots of cytosolic or mitochondrial fractions of TCR-activated 
CD4
+
 T cells untreated or treated with sodium lactate (10 mM) for 1 and 4 hours, 
detected with antibodies against P-ACC (P-S79-ACC) and ACC.  Beta-actin and voltage-
dependent anion-selective channel protein (VDAC) were used as control. (F) Fatty acid 
oxidation (FAO) in TCR-activated CD4
+
 T cells treated or not with sodium lactate (10 
mM) for 1h and 4h in the presence of 2.5 mM Glucose, BSA-palmitate (167 μM) or BSA 
alone or CPT1a inhibitor Etomoxir (40 uM). (G) Quantification of [
13
C] labelled 
palmitate in TCR-activated CD4
+
 T cells treated or not with [
13
C]-lactate (10 mM) in 
presence or not of anti-SLC5A12 Ab. (H) Densitometric quantifications of P-ACC (P-
S79-ACC), ACC, P-AMPK (P-T172-AMPK) and AMPK in TCR-activated CD4
+
 T cells 
treated with metabolic drugs C75 (10 uM), TOFA (20 uM) and DHEA (20 uM). (I) 
Western blots (left panel) and densitometric analysis (right panel) of P-Stat3 (P-T705-
Stat3) and Stat3 in activated human CD4
+
 T cells in presence or not of sodium lactate and 
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metabolic drugs C75 (10 uM), TOFA (20 uM) and DHEA (20 uM). (J) IL-17A 
production (pg/mL) from supernatants of TCR-activated CD4
+
 T cells treated overnight 
with sodium lactate and metabolic drugs C75 (10 uM), TOFA (20 uM), DHEA (20 uM), 
DASA (20 uM), AICAR (1 mM). (K) Schematic depicting selected intracellular 
metabolic pathways and signalling modulated by lactate. Data is representative of n = 3 
biological replicates (A, C, D, F), n = 2 biological replicates with technical duplicates (G-
I), n = 5 biological replicates with technical duplicates (J). Comparisons were evaluated 
using two-tailed Student’s t-test (A-D, G), two-way ANOVA (F) or one-way ANOVA (I, 
J). Data are expressed as mean ± s.e.m.*P<0.05; **P<0.01; ***P<0.001. 
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5.4 CHAPTER IV – LACTATE INDUCES T CELL ENTRAPMENT IN THE 
INFLAMMATORY SITE 
 
5.4.1 SLC5A12 blockade reverses lactate inhibition of CD4+ T cell locomotion  
 
Building upon our previous findings that inflamed tissue levels of lactate induce a ‘stop 
migration signal’ in activated CD4+ (Haas R, 2015; Pucino V, 2017), I then assessed the 
impact of interfering with SLC5A12 function on human CD4
+
 T cell migration in vitro 
and ability to egress from the inflamed tissue ex vivo. HC CD4
+
 T cells were isolated 
using negative selection beads, activated with anti-CD3 and anti-CD28 antibodies for 3 
days and the chemotactic response was induced by the pro-inflammatory chemokine 
CXCL10. Isolated activated CD4
+ 
T cells were treated with sodium lactate (10 mM) in 
presence or not of anti-SLC5A12 Abs. I used in parallel the polyclonal Ab (2.5 ug/mL, 
HPA060904 - Atlas Antibodies) and the monoclonal anti-SLC5A12 mAb (1:50) 
generated by our group (see paragraph 4.8). Chemokinesis was evaluated after 4 hours in 
a trans-well (Figure 7A). As expected, SLC5A12 Ab reversed the ‘stop migration signal’ 
induced by lactate (Figure 7A; Haas et al., 2015). Furthermore, the mAb clones 3C7 and 
9G7 were able to significantly restore the lactate-mediated inhibition of T cell locomotion 
(Figure 7A).  
Prompted by these results, I sought to assess the impact of SLC5A12 blockade, on T cell 
egress, ex vivo. I started by culturing equal size tissue sections (1-3 mm
2
) from 
juxtaposing areas of tonsil biopsies – isolated from patients who had been subjected to 
tonsillectomy – in the presence or absence of lactate and/or anti-SLC5A12 Ab. I then 
assessed by flow cytometry the type and number of immune cells released in the culture 
media in each condition (Figure 7B). Lactate reduced the egress of CD4
+
 T cells as 
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compared to the control condition and this effect was reversed by anti-SLC5A12 Ab. 
Interestingly, SLC5A12 Ab blockade did not significantly reverse lactate mediated 
inhibition of cell egress in CD8
+
, CD19
+
 or CD14
+
 cells (Figure 7B). I therefore tested 
3C7 mAb alongside SLC5A12 Ab in the ex vivo egress model in synovial tissues. Again 
SLC5A12 Ab was able to reverse the lactate-mediated retention of CD4
+
 T cell in the 
tissue and a similar effect was obtained with 3C7 mAb (Figure 7C, D). 
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Figure 7 - SLC5A12 blockade promotes the egress of CD4
+
 T cell from the inflamed 
tissue. (A) In vitro chemotaxis (4 hours) of activated human CD4
+
 T cells towards 
CXCL10 (300 ng/mL) in the presence or not of sodium lactate (10 mM) +/- anti-
SLC5A12 polyclonal Ab (2.5 ug/mL) or monoclonal mAbs (1:50; 3C7, 4G2, 6E1, 7C1, 
9G4, 9G7 and 10E11 mAb clones), as shown. CXCL10 untreated CD4
+ 
T cells (dotted 
line) were set to 100. (B) Analysis of MCs egress (4 hours) from human tonsil tissues 
treated with anti-SLC5A12 Ab, sodium lactate or the combination of both.  Cells were 
stained for CD4
+
, CD8
+
, CD19
+
 and CD14
+
. (C, D) Representative flow cytometry plots 
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(C) and quantification (D) of egressed CD4
+
 T cells from RA synovial tissue culture in 
the shown experimental conditions. Data is representative of n = 3 biological replicates 
with technical duplicates (A, B), n = 3 biological replicates (D). Graphs show mean ± 
s.e.m. Comparisons were evaluated using two-tailed Student’s t-test. Data are expressed 
as mean ± s.e.m. ∗P≤0.05; ∗∗P≤0.01; ∗∗∗P≤0.001. 
  
135 / 231 
 
5.4.2 Lactate limits T cell motility via reducing glycolysis and potentiating FAS 
 
Next, I asked how the metabolic adaptation of activated CD4
+
 T cells to inflamed tissue 
levels of lactate impacted on their response to migratory stimuli. Glycolysis is required 
for the motility of activated, murine CD4
+
 T cells (Haas R, 2015) and FAS supports 
invasiveness of inflamed tissues by peripheral CD4
+
 T cells (Shen Y, 2017). Based on 
these findings, I started to investigate how T cells adapt their metabolism in response to 
the exposure to extracellular lactate. I first analysed the effect of exposure of activated, 
human CD4
+
 T cells to lactate on several glycolytic enzymes in a time-course 
experiment. I observed reduced levels of hexokinase 1 (HK1), HK2, phosphofructokinase 
(PFK), enolase 1 and pyruvate kinase (PKM1/2; Figure 8A), indicating reduced rates of 
glycolysis, consistent with data in Figure 4A-C. However, lactate-induced 
downregulation of HK1 and enolase1but not of HK2 and PKM1/2 was impeded by cell 
incubation with SLC5A12 Ab (Figure 8B). These data suggest specific checkpoints of 
lactate-mediated control of glycolysis, in addition to the observed increased conversion of 
NAD
+
 to NADH, as shown in Figure 4B. 
Based on the observation that lactate is converted to citrate and increases acetyl-CoA 
(Figure 4D-G), I began to investigate whether the effect of reduction of glycolysis could 
be related to lactate-induced acetylation followed by protein degradation (Figure 8C). 
Acetylation is mediated by sirtuins, a family of histone deacetylases (HDACs) that are 
involved in mitochondrial metabolism, aging, and mediate the effect of calorie restriction 
(Canto C, 2009). Sirtuins catalyze the deacetylation reaction and NAD
+
 is the coenzyme. 
The expression of sirtuins increases when the NAD
+
/NADH ratio rises (Gambini J, 
2011). When lactate levels increase and this metabolite is re-converted to pyruvate, the 
NAD
+
/NADH ratio decreases as shown in Figure 4B, lowering sirtuin activity. The 
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regulation of protein acetylation is considered to be of great importance for mitochondria, 
which contain high levels of NAD and low number of acetylated proteins, which in turn 
regulate mitochondrial function (Kim SC, 2006). In the absence of mitochondrial Sirt3, 
mitochondrial proteins become hyperacetylated, leading in turn to mitochondrial 
dysfunction, which is a common phenomenon of age and -related diseases (Anderson 
KA, 2013). On the same line, another study shows that acetylation is also important to 
regulate glycolysis. The authors found that HK2 binding to the mitochondria is decreased 
in muscle from high fat diet-fed SIRT3 KO mice, suggesting decreased HK2 activity 
(Lantier L, 2015). 
To test sirtuin activity I probed whole cell protein lysates with an antibody that detects 
acetylated lysine residues. Interestingly lactate treatment did not change the level of 
protein acetylation in a time course experiment (Figure 8C) but this checkpoint control 
will require further investigations. 
Another important checkpoint for the glucose fate is HK2 cellular localization. While 
cytosolic HK2 mediates glycolysis, mitochondrial HK2 promotes anabolic pathways. 
More specifically, HK2 localization on to the outer membrane of the mitochondria 
diverts glucose-6-phosphate in to the PPP producing NADPH equivalents and anabolic 
intermediates rather than being used in glycolysis to produce energy (Mathupala SP, 
2009). Based on this evidence and on the data in Figure 8A showing a marked 
modulation of HK2 upon lactate, I then focused on HK2 and its intracellular localization. 
I found an increase in mitochondrial HK2 after 4 hour lactate treatment compared to 
untreated cells (Figure 8D). This observation was supported by confocal microscopy data 
showing co-localization of HK2 with mitochondria upon 4-hour treatment with lactate 
(Figure 8E). We also found a reduction in the NADP
+
/NADPH ratio at 1 hour and 4 
hours after cell treatment with lactate (Figure 8F), consistent with an induced shunt of 
glucose-6-phosphate into the PPP and with the observed induction in FAS. 
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Therefore, I asked whether induction of FAS mediated by lactate is required to limit T 
cell locomotion in the inflamed tissue. Specifically, activated CD4
+
 T cells were treated 
with lactate (10 mM) with or without DHEA, TOFA and C75 or left untreated and then 
subjected to chemokinesis in response to CXCL10. All compounds blocking FAS at 
different key steps unblocked lactate-induced inhibition of CD4
+
 T cell motility (Figure 
8G). Overall, these observations indicate that lactate-induced inhibition of CD4
+
 T cell 
response to migratory stimuli and retention in the inflamed tissue is due to a metabolic 
adaptation which entails reduced glycolysis and translocation of HK2 to the outer 
membrane of mitochondria, which in turn supports NADPH-dependent de novo FAS 
(Figure 8H). 
 
 
  
138 / 231 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
139 / 231 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 - Lactate reduces expression of glycolytic enzymes and modulates the 
activation state of enzymes regulating fatty acid metabolism in CD4+ T cells. (A) 
Time course western blot (left panel) and densitometric analysis (right panel) of  HK1, 
HK2, phosphofructokinase (PFK), enolase 1 alpha  and  pyruvate kinase M1/2 (PKM1/2) 
in activated CD4
+
 T cells treated with sodium lactate (10 mM) for 10’, 30’, 1h and 4h. 
Densitometric quantification of western blots denotes mean ± s.e.m. (B) Western blot 
analysis of HK1, HK2, glucokinase (GCK), enolase 1 alpha, PKM1/2, aldolase; -actin 
was used as control (left panel). Activated CD4
+ 
T cells were treated or not with lactate 
+/- SLC5A12 Ab for 12-24h. Densitometric quantification of western blots (right panel) 
denotes mean ± s.e.m. (C) Representative western blot of whole CD4
+
 T cell lysates 
exposed for different times to 10 mM sodium lactate and probed with antibodies against 
total Lysine-Acetylation (K-Ac). (D) Western blot analysis of cytosolic (C), 
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mitochondrial (M) or nuclear (N) fractions of activated CD4
+
 T cells, treated with sodium 
lactate (10 mM) for 1h and 4h. Antibodies against HK2, β-actin, VDAC, and Histone H3 
were used. (E) Immunofluorescence images of CD4
+
 T cells untreated or exposed to 4h 
sodium lactate (10 mM), stained with DAPI, anti-HK2 antibody or MitoTracker Deep 
Red FM (300 nM). Scale bars 10 uM. (F) NADP
+
, NADPH, were measured in activated 
CD4
+
 T cells (n = 5 with technical duplicates) treated with sodium lactate (10 mM) at 
different time points and shown as ratio. Untreated CD4
+
 T cells (Ctrl - dotted line) were 
set to 1. (G) In vitro chemotaxis of activated CD4+ T cells toward CXCL10 (300 ng/mL) 
in the presence of sodium lactate (10 mM) and metabolic drugs C75 (10 uM), TOFA (20 
uM) and DHEA (20 uM). CXCL10 untreated CD4
+
 T cells (without CXCL10 - dotted 
line) were set to 100. (H) Schematic of the proposed mechanism of lactate modulation of 
pentose phosphate pathway and fatty acid synthesis via mitochondrial localization of 
HK2.  
Data is representative of n = 3 biological replicates (A-D), n = 2 biological replicates (E), 
n = 5 biological replicates with technical duplicates (F), n = 3 biological replicates with 
technical duplicates (G). Comparisons were evaluated using two tailed Student’s t-test [A 
(right panel), B (right panel), F] and one-way Anova (G). Data are expressed as mean ± 
s.e.m. *P<0.05; **P<0.01; ***P<0.001.   
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5.5 CHAPTER V - CLINICAL RELEVANCE AND THERAPEUTIC ASPECTS:  
A FOCUS ON RHEUMATOID ARTHRITIS  
 
5.5.1 Lactate signalling in RA 
 
For more than 50 years, the inflamed joint has been recognized as a site of low glucose 
and high lactate (Goetzl EJ, 1971; Treuhaft and McCarty, 1971), reflective of the intense 
cellular turnover in the rheumatoid pannus. Accumulation of lactate in RA synovial fluid 
is in part responsible of the acidic environment of RA synovitis. It is well established that 
synovial fluid pH was significantly lower in active rheumatoids with inflammatory joints 
than in normal (7.2 vs 7.48) (Cummings NA and Nordby GL, 1966). 
The rheumatoid synovial environment is paradigmatic of some of the lactate-induced 
changes seen in T cells, including cell entrapment, IL-17 secretion and loss of antigen 
responsiveness (Croia C, 2013). In particular, our group pioneered the discovery that 
lactate modulates specific T cell subsets via the interaction of lactate transporters. 
Sodium lactate selectively affects CD4
+
 T cell functions via SLC5A12, while lactic acid 
was found to have an impact on CD8
+
 T cell motility and cytolytic capability via its 
influx through SLC16A1 (Haas R, 2015; Pucino V, 2017; Figure IX and Figure X). 
It has also been found by our group that lactate transporter SLC5A12 is highly expressed, 
at protein and molecular level, in RA synovial tissues and this expression significantly 
increased in correlation with the inflammatory T cell score of the samples tested (Figure 
IX, Haas R, 2015). Furthermore, lactate in the RA synovial fluid directly promotes an 
upregulation of the lactate transporter SLC5A12 by CD4
+
 T cells (see paragraph 5.1.2). 
In line with this evidence, a positive correlation between synovium SLC5A12 and disease 
activity (measured as the difference between DAS28-CRP at baseline and DAS28-CRP at 
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6 months), was also found (Figure 9A, B). In addition, synovium SLC5A12 was less 
expressed in patients with a good response to treatment, according the EULAR response 
(Table 5), than in the one with a poor response (Figure 9A, B). These findings 
established lactate signalling as integral feature of RA and open up the possibility of a 
new biomarker for diseases progression and response to treatment and a novel target for 
therapeutic intervention. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure IX - SLC5A12 expression in RA synovium. Representative images of RA 
synovial tissues stained for CD3 displaying progressively higher degree of T cell 
infiltration as quantified using a semi-quantitative score from T0 (absence of infiltrating 
T cells) to T3 (large number of infiltrating T cells organizing in ectopic follicles). (B) 
Relative mRNA expression levels of SLC16A1 and SlC5A12 in the synovial fluid 
isolated from the joints of RA patients. (C) Double immunofluorescence staining for 
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SLC5A12 and CD4 or CD8 in the synovial tissue of RA patients. SLC5A12 (green) is 
highly expressed within the RA synovium in the presence of a high degree of CD4
+
 (red) 
T cell infiltration. Merging (yellow) of the green and red channels demonstrates that 
SLC5A12 is selectively expressed by CD4
+
 but not CD8
+
 infiltrating T cells. 
Quantification of the percentage of double positive cells is provided upon counting 
positive cells (single and double positive for each marker) in 6 images per condition. 
Columns represent % of double positive CD4
+
SLC5A12
+
 population within the CD4
+
 or 
SLC5A12
+
 cells and % of double positive CD8
+
SLC5A12
+ 
population within the CD8
+
 
or SLC5A12
+ cells. Scale bars: 50 μm (Adapted from: Haas R, 2015). 
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A   B 
 
 
 
 
 
Figure 9 - SLC5A12 correlates with disease activity and response to treatment. (A) 
Synovium SLC5A12 transcript positively correlates with delta disease activity score 
(DAS28-CRP) calculated as the difference between DAS28-CRP at baseline and DAS28-
CRP at 6 months. (B) Synovium SLC5A12 levels are reduced in patients with good 
EULAR response to treatment in comparison to non responder patients. Analysis was 
performed by using R program. Correlation analyses were performed using Spearman's 
correlation coefficients. One-way ANOVA test was used for comparisons in B; P=0.029 
refers to the comparison between non and good response. P≤0.05 was considered 
significant. 
  
P=0.029 r=0.28, P=0.032 
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Figure X - Lactate modulates T cell functions in the RA joint. Lactate accumulates in 
synovial joints of RA patients and modulates T cell functions. Lactate accumulates in the 
synovial joints during inﬂammation, where it is in part responsible of the acidic 
environment. Here, T cells sense high concentrations of lactate via their speciﬁc carriers, 
the sodium lactate transporter SLC5A12 in CD4
+
 T cells and the lactic acid transporter 
SLC16A1 in CD8
+
 T cells. Via this interaction, lactate inhibits T cell motility by 
interfering with the glycolytic pathway, which is important for T cell migration. Loss of 
motility might lead to T cell entrapment in the synovial joint, where CD4
+
 T cells 
produce high amounts of IL-17 and CD8
+
 T cells lose their cytolytic activity. Increased 
retention of CD4
+ 
T cells accompanied by increased local levels of IL-17 might in turn be 
responsible of the formation of ELSs (Adapted from: Pucino V, 2017). 
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5.5.2 Lactate/SLC5A12-induced metabolic signalling network is impaired in RA 
patients      developing ELSs 
 
Recently there has been increasing interest in synovial biopsies to obtain inflamed 
synovial tissue from joints and thereby gain better understanding of the pathogenic events 
in these diseases. Histopathotype and pathological pathways-based patient stratification 
prior to therapeutic intervention is becoming an emergent field to identify biomarker 
predictors of clinical outcomes and responses to therapy (Dennis GJr, 2014; Pitzalis C, 
2013) 
During these years I have had the opportunity to work on a cohort of naïve-to-treatment 
RA patients belonging to the Pathobiology of Early Arthritis Cohort (PEAC) available in 
Prof. Pitzalis’ lab. This includes 300 DMARD-naïve early arthritis patients with linked 
detailed pathobiological data, including gene expression profiling, serum and synovial 
fluid cytokine and chemokine analysis, biological tissue characterization, state-of-the-art 
ultrasound imaging and clinical phenotyping (see paragraphs 2.5.2 and 4.1).  
 Synovial biopsies collected for this cohort were classified by histological analysis 
according to pathotype (i.e. lymphoid, myeloid or fibroid) and presence of ectopic 
lymphoid structures (ELSs) (Pitzalis C, 2013). These are organized aggregates of T and B 
cells that develop at sites of chronic inflammation and are associated with more severe 
disease course and autoimmune responses, as well as reduced response to therapy 
(Pitzalis C, 2013; Cañete JD, 2009). ELSs are rich in CD4
+
IL17A
+
 cells which play a 
pivotal role in ELS formation and maintenance (Jones G, 2016). Synovial biopsies were 
also classified by histological analysis according to inflammatory score (Krenn score; 
Krenn V, 2002) and expression of cell-lineage CD4
+
 T cell gene modules. As expected, 
the synovial biopsies with a lymphoid pathotype were also ELS positive and showed the 
highest inflammatory score and degree of infiltration by CD4
+
 T cells (Figure 10A). In 
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this cohort I analysed by RNA-sequencing the expression of groups of metabolic genes 
by n = 87 synovial biopsies. In the lymphoid pathotype, I found evidence of expected 
patterns of Th17 differentiation genes, i.e. reduced FOXO1 and increased IL17A, as well 
as of ELS genes. When metabolic genes were analyzed, I found a downregulation of 
glycolytic genes concurrent with an upregulation of PPP and TCA cycle genes in the 
lymphoid pathotype as compared to the other pathotypes (Figure 10A). These data 
support a role for lactate/SLC5A12-induced metabolic reprogramming in CD4
+
 T cells as 
a distinctive mechanism of lymphoid RA pathogenesis. 
Overall, lactate levels in the synovial fluid did not differ between ELS+ and ELS- RA 
patients (Figure 10B). 
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Figure 10 - Synovial RNA-Sequencing in early rheumatoid arthritis shows 
differential expression of metabolic genes according to the histological patterns of 
synovitis. (A) Heatmap showing synovial RNA-seq expression of groups of metabolic 
genes differentially expressed (FDR < 0.05) between synovial biopsies (n = 87) from 
early rheumatoid arthritis. Synovial biopsies were classified as positive or negative for 
ELS by histological analysis. Upper tracks show synovial histology inflammatory score 
(Krenn score), expression level of cell-lineage CD4
+
 T cell gene modules, ELS histology 
grouping and overall histology pathotype (Lymphoid, Myeloid or Fibroid). (B) Lactate 
levels (mM) in the synovial fluid of ELS- (n = 7) and ELS+ (n = 9) RA patients (B). 
Comparisons were evaluated using one-way ANOVA. Data are expressed as mean ± 
s.e.m. *P<0.05; **P<0.01; ***P<0.001. 
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5.5.3 Antibody-mediated blockade of SLC5A12 ameliorates the clinical course of 
CD4
+
 T cell-driven human-glucose-6-phosphate-isomerase (hG6PI)-induced arthritis 
 
I next interrogated the possible therapeutic implications of my findings. To evaluate the 
impact of SLC5A12 blockade on arthritis severity, a human glucose 6 phosphate 
isomerase (G6PI) mouse model was used. This model was chosen because of its 
similarity with human disease; indeed, G6PI in adjuvant induces symmetric polyarthritis 
of the small distal joints in genetically susceptible normal mice. Furthermore, CD4
+
 T 
cells were the major drivers of arthritis (Schubert D, 2004) hence representing an as close 
a model as possible to human lymphoid RA. In brief, DBA/1 mice were immunized s.c. 
with 20 μg human hG6PI synthetic peptide. At the onset of disease (10 days), mice were 
untreated or treated sub-plantar into the rear paws with infliximab (Remicade, Janssen 
Biologics), TNF mAb (TN3-19.12, BD bioscience), SLC5A12 Ab, iso-TNF Ab and iso-
SLC5A12 Ab. Antibody and the corresponding isotype control was injected into the right 
or left back paw respectively of the same mouse.  
SLC5A12 Ab treatment reduced the arthritis score after 18 days from the onset of the 
disease as well as the histological score compared the isotype control (Figure 11A-D).  
This effect was even more remarkable than treatment with TNF mAb and Infliximab 
(Figure 11A, C). 
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Figure 11 - Antibody-mediated blockade of SLC5A12 ameliorates the clinical course 
of CD4
+
 T cell-driven human-glucose-6-phosphate-isomerase (hG6PI)-induced 
arthritis. (A) Arthritis score in mice treated with SLC5A12 Ab, infliximab, TNF mAb 
and an isotype control at day 7 and 11. (B) Representative images of the paws at day 21 
post-immunization with hG6PI showing the effects of treatment of SLC5A12 Ab as 
compared to an SLC5A12 isotype control antibody (i.e. swelling, redness). (C) 
Histological score (max 4) and (D) representative H&E staining of ankles and pads 
sections showing reduced immune infiltrate in the SLC5A12 Ab treatment group (D, 
right panel) as compared to PBS and isotype control antibodies (D, left panel). Values 
denote mean ± SD, A (number of mice per group, n = 6), C (each dot corresponds to an 
H&E slide acquired from the representative group, n = 19-24 slides/group). Comparisons 
were evaluated using two tailed Student’s t-test *P<0.05; **P<0.01.  
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6 DISCUSSION 
 
For a long time after its discovery at the beginning of the 20th century, lactate has been 
considered a bystander molecule produced at the end of glycolysis. Only in the 90’s, 
lactate has begun to be recognized as an active metabolite able to regulate immune cell 
responses. RA is characterized by the accumulation of lactate in the inflamed synovium, 
which is partly responsible for the establishment of an acidic and hypoxic environment. 
Here lactate inhibits T cell motility. Furthermore, sodium lactate promotes a plastic 
switch toward a Th17 subset by CD4
+
 T cells while lactic acid reduces the cytotoxic 
capacity of CD8
+
 T cells. Interestingly, all these events are dependent upon lactate's 
interference with intracellular metabolic pathways, specifically glycolysis and fatty acid 
synthesis. These phenomena contribute to the exacerbation of chronic inflammation and 
might be responsible for the breach of tolerance and the formation of long-lasting ELS at 
the site of inflammation such as in RA synovitis.  
Lactate modulates T cell functions via carriers that belong to two families, the proton-
linked-monocarboxylate-transporters (MCTs) and the Na
+
-coupled- electrogenic-
transporters that are expressed by several tissues including immune system, endothelium 
and epithelium. Their expression can increase during inflammation or in the tumor site. 
For this reason, targeting lactate transporters is becoming a new attractive area to develop 
new therapeutics for inflammation and cancer. 
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6.1 Lactate promotes metabolic rewiring in human CD4+ T cells 
 
Lactate has been shown to have a variety of effects on cellular metabolism, including the 
the increase of mitochondrial OXPHOS in neurons (Pellerin L and Magistretti PJ, 1994; 
Pellerin L, 1998; Magistretti PJ, 2018), the induction of gluconeogenesis during the Cori 
cycle in the liver and the synthesis of glycogen in skeletal muscle cells (Cornell NW, 
1973). Furthermore, our group has recently discovered that lactate directly regulates 
glycolysis (Haas R, 2015). This takes place via different mechanisms I have investigated 
throughout these years that are in line with previous evidence showing that lactate acts as 
a potents glycolysis inhibitor affecting the rate limiting glycolytic enzyme 
phosphofructokinase (PFK; Leite TC, 2011). In particular, I have observed a decrease in 
the glucose flux as well as a reduced ECAR upon lactate treatment. Consistent with this 
observation, also the ratio NAD/NADH was dropped within the first 10 minutes up to 4h 
of lactate treatment, which is most likely due to the reversal of the LDH reaction due to 
lactate abundance (Figure 4B). NADH is used as an essential cofactor to allow the 
conversion of pyruvate to lactate by LDH. NADH is oxidized to NAD
+
, which allows the 
glycolysis to persist. Excreting lactate through MCTs/SMCTs eliminates protons arising 
from the glyceraldehyde 3-phosphate dehydrogenase reaction in glycolysis, thus 
maintaining the pH homeostasis inside the cells and acidifying the extracellular space. 
Interestingly, together with reduced glucose flux in the presence of lactate I also observed 
a decreased lactate release that may suggest that T cells continue to use lactate as a 
carbon source during glucose deprivation. 
This evidence is in line with a recent publication of Faubert et al, where the authors 
showed that lactate is a TCA cycle carbon source for cancer cells (Faubert B, 2017).  
Using intra-operative infusions of [
13
C]-labeled nutrients, they were able to analyze the 
pattern of enrichment of labelled metabolites directly within the tumour (i.e. lung 
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tumours). The infusion of [U-
13
C] glucose showed a different pattern of enrichment in the 
cancer tissue as compared to the benign lung, with an excess of labelled lactate (rather 
than other upstream glycolytic metabolites) within the tumour. Interestingly, the infusion 
of [
13
C]-lactate caused not only the accumulation of labelled lactate itself in the tumour, 
but also of labelled pyruvate, alanine and TCA cycle intermediates, showing that lactate 
was actively being used to supply the TCA cycle. Lactate behaves as a major fuel for 
TCA cycle intermediates, not only for cancer cells but also for healthy activated T cells 
as confirmed by flux analysis data labelling lactate with [
13
C] (Figure 4D). An increase 
of pyruvate and citrate was observed in the presence of [
13
C]-lactate while a decrease was 
shown when cells were pre-treated with SLC5A12 Ab, confirming a reduced lactate flux 
in the TCA cycle by blocking this lactate transporter. These experiments were conducted 
in low glucose environment (5 mM) thus suggesting that in conditions of glucose 
deprivation and lactate excess, such as during inflammation, CD4
+
 T cells utilize lactate 
as a fuel to sustain their metabolism. 
 NADH generated upon lactate treatment is taken up by electron transport chain for the 
generation of ROS (Ying W, 2008). In line with this, the levels of ROS in whole cell 
extracts after lactate exposure increased rapidly (Figure 6A). A possible mechanism for 
ROS generation can be the presence of flavin-dependent lactate oxidase in the 
intermembrane space of hepatic mitochondria (de Bari L, 2010). In this paper, the authors 
demonstrated that exposure of isolated rat mitochondria to lactate produced pyruvate in a 
1:1 stoichiometry with the concomitant release of H2O2 that was independent of the 
respiratory chain. The reaction was subsequently inhibited by NAD
+
 in a competitive 
manner. It is possible that a similar mechanism also led to the transient increase in ROS 
levels in CD4
+ 
T cells. ROS production is regulated by antioxidants such as manganese-
dependent superoxide dismutase (MnSOD or SOD2) or glutathione (GSH). How lactate 
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affects these molecules is still unknown. It is possible that a direct or indirect inhibition 
of antioxidant systems mediated by lactate might explain the increased levels of ROS. 
It is worth mentioning that, although lactate is a carbon fuel for TCA cycle and is able to 
increase OXPHOS in the brain (Pellerin L, 1994; Pellerin L, 2012; Magistretti PJ, 2018) 
as well as ROS production, CD4
+
 T cell mitochondrial respiration, measured as OCR, 
was not influenced by lactate when compared to untreated cells (Figure 4C). Conversely, 
OCR was decreased by SLC5A12 Ab treatment, a finding that will require further 
investigations. A possible explanation is that SLC5A12 mediates the transport of other 
monocarboxylic acids such as pyruvate, propionate, butyrate, nicotinate, and short-chain 
fatty acids which, differently from lactate, might affect T cell mitochondrial respiration. 
In support of the data showing that lactate is a feeder for the TCA cycle, an increase in 
acetyl-CoA and citrate levels under lactate exposure was also observed. 
Acetyl-CoA is produced by the breakdown of both carbohydrates (by glycolysis) and 
lipids (by β-oxidation). It then enters the TCA cycle in the mitochondrion by combining 
with oxaloacetate to form citrate. In the cytosol, citrate can be reconverted to acetyl-CoA  
and then be used to synthesize fatty acids through carboxylation by acetyl-CoA 
carboxylase into malonyl-CoA, the first committed step in the synthesis of fatty acids. 
Notably, after lactate treatment I detected activation of the rate limiting enzyme for fatty 
acid synthesis acetyl-CoA carboxylase (ACC) (Figure 6D), which has been shown to be 
indispensable for IL-17 production in CD4
+
 T cells (Berod L, 2014). This mechanism 
will be discussed in detail in the following paragraph 6.2. 
Acetyl-CoA serves as a substrate for lysine acetyltransferases (KATs), which catalyze the 
transfer of acetyl groups to the epsilon-amino groups of lysine in histones and many other 
proteins. Fluctuations in the concentration of acetyl-CoA, reflecting the metabolic state of 
the cell, are translated into dynamic protein acetylation that regulate a variety of cell 
functions, including transcription, replication, DNA repair, cell cycle progression, and 
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aging (Shahbazian MD, 2007). Acetylation of cellular proteins creates specific 
degradation signals (Hwang CS, 2010) which can in turn modulate the expression of 
metabolic enzymes, including glycolytic ones, inducing a metabolic reprogramming (Cha 
Y, 2017). Interestingly, I did not observe an increased acetylation upon lactate treatment 
(Figure 8C) thus suggesting that the reduction of glycolytic enzymes may not be 
ascribed to protein degradation following acetylation but further investigation to 
understand this phenomenon is needed. 
Along acetyl-coA, citrate levels were also found increased upon lactate treatment (Figure 
4G). Citrate has been recently shown associated to drive an inflammatory response in M1 
macrophages (Jha AK, 2015). Citrate is required for fatty acid biosynthesis, and once in 
the cytosol it is cleaved by citrate lyase into acetyl-CoA and oxaloacetate. Fatty acids 
derived from citrate and other metabolic pathways are essential for cellular growth and 
proliferation, and have been also implicated in DC activation and the production of pro-
inflammatory mediators in those cells (Everts B, 2014). The incorporation of glucose-
derived carbon into lipids in LPS-stimulated DCs is prevented by C75, an inhibitor of 
fatty acid synthase. Treatment with C75 impairs the expansion of endoplasmic reticulum 
and golgi in response to LPS, and subsequently the ability of DCs to present antigen and 
to generate pro-inflammatory cytokines such as IL-6, IL-12 and TNF, which suggests that 
the generation of fatty acids is essential for an appropriate immune response in these cells 
(Michelucci A, 2013). Moreover, citrate is a known inhibitor of glycolysis and its 
accumulation might be responsible for the prolonged glycolysis inhibition observed 
(Newsholme EA, 1977).  
Notably, these data obtained in vitro, showing an increase in TCA cycle substrate 
availabilty and reduced glycolysis upon lactate treatment, were further confirmed in RA 
joints that, it is known, are rich in lactate. In particular, this metabolic signature, is 
characteristic of a specific subset of RA patients (ELS+ or lymphoid "pathotype") 
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characterized by high number of CD4
+
 T cells. This evidence is also in line with the 
findings made by Weyand's group, showing a glycolytic deficiency along with increased 
PPP and FAS displayed by peripheral RA T cells (Yang Z, 2013; Yang Z, 2016; Shen Y, 
2017). This is a very important point, which highlights the strong metabolic correlation 
between the peripheral and tissue compartment in a disease like RA. Correlation studies 
between serum/synovial fluid, blood and synovial biomarker profiling may be a 
promising tool for predicting specific pathogenic pathways in the inflamed synovium of 
patients with RA. 
 
6.2 Lactate modulation of IL-17 production by human T cells 
 
The mechanisms underpinning the crosstalk between the immune system and metabolism 
have been intensively studied for the last few years.  As a metabolite produced at the end 
of glycolysis, lactate is emerging as an important signalling molecule promoting specific 
immune-inflammatory responses. The discovery of specific lactate transporters on the 
surface of immune cells has opened novel and important perspectives for the 
understanding of the pathogenesis of inflammatory and autoimmune disorders. Indeed, 
the effect of lactate on T cells recapitulates key features of T lymphocytes found in 
chronic inflammatory infiltrates, including their entrapment and production of high levels 
of IL-17 and loss of cytolytic activity by CD4
+
 and CD8
+
 T cells, respectively (Haas R, 
2015). These events lead to the perpetuation of chronic inflammation such as in RA 
synovitis. 
It became clear that this pro-inflammatory cytokine plays a key role in autoimmunity and 
more specifically in RA. The human IL-17A was first cloned in 1996 and it was found to 
be produced by activated CD45(RO)
+
 memory helper T cells (Chabaud M, 1999). It was 
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shown in the same study that IL-17A induces the production of IL-6, IL-8, PGE2, and 
GCSF in a dose-dependent manner in cultures of RA synovial fibroblasts. The IL-17A 
effect was blocked with anti-IL-17 antibodies (Chabaud M, 1999). Interestingly, TNF-𝛼 
had an additive effect on IL-17 induced secretion of IL6. Soon after this observation, it 
was found that synovial fluids of RA patients have high IL-17A levels compared to those 
with osteoarthritis. IL-4 or IL-13 completely inhibited the IL-17 production of cultured 
RA synovium tissue (Chabaud M, 1999) whereas exogenous IL-17 increased IL-6 
production in synovial tissue cultures. These observations led to the conclusion that 
through the production of other pro-inflammatory cytokines, IL-17 has a significant, if 
not a central, role in the pathogenesis of RA (Chabaud M, 1999). IL-17, in particular, is 
also considered to be osteoclastogenic and involved in RA bone reabsorption and 
marginal erosions (Kotake S, 1999). Several mouse models of arthritis show the central 
role of IL-17 in the pathogenesis of the disease (Kugyelka R, 2016).  
Several cell functions, including cytokine production, require energy from metabolic 
pathways. In this context, glycolysis fuels the energetic demands of CD4
+
 T cell 
activation, growth and differentiation. Previous reports have shown that HIF induced 
glycolysis is necessary to promote the differentiation of naïve CD4
+
 T cells toward the 
Th17 subset (Dang EV, 2011). Glycolysis is also necessary for the generation of 
inducible Treg cells from Tconv; indeed, it was found that the binding of the glycolytic 
enzyme enolase-1 to the FOXP3 promoter and to the conserved non-coding sequence 2 
(CNS2) of the FOXP3 locus directly affected the expression of FOXP3 splicing variant 
containing exon 2 (FOXP3-E2) which is related to Treg suppressive activity. Patients 
with multiple sclerosis or type 1 diabetes, show an altered expression of FOXP3-E2 along 
with impaired glycolysis and IL-2 signalling. This suggests a close link between 
metabolism and immune tolerance (De Rosa V, 2015). 
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As emphasized in this paper by De Rosa et al., metabolic enzymes can, in certain 
circumstances, translocate in to the nucleus, a phenomenon called “moonlighting”, 
where, as RNA-binding proteins (RBPs), in some instances, they regulate the expression 
of their target mRNAs and immune responses (De Rosa V, 2015; Boukouris AE, 2016).  
This metabolism-epigenetics axis facilitates adaptation to a changing environment in 
normal (e.g., development, stem cell differentiation) and disease states (e.g., cancer and 
autoimmunity), providing a potential novel therapeutic target.  
 In this context, the glycolytic enzyme PKM1/2 plays a crucial role in the regulation of 
transcription factors and cytokine production (Shirai T, 2016). PKM catalyzes the last 
step within glycolysis, the dephosphorylation of phosphoenolpyruvate to pyruvate, and 
consists of two isoforms PKM1 and 2. 
In contrast to its splice variant PKM1, which is expressed in many adult tissues, PKM2 is 
allosterically activated in a feed-forward regulatory loop by an upstream glycolytic 
metabolite, fructose-1,6-bisphosphate (FBP) and is susceptible to inhibition by growth 
factor signalling through interaction with phosphotyrosine containing proteins 
(Anastasiou D, 2011). 
These properties of PKM2 allow proliferating cells to divert glucose into anabolic 
pathways emanating from glycolysis in order to meet the increased biosynthetic demands 
of proliferation. 
Association of PKM2 subunits into homotetramers is required for optimal enzymatic 
activity (Eigenbrodt E, 1992). Exposure of A549 human lung cancer cells to 1 mM H2O2, 
250 mM diamide (a thiol-oxidizing compound), or hypoxia (1% O2) [which causes 
increased ROS production by mitochondrial complex III (Brunelle JK, 2005)] has been 
shown to increase the intracellular concentrations of ROS with a concomitant decrease in 
PKM2 activity (Anastasiou D, 2011).  
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This inhibition of PKM2 is able to divert glucose into the pentose phosphate pathway and 
thereby generate NADPH (Le Goffe C, 2002), which in turn provides sufficient reducing 
potential for detoxification of ROS by increasing reduced glutathione (GSH) allowing 
cells to withstand oxidative stress. It maybe possible that during excess lactate (i.e. 
inflammation or tumour), all the NADPH is used for a rapid antioxidative response 
determining GSH exhaustion.  
Of note, treatment of purified recombinant PKM2 with the small-molecule PKM2 
activator DASA-10 (NCGC00181061, a substituted N,N′- diarylsulfonamide) prevented 
inhibition of PKM2 by H2O2 (Anastasiou D, 2011).  
The PKM2 potential has also been investigated in atherosclerotic coronary artery disease 
(CAD) and RA patient-derived macrophages. Here, the increased glucose uptake and 
glycolytic flux due to inflammation fuel the generation of mitochondrial ROS, which in 
turn promote dimerization of the glycolytic enzyme pyruvate kinase M2 (PKM2) and 
enable its nuclear translocation. Nuclear PKM2 functions as a protein kinase that 
phosphorylates the transcription factor Stat3, thus boosting IL-6 and IL-1β production 
(Shirai T, 2016; Weyand CM, 2017). Reducing glycolysis, scavenging superoxide and 
enforcing PKM2 tetramerization corrected the proinflammatory phenotype of CAD 
macrophages (Shirai T, 2016).  
In line with these findings, an increase of PKM2 nuclear translocation with concomitant 
enhanced Stat3 phosphorylation upon lactate treatment was observed. Stat3 is involved in 
the Th17 differentiation (Yang XO, 2007) and interestingly, the inhibition of PKM2 
nuclear translocation with DASA was able to reduce lactate mediated IL-17 production 
supporting the important role of this signalling pathway in the regulation of IL-17 by 
lactate.  
Naive T cells mature and exit from the thymus primarily relying on OXPHOS for their 
metabolic needs, although they augment with glycolytic metabolism during times of 
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proliferation that follow TCR gene rearrangements. In secondary lymphoid organs, TCR 
ligation, co-stimulation, and growth factor cytokine signals induce clonal expansion and 
metabolic reprogramming of an antigen-specific T cell. This conversion to an activated 
effector T cell is marked by the engagement of aerobic glycolysis and increased 
OXPHOS activity. Glycolytic metabolism differentiates CD4 Th1, Th2, and Th17 
effector cells (and possibly Tfh cells) from Treg cells. Promoting FAO and catabolic 
metabolism enhances Treg and memory T cell development (Buck MD, 2015) while FAS 
mainly sustains Th17 differentiation (Berod L, 2014).  
In this project, I have analyzed total CD4
+
 T cells, to understand the impact of sodium 
lactate on different CD4
+
 T cell subsets during a TCR natural activation. Interestingly, in 
vitro incubation with sodium lactate, increased the expression of RORγT and IL-17 
without affecting Treg population within the total CD4 population. This is in line with 
our previous findings performed in mouse showing that sodium lactate was able to induce 
a Th17 signature in different T cell subsets (Th0, Th1, Th2, and Th17) under polarized 
conditions (Haas R, 2015). In this context, it has been suggested that increased salt 
(sodium chloride, NaCl) concentrations found locally under physiological conditions in 
vivo markedly boost the induction of murine and human Th17 cells in autoimmune 
conditions (Kleinewietfeld M, 2013). The results presented in this thesis expand this 
observation to a broader range of salts, including sodium lactate. Th17 differentiation 
requires the engagement of glycolysis but also relies on de novo FAS (Berod L, 2014). In 
particular, FAS rate limiting enzyme, ACC1, is crucial for the formation of human and 
mouse Th17 (Berod L, 2014). Acetyl-CoA carboxylase (ACC) is rapidly regulated by 
reversible phosphorylation; phosphorylation inactivates ACC, whereas 
dephosphorylation activates the enzyme. ACC is AMPK downstream target (Winder 
WW, 1996). In this context, I found a reduced phosphorylation of ACC along with 
reduced pAMPK levels upon lactate exposure. This is quite surprising considering that 
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they are normally inversely regulated: when AMPK is active (phosphorylated), it 
negatively regulates ACC activation and vice versa. This suggests that lactate modulation 
of ACC does not depend on AMPK activation. Other mechanisms might be involved in 
the regulation of AMPK. It is reported that an excess of nutrients (glucose, amino acids), 
hormones (i.e. leptin) and cytokines such as TNF can downregulate AMPK (Viollet B, 
2010). Some of these factors might be directly regulated by lactate and could be 
worthwhile to investigate in the future. 
De novo FAS requires the cofactor NADPH, produced in the PPP, in order to take place. 
In this regard, I found a reduced glycolysis and decreased NADP/NADPH ratio in lactate 
treated compared to untreated CD4
+ 
T cells. This is in line with a previous publication 
from Weyand’s lab where they showed that RA T cells have an intrinsic deficit in the 
glycolysis breakdown due to the up-regulation of glucose-6-phosphate dehydrogenase 
(G6PD). Excess G6PD shunted glucose into the PPP, resulting in NADPH accumulation. 
NADPH serves as the ultimate donor of reductive power for the large majority of ROS-
detoxifying enzymes (Fernandez-Marcos PJ, 2016). The increase of FAS induced by 
lactate may decrease the NADPH availability for the convertion of GSSG to GSH.  This 
could lead to elevated intracellular reactive oxygen species, (Figure 6A), as a result of a 
perturbation of the glutathione pathway. These observations suggest that lactate 
promotes, on activated human healthy CD4
+
 T cells, a shunt toward a lipid-biosynthesis 
program. Blocking lactate flux on CD4
+
 T cells via SLC5A12 Ab was sufficient to 
reduce FAS and consequently the Stat3-IL-17 signalling pathway. These findings 
highlight a new mechanism consisting in the nuclear PKM2-Stat3 signalling and 
enhanced FAS through which lactate modulates IL-17 synthesis (Figure 12). 
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6.3 Lactate promotes T cell entrapment in the inflamed site 
 
T lymphocyte motility is directly regulated by aerobic glycolysis (Haas R, 2015; Kishore 
M, 2017). Several studies show how chemokine treated activated T cells increase glucose 
uptake via the upregulation of specific glucose transporters and the engagement of 
intracellular signalling pathway (i.e. mTOR, AMPK).  Glycolysis and AMPK signalling 
are required for efficient T cell migration. Indeed, CCL5 treatment of ex vivo activated 
human T cells induced the activation of the nutrient-sensing kinase AMPK and 
downstream substrates ACC1, PFKFB2, and GSK3. Treatment with 2-DG, an inhibitor 
of glycolysis, and an inhibitor of AMPK, reduced CCL5-mediated chemotaxis in a dose-
dependent manner (Chan O, 2012). A similar investigation has shown that CXCL10 
treatment was able to further up-regulate glycolytic enzymes as well as glucose 
transporters in activated CD4
+
 T cells. This effect was inhibited by lactate treatment. 
These data pointed to  lactate-mediated inhibition of CD4
+
 T cell motility being due to an 
interference with glycolysis activated upon engagement of the chemokine receptor 
CXCR3 with the chemokine CXCL10 (Haas R, 2015). These findings were further 
confirmed in a mouse model of zymosan-induced peritonitis in which T cells are 
recruited to the inflamed site 5 days after zymosan injection (Haas R, 2015). 
Intraperitoneal injection of anti-SLC5A12 antibody caused a significant reduction of 
CFSE-labelled CD4
+ 
T cells in the peritoneum and their accumulation in the spleen in 
comparison to an isotype-matched control antibody (Haas R, 2015). 
Lactate modulation of glycolysis has also been investigated in basal conditions in absence 
of a chemotactic stimulus. In particular, I obseved that in addition to a reduced glucose 
flux, several glycolytic enzymes, including HK, where decreased upon lactate exposure 
in a time dependent manner (Figure 8A).  
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HK catalyze the first committed step of glucose metabolism. Glucose transported through 
glucose transporters (GLUTs) on the plasma membrane is phosphorylated by HKs to 
produce glucose-6-phosphate (G6P). The two most common isoforms, HK1 and HK2, 
have overlapping tissue expression, but different subcellular distributions, with HK1 
associated mainly with mitochondria and HK2 associated with both mitochondrial and 
cytoplasmic compartments. HK2 binds to voltage-dependent anion channel 1 (VDAC1), 
the outer mitochondrial membrane protein, which interacts with the adenine nucleotide 
translocase (ANT), forming a contact site between the outer and inner membranes (Fiek 
C, 1982; Vyssokikh MY, 2003). The mitochondrial bound HKs, has been shown to 
provide facilitation of coupling between glycolysis and oxidative phosphorylation 
through privileged/preferential access of HKs to ATP generated by mitochondria. The 
ADP generated by mitochondrial HK catalytic activity is shuttled back into mitochondria 
for re-phosphorylation conferring metabolic advantage (Arora KK, 1988). HK plays 
important roles in the regulation of anabolic and catabolic processes (Wilson JE, 1995; 
Wilson JE, 2003). Indeed, it has been shown that different subcellular distributions are 
associated with different metabolic roles (John S, 2011). In particular, HK2 is thought to 
play a key role in promoting anabolic pathways when bound to mitochondria (Matuphala 
SP, 2006). 
In line with this evidence, I found an increased mitochondrial localization of HK2 after 4 
hour lactate treatment in comparison to untreated cells as well as a reduction of 
NADP
+
/NADPH ratio which suggests a shunt toward PPP and anabolic metabolism 
(Figure 8D-F). 
HK2 acts as a proper glucose/G6P sensor, adjusting the balance between glycolysis-
/mTORC1-mediated growth and autophagy-mediated preservation of energy homeostasis 
(Roberts DJ, 2014). Moreover, HK2 has pro-survival function antagonizing apoptotic 
BCL2 family proteins and thereby protects cells against apoptotic stimuli and 
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competitively inhibits Bax binding to mitochondria HK2 (Pastorino JG, 2002). Whether 
lactate regulates cell survival and apoptosis is still unknown and it might be very 
important to investigate this aspect in the future. The reduced locomotion observed under 
lactate treatment may be an adaptive response of T cells to stress in order to facilitate 
other processes such as cell survival. 
HK2 was found expressed at high levels in RA synovitis where it regulates fibroblast 
aggressive function including tissue invasiveness and cytokine production (Bustamante 
MF, 2018). Interestingly these effects associated with an increased HK2 mitochondrial 
localization (Bustamante MF, 2018). 
On the same line, HK2 was shown to be expressed at high levels by some cancer cells 
where it is necessary for their growth and immortalization (Mathupala SP, 2009). 
 Based on this evidence HK2 might be an attractive selective metabolic target for cancer 
and autoimmune disorders. 
 Glycolysis is also instrumental for regulatory T cell (Treg) migration. However, unlike 
in conventional T cells, in which migration is dependent upon mTORC1-induced 
glycolysis, Treg motility is sustained by a PI3K-mTORC2-mediated pathway leading to 
the induction of the enzyme GCK. GCK promoted cytoskeletal rearrangements by 
associating with actin, allowong Treg cells to migrate. Treg cells lacking this pathway 
were functionally suppressive but failed to migrate to skin allografts, prolong their 
survival and inhibit organ rejection (Kishore M, 2017). 
Lymphocyte traffic is required to maintain homeostasis and perform appropriate 
immunological reactions (Marelli-Berg FM, 2018). To migrate into inflamed tissues, 
lymphocytes acquire spatial and functional asymmetries. Motile T cells display a 
polarized morphology with two distinct cell compartments: the leading edge and the 
uropod. During cell polarization, chemoattractant receptors, cell-adhesion molecules and 
cytoskeletal proteins are re-distributed within these cellular compartments. In this 
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context, mitochondria are highly dynamic organelles that distribute in the cytoplasm to 
meet specific cellular needs, and specifically concentrate at the uropod during 
lymphocyte migration by a process involving rearrangements of their shape. In particular, 
mitochondrial fission facilitates relocation of the organelles and promotes lymphocyte 
chemotaxis, whereas mitochondrial fusion inhibits both processes. Mitochondrial ATP 
from OXPHOS fuels this process (Marelli-Berg FM, 2018; Campello S, 2006). 
In addition, the cytoskeleton rearranges during T cell migration (Serrador JM, 1999). 
Movement along microtubules, mediated by kinesin and dyneinmotors, controls 
intracellular distribution of mitochondria. It is possible that the close interactions of these 
organelles with microtubules might provide a convenient source of ATP and GTP, the 
latter used for tubulin polymerization, for cytoskeleton reorganization, at the uropod 
(Morris RL, 1993; Li Z, 2004). Whether or not lactate or other metabolites modulate T 
cell motility via cytoskeleton rearrangement is still under investigation. 
Leukocyte recruitment is a pivotal process in the regulation of an inflammatory episode. 
Leukocyte subsets continuously traffic into, through and out of the stromal compartments 
of the bone marrow, thymus, lymphnodes and peripheral tissues throughout life. Growing 
evidence indicates that leukocyte trafficking through these compartments is altered to 
some extent in patients with chronic inflammatory arthritis and that this trafficking can 
vary between different patients and across the course of the disease (for example, 
between each phase of disease or following therapeutic intervention). Indeed, it is now 
recognized that patients with RA have defects in at least one, if not multiple, checkpoints 
that regulate the exit of leukocytes from primary and secondary lymphoid tissues and the 
entry of these cells into the joint itself (Buckley CD, 2018). However, attempts to target 
leukocyte accumulation within the joint by modulating the recruitment and retention of 
these cells (for example, with chemokine receptor inhibitors) have not been successful to 
date (Asquith DL, 2015). This lack of success is possibly explained by the multifactorial 
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nature of the leukocyte adhesion cascade and by the current lack of understanding of the 
molecular processes that are dysregulated at given disease phases in an individual patient. 
The increased ‘stickiness’ of T cells expressing PTPN22 (R620W) could potentially be 
responsible for reduced cell migration speeds in synovial tissue and increased tissue 
residency times (Burn GL, 2016). The bioactive lipid sphingosine-1-phosphate (S1P) 
reportedly promoted the persistence of activated CD4
+
 T cells in a murine ear model of 
acute inflammation (Jaigirdar SA, 2017). Synovial tissue from patients with RA had 
increased levels of the enzyme sphingosine kinase 1, which is necessary for S1P 
synthesis, suggesting that S1P also contributes to the survival and persistence of T cells 
in the joint (Jaigirdar SA, 2017). 
Finally, the results of a 2017 study demonstrated that the cellular metabolism of T cells 
from patients with RA is rewired in such a way that impairs their locomotion programme. 
Reduced glycolytic flux induced the upregulation and overexpression of the podosome 
scaffold adapter protein TKS5 (also known as SH3PXD2A), which is critically involved 
in the localization of membrane protrusions in migrating cells (Shen Y, 2017). As a 
result, T cells from patients with RA are much more hypermotile and tissue-penetrating 
than HC (Shen Y, 2017). This ‘hypermotility’ was caused by insufficient glycolytic 
breakdown due to a PFKFB3 deficiency, pyruvate reduction and a shunt toward anabolic 
glucose utilization (increased PPP and FAS). Enhanced FAS led to cytoplasmic lipid 
droplets accumulation, which are requisites for cell growth, proliferation and naïve to 
memory T cell conversion. Interestingly, the replenishment of pyruvate was sufficient to 
restore T cell locomotion, tissue-invasiveness and inflammation in a NOD scid gamma 
mice (NSG mice) engrafted with human synovial tissue. 
In line with this finding, lactate treated CD4
+
 T cells, like RA T cells, are also able to 
shunt toward anabolic pathways such as PPP and FAS. Blocking FAS and NADPH 
production with specific compounds was sufficient to restore T cell locomotion even in 
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the presence of lactate. This suggests that glycolytically impaired RA CD4
+
 T cells utilize 
anabolic PPP and FAS to infiltrate the synovium and remain on the site. The same 
metabolic signature is displayed by healthy T cells exposed to high concentration of 
lactate.  
The impairment of T cell motility along with a Th17 signature displayed by T cells, due 
to lactate excess, may lead to the establishment of long-lasting, highly efficient tertiary 
lymphoid structures in RA synovium as previously shown (Shen Y, 2017). ELSs 
structures develop in 40% of RA patients and their role is still poorly understood. In this 
subgroup of patients (ELS/lymphoid), a high percentage of CD4
+
 T cells expressing 
SLC5A12 in the tissue was found (Haas R, 2015). Moreover, the synovial expression of 
SLC5A12 correlated with disease activity and response to therapy, thus supporting the 
role of lactate/SLC5A12 signalling as a possible biomarker of disease progression and 
therapeutic response. 
The enrichment of SLC5A12 in the inflammatory sites raised the question of whether this 
lactate transporter may be involved in the entrapment of CD4
+
 T cells within the 
chronically inflamed “milieu” of the RA synovia. Blocking SLC5A12 transporter with 
both polyclonal and monoclonal antibodies resulted in an increased T cell egress from the 
inflamed synovial tissue, in a reduced IL-17 production and in a decreased inflammation 
in a mouse model of arthritis. These observations make SLC5A12 a possible novel 
candidate as therapeutic target in inflammatory disorders. 
 
6.4 Therapeutic potential 
 
For many years, lactate has been considered a bystander product of glycolysis, produced 
during hypoxia or by highly proliferating cells. Only recently, lactate has received a well-
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deserved consideration as a signalling metabolite. Its role in cancer biology and immunity 
is getting into the spotlight nowadays. The breakthrough that lactate plays a very 
important  role in the interplay between inflammation, cancer, metabolism and immunity 
together with the discovery of lactate transporters expressed by different variety of cells 
(i.e. immune, stromal and cancer cells) has opened a new area of research and novel 
potential therapeutics. The emerging evidence that solid cancers can deprive the tumour 
environment of glucose and enrich it with lactate which in turn depresses effector and 
cytotoxic T cell functions and promotes suppressive Treg cells, has also shed lights on 
new immunosuppressive therapy approaches, based on potentiating Treg cell activity, in 
conditions where Treg cell functionality is overthrown (i.e. autoimmunity,  
transplantation). On the other side, in cancer this can offer a new potential therapeutic 
approach based on targeting cancer metabolism that can reduce detrimental Treg cells in 
favor of effector T cells thus enhancing anti-tumour response (Angelin A, 2017). 
Targeting lactate signalling via lactate transporters is becoming a new promising field in 
cancer. However, little is currently known about the regulation of MCT/SMTCs 
expression and activity in different tissues and peripheral blood and their regulation 
during inflammation or tumours. The discovery that MCTs can transport anticancer 
agents (i.e. 3-bromopyruvate, dichloroacetate and iodoacetate) across cell membranes 
(Baltazar F, 2014) suggests that those substrates can also act as anticancer compounds. 
Moreover, in some tumours MCT activity is being studied to identify new biomarkers 
that would allow predicting a therapeutic response.  
If in cancer lactate suppresses T cell effector functions enabling the tumour to grow in the 
context of inflammatory disorders, such as RA, lactate behaves as a pro-inflammatory 
signal. Indeed, in the presence of high concentration of lactate, such as in the RA 
synovium, T cells are unable to egress ending up "entrapped" in the inflammatory site 
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(Haas R, 2015; Pucino V, 2017). Here, T cells produce a high amount of pro-
inflammatory cytokines contributing to the establishment of chronic inflammation.  
Importantly, the expression of lactate transporters positively correlated with the extent of 
T cell infiltrates in the synovium of RA patients (Haas R, 2015) suggesting a role of 
lactate in driving inflammation via these specific transporters. The clinical relevance of 
this study was further emphasized by the finding that pharmacological or antibody-
mediated blockade of subtype-specific lactate transporters on T cells resulted in their 
release from the inflammatory site in an in vivo model of peritonitis. This evidence was 
confirmed in vitro on isolated activated human T cells and ex vivo evaluating the effect of 
SLC5A12 blockade on cell egress from an RA synovial tissue. Moreover, a much higher 
expression of SLC5A12 was found in tissue-resident compared to peripheral CD4
+
 T 
cells that may correspond to a higher concentration of lactate in the inflamed tissue than 
in the peripheral blood. This aspect can be useful for the construction of a tissue specific 
antibody against SLC5A12, able to reduce the inflammation locally, minimizing the 
collateral effects of a systemic therapy. In support of this hypothesis, local injection of a 
commercially available SLC5A12 Ab was able to reduce the clinical and histological 
score of the disease in a mouse model of arthritis. 
Taken together, targeting the lactate/SLC5A12 signalling pathway re-established T cell 
migration away from the inflammatory site and reduced the production of high amounts 
of IL-17, with potential therapeutic implications in the management of inflammatory 
disorders. 
The distinct lactate transporter expression by CD4
+
 and CD8
+
 T cells (Haas R, 2015) may 
orchestrate their differential distribution in the inflamed tissues as well as affect their 
functional and migratory responses depending, for example, on the nature of the 
inflammatory exudate (i.e., more lactic acid versus sodium lactate). Targeting selected T 
cell subtypes via different lactate transporters might prove crucial in the modulation of 
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immune cell functions and to achieve beneficial therapeutic effects in diseases that are 
driven by these specific T cell subsets. 
In this context, Th17 play an important role in RA, IBD, MS/EAE (Oukka M, 2008). 
Rising levels of circulating Th17 cells and IL-17 were observed in patients with an 
inadequate response to anti-TNF-α therapy (Chen DY, 2011). Despite several studies 
revealed the importance of IL-17 in the pathogenesis of RA, clinical trials with IL-17 
blocking agents in RA have not reached striking results so far (Kugyelka R, 2016) thus 
other targets are needed.  
This can be in part due to the heterogeneity of RA in terms of pathogenesis and 
histological patterns of synovitis (Pitzalis C, 2013) as well as the high variability of 
cytokine pathways that are activated can differ from patients to patients.  
IL-17 and IL-17R family members show a high variability in the expression in individual 
patients (van Baarsen LG, 2014). Moreover, IL-17 is a complex system by itself. Indeed, 
it consists of 6 members with 5 known receptors. Therefore, it is not surprising that the 
blockade of IL17A or its receptor with monoclonal antibodies did not lead to complete 
disease remission so far. Currently it is more likely that IL-17 targeting agents could be 
used to in association with current therapies (Kugyelka R, 2016). For this reason, 
targeting the IL-17 axis in RA at different levels (i.e. Th17 differentiation, signalling, 
etc.), such as blocking SLC5A12, may provide better therapeutic results than the 
currently available monoclonal antibodies, in some selected patients, such as RA 
limphoid (ELS+), who have failed previous treatments (i.e. anti-TNF non responders). 
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7 CONCLUSIONS 
 
Overall, in this thesis I have provided a summary of the potential role of lactate that, via a 
distinctive metabolic signalling network, may promote pathogenic characteristic typical 
of the inflammatory “milieu” (Figure 12). Thus, targeting specific metabolic pathways 
via lactate transporter-blocking agents may provide a promising therapeutic approach to 
reduce inflammation and induce immunosuppressive responses. Modulating selective T 
cell subsets via targeting specific lactate transporters may furnish a novel tool to reduce 
inflammation and may help to better understand the pathogenesis of inflammatory 
disorders. 
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Figure 12 – Schematic summary. Lactate accumulation at the site of inflammation 
contributes, together with activation and inflammatory stimuli, to the up-regulation of the 
sodium-coupled lactate transporter SLC5A12 by human CD4
+
 T cells. SLC5A12-
mediated lactate influx in to human CD4+ T cells initiates a nuclear PKM2/Stat3 
signalling and enhances fatty acid synthesis leading to increased IL-17 production. 
SLC5A12-mediated lactate influx into human CD4+ T cells also causes their damaging 
retention at the inflamed tissue as a consequence of reduced glycolysis and enhanced 
fatty acid synthesis. These events promote the perpetuation of chronic inflammation in 
diseases such as RA. Targeting SLC5A12 may constitute a novel therapeutic option to 
reduce inflammation. 
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9 APPENDIX 
 
   Table 6 - Demographical patient data 
Parameter Study 
Population 
(n = 17) 
Age (range) 35-76 
Gender (%)  
   Female 80 
   Male 20 
ESR (range) 2-113 
CRP (range) 5-26 
DAS28 (%) 
< 2.1 
> 5.2 
 
50 
50 
Erosive (%) 63 
Treatment (%)  
  Naïve to treatment 53 
  DMARDs 35 
  Steroids 5 
  Biologics 29 
RF
+
 and/or CCP
+
 (%) 95 
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Table 7 - Primary and secondary antibodies used for immunofluorescence 
Antigen Specificity Clone Host Source Diluition 
CD20 B lymphocytes L-26 Mouse DAKO 1:20 
CD8 Cytotoxic/suppressor  T cells subset C8/144B Mouse DAKO 1:50 
CD4 T-helper cells 4 B12 Mouse DAKO 1:50 
CD68 Monocytes/macrophages M0876 Mouse DAKO 1:50 
SLC5A12 N/A HPA045181 Rabbit 
 
NOVUS 1:50 
 
 
- Secondary antibodies used for immunofluorescence 
 
 
 
 
 
  
Primary 
antibodies 
Secondary antibodies immunofluorescence 
CD20 Goat anti-mouse IgG2a ALEXA-488 (Invitrogen) 
CD8 Goat anti-mouse IgG1 ALEXA-488 (Invitrogen) 
CD4 Goat anti-mouse IgG1 ALEXA-488 (Invitrogen) 
CD68 Goat anti-mouse IgG1 ALEXA-488 (Invitrogen) 
SLC5A12 Goat anti-rabbit IgG ALEXA-555 (Invitrogen) 
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Table 8 - Primers used for qRT-PCR 
 
Name Sequence  Species Description 
BCL6_F CGAATCCACACAGGAGAGAAA human B-cell lymphoma 6 protein 
BCL6_R ACGCGGTATTGCACCTTG human B-cell lymphoma 6 protein 
CXCR5_F GCTAACGCTGGAAATGGA human C-X-C chemokine receptor type 5  
CXCR5_R GCAGGGCAGAGATGATTT human C-X-C chemokine receptor type 5  
Foxo1_F AGGGTTAGTGAGCAGGTTACAC human Forkhead box protein O1  
Foxo1_R TGCTGCCAAGTCTGACGAAA human Forkhead box protein O1  
Foxp3_F CTGACCAAGGCTTCATCTGTG human Forkhead box P3 
Foxp3_R ACTCTGGGAATGTGCTGTTTC human Forkhead box P3 
GAPDH_F TCCTCTGACTTCAACAGCGA human Glyceraldehyde 3-phosphate 
dehydrogenase 
GAPDH_R GGGTCTTACTCCTTGGAGGC human Glyceraldehyde 3-phosphate 
dehydrogenase 
IFN_F GGCATTTTGAAGAATTGGAAAG human Interferon gamma  
IFN_R TTTGGATGCTCTGGTCATCTT human Interferon gamma  
IL10_F ACCTGCCTAACATGCTTCGAG human Interleukin 10 
IL10_R CCAGCTGATCCTTCATTTGAAAG human Interleukin 10 
IL17A_F TGTCCACCATGTGGCCTAAGAG human Interleukin 17A 
IL17A_R GTCCGAAATGAGGCTGTCTTTGA human Interleukin 17A 
IL22_F TCCAGAGGAATGTGCAAAAG human Interleukin 22 
IL22_R ACAGCAAATCCAGTTCTCCAA human Interleukin 22 
IL6_F AGTGAGGAACAAGCCAGAGC human Interleukin 6 
IL6_R GTCAGGGGTGGTTATTGCAT human Interleukin 6 
PD1_F ACCTGGGTGTTGGGAGGGCA human Programmed cell death protein 1 
PD1_R GGAGTGGATAGGCCACGGCG human Programmed cell death protein 1 
RORt_F CCTGGGCTCCTCGCCTGACC human RAR-related orphan receptor 
gamma  
RORt_R TCTCTCTGCCCTCAGCCTTGCC human RAR-related orphan receptor 
gamma  
SLC5A12_F GTGTGCTGTCTTCTCTGGCT human sodium-coupled monocarboxylate 
transporter 2 
SLC5A12_R GCCACAAAAAGTCCTGGCAG human sodium-coupled monocarboxylate 
transporter 2 
TGF_F AGCGACTCGCCAGAGTGGTTA human transforming growth factor beta  
TGF_R GCAGTGTGTTATCCCTGCTGTCA human transforming growth factor beta  
Actin_F AGTTGCGTTACACCCTTTCTTG human Actin 
Actin_R TCACCTTCACCGTTCCAGTTT human Actin 
